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Abstract 
Oxidative stress is a feature of many chronic neurodegenerative diseases as well as a 
contributing factor in acute disorders including stroke. Fork head class of 
transcription factors (Foxos) play a key role in promoting oxidative stress-induced 
apoptosis in neurons through the upregulation of a number of pro-apoptotic genes. 
Here I demonstrate that synaptic NMDA receptor activity not only promotes Foxos 
nuclear exclusion but also suppresses the expression of Foxo1 in a PI3K-dependent 
fashion. I also found that Foxo1 is in fact, a Foxo target gene and that it is subject to 
a feed-forward inhibition by synaptic activity, which is thought to result in longer-
term suppression of Foxo downstream gene expression than previously thought. The 
nuclear factor (erythroid 2-related) factor 2 (Nrf2) is another transcription factor 
involved in oxidative stress and the key regulator of many genes, whose products 
form important intrinsic antioxidant systems. In the CNS, artificial activation of Nrf2 
in astrocytes has been shown to protect nearby neurons from oxidative insults. 
However, the extent to which Nrf2 in astrocytes could respond to endogenous signals 
such as mild oxidative stress is less clear. The data presented herein, demonstrate for 
the first time that endogenous Nrf2 could be activated by mild oxidative stress and 
that this activation is restricted to astrocytes. Contrary to the established dogma, I 
found that mild oxidative stress induces the astrocytic Nrf2 pathway in a manner 
distinct from the classical Keap1 antagonism employed by prototypical Nrf2 
inducers. The mechanism was found to involve direct regulation of Nrf2's 
transactivation properties. Overall these results advance our knowledge of the 
molecular mechanism(s) associated with the control of endogenous antioxidant 
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Oxygen consumption through normal cell metabolism results in the generation of 
harmful reactive oxygen species (ROS). It normally would be assumed that, given its 
central role in physiology and survival, the brain would be enriched with protective 
mechanisms against oxidative stress. On the contrary, the brain is particularly 
vulnerable to the deleterious effects of ROS because of its high metabolic activity 
coupled with low levels of antioxidants and high abundance of heavy metal ions. 
(Reiter, 1995; Hardingham and Lipton; 2011Gandhi and Abramov, 2012). 
Oxidative stress is caused by an imbalance between the generation and the 
detoxification of ROS and it has been associated with acute and chronic neurological 
disorders. Cells' intrinsic antioxidant and neuroprotective pathways are subject to 
dynamic regulation, potentially allowing them to adapt to and survive various 
intrinsic and extrinsic stressors. Such pathways are essential, particularly in adult 
neurons, which exhibit a severely limited capacity for regeneration or de novo 
generation of neurons. However, the underlying molecular mechanisms, specifically 
in neural cells, are less understood.  
The aim of this thesis is to gain a better understanding of the control of neural 
intrinsic antioxidant and neuroprotective pathways by N-methyl D-aspartate receptor 
(NMDAR) mediated synaptic activity or mild oxidative stress. This introduction is 
intended to summarize some of the present knowledge on oxidative stress, generation 
of ROS and antioxidant defense mechanisms specifically those regulated by the 
transcription factor nuclear factor (erythroid 2-related) factor 2 (Nrf2), as well as the 
role of the fork head box O family of transcription factors (Foxo) in oxidative stress 
induced neuronal death. In addition, the introduction will include an overview on the 
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1.1 Oxidative stress 
It has been long recognised that oxidative stress plays an important role in the 
etiology of various pathological conditions including acute and chronic 
neurodegenerative disorders. Oxidative stress elicits its deleterious effect through 
inflicting damage to cellular biomolecules and it could occur as a secondary effect of 
a pre-existing pathological condition or could be the primary cause of the disease. 
 
1.1.1 Mechanisms of Oxidative stress damage 
Oxygen is required to sustain life, but paradoxically, highly toxic reactive oxygen 
species (ROS) are produced as a byproduct of its metabolism. Oxidative stress is a 
condition in which there is a mismatch between the production of ROS and the cell’s 
ability to detoxify these species and repair the damage. However, this imbalance 
results in the accumulation of damaged biomolecules that can cause cellular 
dysfunction, and for post-mitotic cells with relatively restricted replenishment such 
as neurons, cell death (Simonian and Coyle, 1996; Wang and Michaelis, 2010). ROS 
react with cellular components resulting in deleterious effects on their function. They 
can damage both nuclear and mitochondrial DNA, through inducing strand breaks 
and chemical alterations in the deoxyribose and in the purine and pyrimidine bases 
(Simonian and Coyle, 1996; Reiter, 1995). In addition to their role in 
pathophysiology, ROS are beneficial to cells in certain physiological processes such 
as signal transduction, immune defence and oxygen homeostasis (Allen and 
Bayraktutan, 2009). 
In terms of protein damage, ROS can oxidize the protein backbone, amino acid side 
chains and induce extensive protein-protein cross-linking at cysteine residues, 
carbonyl derivatives and other oxidized residues (Berlett and Stadtman, 1997; Kregel 
and Zhang, 2007). Oxidatively damaged proteins, many of which are critical in 
neuronal physiology or structure, lose their efficiency and eventually disturb cellular 
functions. For instance, oxidative damage can alter enzyme activity, modulate 
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transcription factor activity and lead to the formation of protein aggregates (Kregel 
and Zhang, 2007). 
 
Polyunsaturated fatty acids (PUFA), which are abundant in the neural tissues, render 
lipids highly sensitive to oxidation by ROS (Kregel and Zhang, 2007). Oxidative 
lipid damage, termed lipid peroxidation, is initiated by the incorporation of oxygen 
into PUFA. This process compromises the membrane integrity by decreasing its 
fluidity, reducing membrane potential and thereby allowing ions such as Ca2+ to leak 
into the cell (Simonian and Coyle, 1996). 
 
1.1.2 Generation of reactive oxygen species (ROS)  
The term free radical refers to any species with an unpaired electron. The majority 
of free radicals have a high chemical reactivity, and can either react with each other 
or with non-radicals. Molecular oxygen O2 qualifies as a radical because it possesses 
two unpaired electrons each on a different orbital and both spinning in the same 
direction, however, unlike other radicals O2 reactivity is poor due to this parallel 
spin. Reactive oxygen species (ROS), is a collective descriptor that includes not 
only the oxygen radicals such as superoxide (O2•—) and hydroxyl radical (OH•), but 
also some  (non-radical) derivatives such as hydrogen peroxide H2O2 (Halliwell, 
2006).  
 
 O2•— is produced via the activity of mitochondrial and microsomal electron 
transport chains (McCord and Omar, 1993). Most of the O2 in aerobic organisms is 
reduced to water by the mitochondrial cytochrome c oxidase enzyme, which adds 
four electrons to O2 in a step-wise fashion resulting in the formation of two 
molecules of water. Although the partially reduced oxygen intermediates are usually 
retained by the cytochrome c oxidase until full reduction is achieved, other sites in 
the respiratory chain namely complex I and III may directly leak electrons to O2 
resulting in the formation of O2•— (Turrens, 1997; Brookes, 2005).   
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The mitochondrion, though the prime site for O2•—  generation, is not the only source 
of O2•—   in vivo. In fact, various cytosolic and membrane-bound enzymes are 
involved in the generation of O2•—  , including nicotine amide adenine dinucleotide 
phosphate (NADPH) oxidase and Xanthine oxidase (Simonian and Coyle, 1996; 
Gandhi and Abramov, 2012). NADPH oxidase is a membrane enzyme and the first 
identified example of a system that generates ROS as a primary product rather than a 
byproduct (Bedard and Krause, 2007) It is a multi-subunit enzyme consisting of two 
membrane-bound components, several cytosolic proteins and a low-molecular-
weight G protein (Babior, 1999). Activation of the oxidase involves the 
phosphorylation of the cytosolic subunits leading to their translocation to the 
membrane and eventually the complete assembly of the complex.  This enzyme is 
present in phagocytes and in diverse brain cell types such as neurons, astrocytes 
(Noh and Koh, 2000) and microglia (Colton and Gilbert, 1987), in which it catalyses 
the production of O2•—    from O2 and NADPH according to the following reaction 





Xanthine oxidase (XOD) is another major cellular source of O2•— . It originally exists 
in the form of xanthine dehydrogenase (XDH) and is converted to xanthine oxidase 
in cells under some pathological conditions either reversibly by the oxidation of 
sulfhydryl residues or irreversibly by partial cleavage of the xanthine dehydrogenase 
(Chung et al., 1997). However, both enzymes share the same general metabolic 
function, which is the conversion of hypoxanthine to xanthine and the subsequent 
production of uric acid. Xanthine oxidase is the O2•—  producing form. It catalyses the 
conversion of hypoxanthine or xanthine to uric acid and superoxide using O2 as a co-
factor, while xanthine dehydrogenase utilizes the same substrates using NAD as a 
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cofactor to produce uric acid and NADPH instead of superoxide (Chung et al., 1997; 





Owing to its low reactivity and poor membrane permeability, O2•— itself is not 
highly toxic to macromolecules, however, it is readily converted to more toxic 
species (Halliwell and Gutteridge, 1990; Starkov, 2010).  Moreover, O2•— is 
converted spontaneously or enzymatically to H2O2. Unlike O2•— , however, H2O2 has 
a higher oxidant potential, and being uncharged, can easily diffuse through cell 
membranes. Although H2O2 is an oxidizing agent itself, it is not reactive. However, 
in the presence of transition metals such as Fe2+, H2O2 is further reduced to the 
highly toxic radical OH•  via the Fenton reaction (Fig. I.1) (Halliwell and Gutteridge, 
1990; Hogg et al., 1992).  
 
Superoxide dismutase (SOD) in its three forms (cytosolic, extracellular Cu, Zn-SOD 
and mitochondrial Mg-SOD) eliminate O2•—    by catalysing its dismutation, one O2•— 
being reduced to H2O2  and the other oxidized to O2 (Fig. 1.1) (Fridovich, 1995). 
Although SOD is classified as a component of the antioxidant defences, due to its 
ability to metabolize the superoxide free radical to non-radical species (H2O2), 
excessive SOD gene expression, such as in individuals with Down syndrome, has 
been linked with premature aging, and neurodegeneration (Lejeune, 1990). 
Moreover, missense mutations in the cytosolic Cu/Zn form of SOD have been 
associated with familial ALS (Rosen et al., 1993).   
 
Besides SOD, a number of enzyme systems also generate H2O2. These include L-
amino acid oxidase, glycolate oxidase and monoamine oxidase (Reiter, 1995). The 
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mitochondrially located flavoenzyme, monoamine oxidase (MAO), catalyses the 
oxidative deamination of important neurotransmitters such as dopamine and 
serotonin. Two subtypes of monoamine oxidase have been identified: MAO-A and 
MAO-B. In the central nervous system (CNS), MAO-A is found in neurons while 
MAO-B is expressed in both neurons and astrocytes. MAO-B have been implicated 
in the etiology of Parkinson’s disease, as MAO-B accelerates the oxidation of 
dopamine in dopaminergic nerve axons resulting in elevated H2O2 generation beyond 
the capacity of cells’ antioxidant defence systems, eventually leading to neuronal 
destruction (Edmondson et al., 2009). In addition, superoxide is formed non-
enzymatically through the auto-oxidation of small molecules such as catecholamines 






Figure 1.1. H2O2 generation by SOD and the conversion of H2O2 to the highly 
toxic hydroxyl radical via the Fenton reaction.  
Molecular oxygen in the presence of electrons forms superoxide, which is readily 
converted to O2 and H2O2. H2O2 in return, can be further reduced in the presence of 
transition metals such as Fe2+ to the highly toxic hydroxyl radical (OH•): (1) The 
formation of superoxide by various sources such as mitochondrial oxidative 
metabolism and by the enzymatic activity of NADPH and xanthine oxidases among 
many other sources. (2) Superoxide conversion to H2O2 either spontaneously or 
enzymatically through the action of SOD. (3) The conversion of H2O2 to (OH•) via 
the Fenton reaction.  
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1.2. Oxidative stress and neuronal death 
It is widely accepted that mammalian neurons are among the longest-living cell 
types. However, neuronal death can occur naturally during embryonic and early 
postnatal development to ensure proper and precise synaptic connection, or as a 
pathological process in disease (Yuan et al., 2003). Oxidative stress can trigger 
neuronal death in various pathological scenarios and in this section I shall discuss the 
two main forms of cell death associated with oxidative stress; apoptosis and necrosis.  
 
1.2.1. Apoptosis 
Cells undergoing apoptosis display distinct morphological hallmarks, which include 
nuclear psyknosis, chromatic condensation, DNA fragmentation and cell rounding 
(Kerr et al., 1972; Yuan et al., 2003). This ordered morphology is a result of ATP-
requiring caspase-mediated cleavage.  Unlike necrosis, apoptotic cells have intact 
membranes and are not associated with inflammation. 
Apoptosis centres on proteolytic activation of caspases, a family of cysteine 
proteases, which target a wide range of proteins involved in cell survival, such as cell 
cycle control and DNA repair. Caspases also undergo autolytic activation and in turn 
cleave and activate other downstream caspases in the cascade leading to apoptosis. 
Based on the activation order in the cells, caspases are divided into initiator and 
effector groups, with the former activating the latter. Active initiator caspases 
(caspases 8-10) will cleave and activate effector caspases (caspase-3, -7 and -6) 
which in turn cleave specific substrates to produce the morphological and 
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To date, two major apoptotic pathways have been described: the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway. The extrinsic pathway 
involves the engagement of extracellular ligands with cell death receptors, such as 
Fas and members of the tumour necrosis factor (TNF) family (Ashkenazi and Dixit, 
1998). Fas ligand (FasL) and TNF bind their receptors and stimulate the recruitment 
of adaptor proteins such as Fas-associated death domain (FADD) and the TNF 
receptor 1- associated death domain protein (TRADD). The adaptor proteins in turn 
facilitate the recruitment of pro-caspase-8 (or -10) to the receptor complex and the 
formation of the death-inducing signalling complex (DISC), leading to the activation 
of the initiator caspases and subsequently the down stream effector caspases (Fig. 
1.2) (Yang et al., 1998; Elmore, 2007). 
 
The intrinsic apoptotic pathway is mediated by the mitochondria and is activated by 
a diverse array of non-receptor mediated extracellular and intracellular stimuli 
including toxins, oxidative stress, ischemia-reperfusion, DNA damage and loss of 
trophic/survival factors (Soriano et al., 2011; Foo et al., 2005). All these stimuli 
cause changes in the mitochondrial outer membrane, leading to increased membrane 
permeability and eventually the release of cytochrome c, which binds the cytosolic 
monomer apoptotic peptidase activating factor-1 (Apaf-1). The Apaf-1/cytochrome c 
complex then recruits and activates initiator caspase-9, which in turn activates the 
down stream effector caspases such as caspase-3, caspase-6 and caspase-7 (Fig. 1.2) 
(Nijhawan et al., 2000). 
The regulation of cytochrome c release occurs through members of the Bcl-2 family 
of proteins, which govern the mitochondrial membrane permeability. They are 
characterized by the presence of Bcl-2 homology (BH1-4) domains, and are divided 
into pro-apoptotic (Bax, Bim, Puma, Bak, Bid etc.) and anti-apoptotic (Bcl-2, Bcl-
xL, Bcl-xS, etc.) groups. Following apoptotic stimuli, Bax and Bak form oligomeric 
structures and translocate to the mitochondria where they promote outer membrane 
permeabilization and eventually lead to cytochrome c release (Kroemer et al., 2007). 
On the other hand, the Bcl-2 anti-apoptotic members localized to the mitochondria, 
sequester pro-apoptotic Bcl-2 members through binding to their BH3 domains, 
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preventing their activation/oligomerization and eventually inhibiting the release of 
cytochrome c (Lindsten et al., 2000).  
 
In addition to its detrimental effect, apoptosis fulfils a beneficial role in organs and 
limbs remodelling during embryogenesis, in tumour formation prevention and in 
normal cell turnover (Meier et al., 2000). Apoptosis occurs during neurodevelopment 
not only in the progenitor cells, but also in neurons and glia (Nijhawan et al., 2000). 
Studies underscored the importance of apoptosis in patterning of the CNS, as mutant 
mice deficient in key pro-apoptotic genes Casp3, Casp9 and Apaf1 all exhibited 
brain abnormalities and increased embryonic lethality (Kuan et al., 2000; Buss et al., 
2006). In addition to the physiological role of apoptosis, studies indicate that 
apoptosis plays an important role in neurodegeneration and in neuronal death in 


















Figure 1.2. Apoptosis signalling. 
The two main pathways of apoptosis are extrinsic and intrinsic. The extrinsic 
signalling pathway involves the binding of death receptors such as FasL receptors 
(FLR) and TNF receptors (TNFR) to their corresponding ligands and the subsequent 
recruitment of adaptor proteins such as FADD and TRADD. The adaptor proteins 
then associate with procaspase-8 or -10 forming DISC, which in turn leads to the 
activation of the initiator caspaseses-8, -10 and subsequently the down stream 
effector caspases-3, -7, -6. The intrinsic pathway is a mitochondrial-initiated event 
and is activated by a diverse array of non-receptor mediated stimuli, which cause 
changes to mitochondrial membrane permeability and the subsequent release of 
cytochrome c. The release of cytochrome c triggers effector caspases activation 
through formation of cytochrome c/Apaf-1/ caspase-9 complex. The release of 
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1.2.2.  Necrosis  
Necrosis is usually elicited by exposure of cells to toxic substances or to severe 
mechanical or ischaemic/hypoxic insults, and is morphologically characterized by 
swelling of the intracellular organelles followed by swelling and rupture of both the 
plasma and nuclear membranes (Edinger and Thompson, 2004; Clarke, 1990). The 
loss of membrane integrity may be a consequence of metabolic failure, damage to 
membrane lipids, and/or dysfunction in ion pumps/channels, in addition to the 
release of excitatory amino acid neurotransmitters (in the case of neurons) (Werner 
and Engelhard, 2007; Zong and Thompson, 2006).  
 
While necrosis has long been regarded as an uncontrolled form of death, 
accumulating studies have suggested that necrosis can be a regulated event that 
contributes to pathological and physiological conditions (Edinger and Thompson, 
2004). Holler et al. and others have found receptor-interacting proteins kinase (RIP) 
to be crucial for programmed necrosis (Holler et al., 2000; Chan et al., 2003).  
 
Although necrosis induces inflammation which may lead to the death of 
neighbouring cells through the release of cytokines, the necrosis-induced 
inflammation have a positive role in the protection against viral infections (Edinger 
and Thompson, 2004). In regard to the CNS, necrosis has been associated with 
various acute and chronic neurodegenerative conditions including Alzheimer’s and 
Parkinson’s diseases, ischemia and traumatic brain injury (Yuan et al., 2003; Sattler 
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1.2.3. Mechanisms of oxidative stress-induced cell death  
Oxidative stress-induced cell death displays characteristics of both apoptosis and 
necrosis. However, the same insult can lead to apoptosis or necrosis depending on its 
intensity, cell type, and the species and organism involved. According to the 
hypothesis and observations of Duvall and Wyllie, severe non-physiological levels of 
oxidative stress cause necrosis, rather than apoptosis  (Duvall and Wyllie, 1986). 
Excessive accumulation of lipid hydroperoxides, lipid peroxidation products, in 
response to oxidative stress induced by glutathione (GSH) depletion (an important 
antioxidant discussed in detail in section 1.4) leads to cell's demise by necrosis 
(Higuchi, 2004). However, several lines of evidence suggest the involvement of 
oxidative stress in apoptosis. For instance, H2O2 has been shown to induce apoptosis 
in B-cells (Takada et al., 2011) and in the CNS, chronic SOD inhibition results in the 
apoptotic degeneration of motor neurons (Rothstein et al., 1994) and PC12 neuronal 
cells (Troy and Shelanski, 1994). Moreover, cortical neurons undergoing GSH-
deprivation-induced oxidative stress, either by growing them in low cysteine media 
or through treatments with the glutamate analog homocysteate (HCA), suffer from 
apoptotic degeneration, which can be prevented by co-application of antioxidants 
(Ratan et al., 1994).  
 
Oxidative damage to DNA is believed to trigger apoptosis. Poly (ADP-ribose) 
polymerase, an enzyme involved in DNA damage repair, is activated under various 
conditions of DNA damage and is suggested to contribute to cell death by depleting 
the cell of NAD and ATP (Berger and Petzold, 1985; Schraufstatter et al., 1986).  
 
In addition to DNA damage, membrane integrity is thought to be compromised by 
oxidative stress. Rapid loss of membrane integrity is observed in neurons with 
concomitant nuclear condensation and DNA fragmentation following treatment with 
H2O2 (Higgins et al., 2009a).  
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Furthermore, oxidative stress can trigger apoptosis through disturbing signalling 
pathways associated with growth factor receptor stimulation. Insulin-like growth 
factor I (IGF-I) is a classical neuroprotective factor, which upon binding to its 
receptor triggers the PI3K/Akt signalling pathway. Activation of the PI3K/Akt 
pathway in turn, inactivates Foxo transcription factors, responsible for 
transactivating a number of pro-death genes, through inhibitory phosphorylation. 
However, oxidative stress inactivates IGF-I receptor function through abnormal 
glycation and consequently induces neuronal death by stimulating Foxo3 (Davila and 
Torres-Aleman, 2008). 
1.2.4. Foxos and apoptosis 
The fork head box O family of transcription factors (Foxo) initially described in 
Drosophila melanogaster, are characterized by the presence of a conserved 100 
amino acid DNA binding domain, or forkhead domain. Owing to the presence of the 
DNA-binding domain, Foxo proteins not only act as transcrpitional activators but 
also as transcriptional repressors  possibly through interacting with other 
transcription factors and modulating their activity, hence exerting positive and 
negative effects on gene expression. However, the net effect of Foxos on gene 
expression depends on the promoter context and extracellular conditions. Foxos also 
harbour nuclear export and nuclear localization signal sequences allowing for 
nucleocytoplasmic shuttling (Fu and Tindall, 2008). The subcellular localization and 
transcriptional functions of Foxos are tightly controlled by multiple post-translational 
modifications, such as phosphorylation, acetylation, and ubiquitination (Vogt et al., 
2005). Depending on the nature of the stimuli, Foxos are subject to two types of 
phosphorylation: inhibitory phosphorylation  by a number of protein kinases 
including Akt, serum- and glucocorticoid-inducible kinase (SGK), Cyclin-dependent 
kinases-2 (CDK2) and  I kappa B kinase (IKK), and secondly activating 
phosphorylation mediated by other kinases such as c-Jun NH2-terminal kinase  
(JNK) and mammalian Sterile 20-like kinase 1 (MST1) (Brunet et al., 2004; Huang 
and Tindall, 2007). All Foxo proteins are negatively regulated by Akt-mediated 
phosphorylation at three specific sites in response to growth factor and insulin except 
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for Foxo6, which contains only two sites and is predominantly nuclear (van der 
Heide et al., 2005; Salih and Brunet,  
 
2008). Phosphorylation of Foxo transcription factors by Akt promotes their nuclear 
export and subsequent ubiquitination and degradation. Direct phosphorylation of 
Foxos by Akt is initiated in response to growth factors, insulin and other cell stimuli 
(Obsil and Obsilova, 2008). 
Emerging evidence suggests the involvement of Foxos in multiple biological 
functions including cell cycle arrest, differentiation, stress response and apoptosis 
(Obsil and Obsilova, 2008). Foxos regulate components of both the intrinsic and 
extrinsic apoptosis pathway. In lymphocytes, Foxo1 was reported to induce Bim 
expression upon growth factor withdrawal (Dijkers et al., 2000). Besides Bim, Foxo3 
has been shown to  upregulate Puma gene expression in response to cytokine or 
growth factor withdrawal (You et al., 2006). Furthermore, Foxo4 induces apoptosis 
in part by suppressing the levels of anti-apoptotic BCL-XL through the 
transcriptional repressor BCL-6 (Tang et al., 2002). 
 
In addition, Foxos mediate the extrinsic apoptotic pathway through enhancing the 
transcription of pro-apoptotic factors such as FasL and tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL) (Brunet et al., 1999; Modur et al., 2002). FasL 
was one of the early pro-apoptotic genes identified as a Foxo target gene. Previous 
studies demonstrated a critical role of FasL in mediating Foxo-induced apoptosis in 
cerebellar granule cells and Jurkat T cells (Brunet et al., 1999). Moreover, mutations 
in  phosphatase and tensin homologue (PTEN) are very common in prostate cancers 
leading to constitutive activation of Akt pathway and eventually the loss of FOXO1 
and FOXO3 activity. Reduce TRAIL expression in human prostate cancer was 
directly linked to the loss of FOXO activity. However, studies revealed that 
overexpression of FOXO1 and FOXO3 promoted apoptosis and increased  TRAIL 
mRNA levels in prostate cancer cell lines (Modur et al., 2002). Thus, Foxos regulate 
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apoptosis through controlling the transcription of core components of both the 
intrinsic and extrinsic pathway. 
 
In the CNS, apoptosis is the primary cellular output of Foxo activation in response to 
environmental stressors such as trophic factor deprivation (Gilley et al., 2003), 
oxidative stress (Lehtinen et al., 2006) or extrasynaptic NMDAR activation (Dick 
and Bading, 2010). Foxo activity was shown to mediate Bim-dependent apoptosis in 
sympathetic neurons undergoing neuronal growth factor withdrawal-induced 
apoptosis (Gilley et al., 2003). FasL promoter harbours three Foxo DNA binding 
sites, and activation of Foxo3 was shown to cause cell death in motor and cerebral 
neurons, this killing effect, however, was attenuated in neurons derived from FasL 
mutant mice (Brunet et al., 1999; Barthelemy et al., 2004). In neuroblastoma cells, 
Foxo1 induces apoptosis through activation of pro-death genes Noxa and Bim 
(Obexer et al., 2007). Also Foxos activation was associated with hippocampal injury 
following prolonged seizures (Shinoda et al., 2004). Conversely, Foxo inactivation 
may contribute to the neuroprotective effect of estradiol observed in rodent models 
of stroke (Won et al., 2006). In humans, FOXO3 haplotype analysis revealed 
increased risk of stroke and increased mortality for carriers of certain FOXO3 
haplotypes (Kuningas et al., 2007; Maiese et al., 2007).  
 
Outside the CNS, Foxos coordinate diverse cellular functions. These multi-tasking 
proteins play key roles in many biological process including, cell-cycle progression, 
differentiation, cell growth and development, immune system activation and 
metabolism (Dansen and Burgering, 2008; Maiese et al., 2008; Salih and Brunet, 
2008). For instance Foxo1 plays a significant role in maintaining energy metabolism 
by increasing hepatic gluconeogenesis, reducing insulin secretion and regulating 
energy storage and expenditure through adipose tissue. Foxo1 exerts a further level 
of metabolism control by coordinating neuropeptide production in hypothalamic 
neurons, which regulates food intake and metabolite homeostasis and by regulating 
skeletal muscle atrophy in response to starvation or inadequate trophic support (Salih 
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and Brunet, 2008; Kousteni, 2012). 
 
 
Studies in several animal models support a role for Foxo proteins as tumour 
suppressors, owing to their established involvement in cell-cycle arrest, apoptosis, 
DNA-damage repair and angiogenesis restriction. Moreover, spontaneous tumour 
formation in Foxo conditional knockout mice, confirms the tumour suppressing-
effects of Foxos (Dansen and Burgering, 2008).  
 
1.2.5. Foxos and oxidative stress 
Foxos  play a key role in promoting oxidative stress-induced apoptosis in neurons 
through the upregulation of a number of pro-apoptotic genes (Lehtinen et al., 2006; 
Davila and Torres-Aleman, 2008; Gilley et al., 2003; Brunet et al., 1999). Bonni and 
co-workers demonstrated that oxidative stress activates MST1, which in turn 
phosphorylates Foxo3 at ser 207, resulting in the disruption of Foxo3 interaction 
with 14-3-3 proteins (a family of conserved modulator proteins which regulate 
diverse cellular processes through binding to their target proteins and affecting their 
function by several  means (Tzivion et al., 2011)), which leads to Foxo3 nuclear 
accumulation and thereby induces neuronal cell death (Lehtinen et al., 2006).  
Another study suggested that oxidative stress-induced neuronal death involves the 
activation of Foxo3 via recruiting two independently activated pathways. A rapid 
pathway involving  the attenuation of  Akt inhibition of Foxo3 through p38 MAPK-
mediated inhibition of IGF-I stimulation of Akt and a subsequent delayed pathway 
involving the activation of Foxo3 by jun-kinase 2 (JNK2) (Davila and Torres-
Aleman, 2008). 
 
Although in neurons Foxo has been reported to mediate oxidative stress-induced 
apoptosis, Foxo activation in non-neuronal cells has been shown to reduce levels of 
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oxidative stress by upregulating the expression of two potent antioxidant enzymes; 
MnSOD and catalase (Storz, 2011). Another diversion of Foxo3 function from 
apoptosis to stress resistance has been reported in the context of Sirt1-mediated  
deacetylation. In mammalian cells, the silencing information regulator 2 homolog, 
sirtuins (Sirt1) controls cellular responses to stress by deacetylating various proteins 
including Foxos. Brunet et al. reported an increased Foxo3 acetylation in response to 
H2O2-induced oxidative stress accompanied with increased interaction between Sirt1 
and Foxo3. Interestingly, Sirt1 differentially affected Foxo3 function, potentiating 
Foxo3’s ability to induce cell cycle arrest and resistance to oxidative stress but 
attenuating its ability to induce cell death in the presence of stress stimuli (Brunet et 
al., 2004). However, the mechanism by which Foxos switch from apoptotic 
signalling to antioxidant signalling is unclear (Storz, 2011). 
  
In the context of Foxo regulation, our group has previously shown that synaptic 
NMDAR signalling promotes sustained activation of the Akt pathway, leading to 
Foxo1 phosphorylation and nuclear exclusion and eventually the subsequent 
inactivation of Foxo downstream genes (Soriano et al., 2006; Papadia et al., 2008; 
Martel et al., 2009). In addition synaptic activity protects against oxidative stress by 
triggering a number of changes to the thioredoxin-peroxiredoxin antioxidant system. 
These changes include the downregulation of thioredoxin endogenous inhibitor and 
the newly identified Foxo target gene, thioredoxin interacting protein (Txnip). 
Synaptic activity turns off Txnip transcription by promoting PI3K-directed nuclear 
exclusion of Foxos, and the subsequent dissociation from the Txnip promoter 
(Papadia et al., 2008). Whether the effect of synaptic activity on Foxos nuclear 
distribution extends to the other major neuronal Foxo, Foxo3, or whether it induces 
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1.3. Oxidative stress and neurodegeneration 
Ageing was the earliest degenerative condition to be associated with oxidative stress, 
(Harman, 1956; Muller et al., 2007). Most theories of ageing in general and aging of 
the CNS in particular, are centred on the idea that accumulation of ROS coupled with 
diminished antioxidant defences (as a consequence of normal aging process) lead to 
cellular damage involving mitochondrial dysfunction (Harman, 1972; Lin and Beal, 
2006). More recently, this potential association between oxidative stress and ageing 
has been extended to many ageing-related diseases including Parkinson’s disease 
(PD), Alzheimer’s disease (AD) and Amyotrophic lateral sclerosis (ALS) (Bowling 
and Beal, 1995; Lin and Beal, 2006).  
 
AD is the most common ageing-related neurodegenerative disorder, characterized by 
progressive decline in memory and cognitive abilities, which are accompanied by 
neuronal loss in the forebrain.  Evidence of oxidative damage has been seen in AD 
brains as well as transgenic animal models of the disease, in which markers of lipid 
peroxidation, protein and DNA oxidation were increased (Sayre et al., 2008; Vargas 
and Johnson, 2009). The major neuropathological hallmarks of AD are the 
extracellular β-amyloid protein aggregates (Aβ) and the intracellular neurofibrillary 
tangles (NFT) (Simonian and Coyle, 1996; Selkoe, 2001). Oxidative stress is thought 
to contribute to Aβ toxicity and thus antioxidants protect against Aβ-induced 
neurotoxicity (Hensley et al., 1996; Quintanilla et al., 2005). It is also associated with 
the formation of NFTs, whereby oxidative stress triggers tau (the major protein in the 





	   20	  
 
 
PD is a common neurodegenerative movement disease associated with loss of 
dopaminergic neurons in the substantia nigra and is characterized by movement and 
postural dysfunction (Sayre et al., 2008; Shukla et al., 2011). Postmortem tissues 
from PD patients have shown evidence of mitochondrial   complex I reduced activity 
in the substanita nigra (Dawson and Dawson, 2003). The loss of complex I activity is 
thought to occur due to oxidative damage to certain complex I subunits resulting in 
the disassembly and impairment of the complex (Keeney et al., 2006). Further 
evidence for oxidative stress in PD is obtained from examination of human PD 
brains revealing oxidative damage to DNA and protein within the nigro-striatal 
region (Beal, 2002; Seet et al., 2010; Kikuchi et al., 2002). 
 
Besides being implicated in ageing-related neurological disease, oxidative stress 
plays a key role in the pathogenesis of acute neurological disorders such as ischemic 
stroke (Allen and Bayraktutan, 2009; Cherubini et al., 2005). Oxidative stress 
mediates ischemic injury in part through increasing cerebral vasodilation, blood-
brain barrier permeability and formation of focal lesions (Wei et al., 1996). It also 
has profound damaging cellular effects, leading to cells death and tissue destruction; 
these include nucleic acid modifications, lipid peroxidation and Ca2+ release from 
intracellular stores (Allen and Bayraktutan, 2009).  
 
Although increased oxidative damage has been reported in various human 
neurodegenerative conditions, it is not clear whether oxidative stress is the primary 
pathological mechanism resulting from either overproduction of ROS or a defect in 
cellular antioxidant defences or both, or whether it is a secondary manifestation of 
neurodegenerative process triggered by mitochondrial dysfunction or excitoxicity. 
(Sayre et al., 2008; Vargas and Johnson, 2009). In addition to oxidative stress, 
neurodegenerative conditions involve a number of neuron-damaging events  
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including inflammation, excitoxicity, mitochondrial impairment and calcium 
dysfunction (Andersen, 2004; Wang and Michaelis, 2010). However, the 
interconnection between these events is not necessarily a cascade but they may 
constitute a vicious cycle of which oxidative stress is a major component.  
Regardless of whether oxidative stress is primary or secondary event, it has become 
evident that it is involved in at least the exacerbation of cellular injury that leads to 
neuropathology (Ischiropoulos and Beckman, 2003; Andersen, 2004). Therefore, 
gaining a better insight of the regulation of intrinsic cellular antioxidant defences can 
offer therapeutic strategies to alleviate the burden of oxidative stress or delay the 
progression of neurodegenerative conditions.  
 
1.4. Cellular antioxidant defences 
Cells are equipped with a wide range of endogenous antioxidant defence systems to 
cope with the damaging effects of ROS. These include enzymatic and non-
enzymatic antioxidants that control the levels of ROS. The CNS contains multiple 
antioxidant defences such as the glutathione (GSH) system, 
thioredoxin/peroxiredoxin, and ascorbate.    
 
1.4.1. Glutathione system 
The tripeptide glutathione (GSH; γ-L-glutamyl-L-cysteinylglycine) is the most 
abundant non-protein thiol in mammalian cells, consisting of glutamate, cysteine and 
glycine. Within cells GSH is synthesized in consecutive ATP-requiring reactions of 
two enzymes. The initial reaction is rate limiting and catalysed by glutamate-cysteine 
ligase (GCL), a heterodimeric enzyme consisting of a catalytic subunit (GCLC) and 
a modifier subunit (GCLM), generating the dipeptide γ-glutamyl cysteine; the second 
one is the addition of glycine to the dipeptide by GSH synthetase (Fig. 1. 4) (Meister 
and Anderson, 1983). 
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The importance of the glutathione system for the detoxification of ROS in brain cells 
is becoming more evident (Meister and Anderson, 1983; Cooper and Kristal, 1997; 
Fernandez-Fernandez et al., 2012). Glutathione deficiency induced by the application 
of the GCL inhibitor BSO was shown to enhance the toxic effects of ROS generating 
insults such as ischemia (Mizui et al., 1992) and to induce mitochondrial damage in 
newborn rats brains (Jain et al., 1991).  Furthermore, significant loss of GSH has 
been reported in human brains from patients with AD (Gu et al., 1998), PD (Sofic et 
al., 1992), and schizophrenia (Do et al., 2000), as well as in rat models for 
Huntington’s disease (Cruz-Aguado et al., 2000).  
 
The detoxification of ROS by GSH is achieved either non-enzymatically through the 
direct reaction with radicals such as superoxide or hydroxyl (Saez et al., 1990; 
Winterbourn and Metodiewa, 1994) or through its role as an electron donor in the 
enzymatic reduction of peroxides catalysed by Glutathione peroxidases  (GPx) 
(Chance et al., 1979). GPx are selenium-dependent enzymes that play a major role in 
disposing of H2O2 through catalysing the reduction of H2O2 to water utilizing 
reduced GSH as an electron donor. During the GPx reaction, GSH is oxidized to 
GSSG then recycled back to GSH in an NADPH-dependent reaction catalyzed by 
glutathione reductase (GSR) (Fig. 1.3) (Kosower and Kosower, 1978; Reed, 1986).  
 
In addition to H2O2, glutathione peroxidases catalyse GSH-dependent reduction of 
fatty acid hydroperoxides to alcohol (Reiter, 1995; Gandhi and Abramov, 2012). At 
least five GPx isozymes have been identified in mammalian tissues; with GPx1 being 
the most abundant form (de Haan et al., 1998). The importance of GPx1 in protecting 
against oxidative stress is highlighted by the increased neuronal susceptibility to 
oxidative stress-induced death in GPx1 KO cells/animals challenged with H2O2 or 
paraquat (Haan et al., 1998; Taylor et al., 2005). 
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Whilst GSH has been found, as seen by histochemical and immunohistochemical 
techniques, to be present in neurons and glia (Dringen, 2000), the efficiency of the 
GSH-dependent peroxide detoxification appears to be lower in neurons than in 
astrocytes (Dringen et al., 1999a). This was attributed, at least partially, to the GSH 
concentration being half of that found in astrocytes (Sagara et al., 1993; Makar et al., 
1994) as a result of significantly lower protein levels and enzymatic activity of 
neuronal GCL in comparison with astrocytes (Makar et al., 1994). Consequently, 
cultured neurons are more vulnerable to damaging compounds such as H2O2 than 
cultured astrocytes (Dringen et al., 1999b) while astrocytic-GSH synthesis protects 
neurons from oxidative stress (Shih et al., 2003).   
  
Neurons rely on astrocytes for the provision of the necessary precursors for GSH 
synthesis (Dringen, 2000; Vargas and Johnson, 2009). GSH is released from 
astrocytes into the extracellular space via the multidrug-resistance-associated protein 
1 (MRP1) (Dringen and Hirrlinger, 2003) and subsequently hydrolysed to its 
precursors; first its broken down by γ- glutamyl transpeptidase to the dipeptide 
cysteinyl-glycine (Cys-Gly) (Dringen et al., 1999b), which can then be hydrolysed 
by aminopeptidase N to release cysteine and glycine (Dringen et al., 2001). The 
availability of cysteine, which is extremely unstable extracellulary and rapidly auto-
oxidized to cystine, is the rate-limiting factor in glutathione synthesis (Chen and 
Swanson, 2003; Vargas and Johnson, 2009). Neurons reportedly utilize cysteine but 
not cystine for GSH synthesis, while glia can utilize both (Kranich et al., 1996; 
Sagara et al., 1993). The cystine/glutamate exchange transporter (xCT) imports 
cystine into the cells in exchange with glutamate (Bannai, 1986) and is localized in 
both neurons and astrocytes of the cerebral cortex (Shih et al., 2006). However, xCT 
expression and activity was shown to be higher in astrocytes compared to neurons 
(Jackman et al., 2012). Immature neurons exclusively uptake cystine via xCT 
(Murphy et al., 1990), whereas mature neurons primarily uptake cysteine via the 
excitatory amino acid transporters (EAATs), also known as cysteine-permeable Na+-
dependent glutamate transporter (XAG), which are widely expressed by neurons in  
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mature brain (Shanker et al., 2001; Chen and Swanson, 2003). In addition to 
supplying cysteine, astrocytes release glutamine, thus providing all the necessary 









Figure 1.3. Detoxification of H2O2 by glutathione peroxidases.  
Glutathione peroxidases (GPx) remove H2O2 by coupling its reduction to H2O with 
the oxidation of two molecules of glutathione (GSH) forming glutathione disulfide 
(GSSG) that subsequently can be reduced by glutathione reductase (GR) under the 

























Figure 1. 4. Glutathione synthesis in neurons and astrocytes.  
Within cells GSH is synthesized in consecutive ATP-requiring reactions of two 
enzymes GCL (1) and GSH synthetase (2). The intracellular substrates for GSH 
synthesis; glutamate, glycine and cysteine, may be derived from the extracellular 
precursors a, b and cystine (or other precursors for review see (Dringen et al, 1999a 
and1999b)) respectively. Astrocytes have more efficient GSH synthesis system and 
higher GSH content in comparison with neurons. MRP1 transporter proteins mediate 
GSH export from astrocytes. In the extracellular space, GSH is hydrolysed by γ- 
glutamyl transpeptidase (3) to the dipeptide Cys-Gly, which then can be further 
hydrolysed to Cys and Gly by aminopeptidase N (4). Astrocytes import cystine via 
the glutamate/cystine exchange transporter (xCT) for utilization in GSH synthesis. 
Neurons, on the other hand, import cysteine but not cystine via the excitatory amino 
acid transporter (EAAT) and other transporters (refer to section 1.4.1). In addition, 
astrocytes release glutamine, which is used by neurons as a precursor for the 
glutamate, therefore providing all the necessary precursors for GSH synthesis in 
neurons. 
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1.4.2. Thioredoxins and peroxiredoxins 
Thioredoxins (Trxs) are key players in protection against oxidative stress and are 
characterized by a conserved active site (Cys-Gly-Pro-Cys), which forms a disulfide 
bond between its two cysteine residues when reducing oxidized proteins (Patenaude 
et al., 2005). This oxidized form is then reversibly reduced to its active form by the 
action of thioredoxin reductase (TrxR) and NADPH (Fig. 1.5) (Holmgren, 1985).  
 
Trxs exist in several distinct isoforms, which are localized in specific cell 
compartments; cytoplasmic Trx1 and mitochondrial Trx2, in addition to the more 
recently identified microtubule-associated Trx (Trx1-2) (Sadek et al., 2003) and a 
transmembrane isoform (Tmx) (Matsuo et al., 2001). The cytoplasmic (Trx1) and 
mitochondrial (Trx2) isoforms are widely expressed in rat brains, especially in 
regions with high-energy demands (Lippoldt et al., 1995; Rybnikova et al., 2000).  
The expression of these isoforms is subject to modulation by changes in the cellular 
and molecular redox-status, and also by various stress factors.  
  
 Trxs are considered to be crucial antioxidant proteins, due to their capacity to 
quench singlet oxygen and scavenge hydroxyl radicals. Inhibition of Trx has been 
shown to sensitize cells to oxidative stress (Yoshida et al., 2005), while Trx 
overexpression renders the cells more resistant to H2O2-induced cell death (Berggren 
et al., 2001; Bell and Hardingham, 2011). Additionally, Trx overexpressing 
transgenic mice can achieve extended life span and are more resistant to focal brain 
ischemia or kainite-mediated excitotoxicity than their wild type littermates 
(Patenaude et al., 2005).  
  
Besides its antioxidant potentials, Trx is involved in various redox-regulated 
signalling events and plays a role in the control of many physiological processes 
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such as apoptosis, cell growth and differentiation. For instance, several transcription 
factors are targets for regulation by Trx these include; AP-1, P53 and nuclear factor 
kappa-B (NFĸB). It is also reported to act as potent survival factor through an 
inhibitory binding to the apoptosis signal-regulating kinase-1 (ASK1) (Nordberg and 
Arner, 2001; Powis and Montfort, 2001). 
 
Despite its capacity to directly quench singlet oxygen and scavenge hydroxyl 
radicals independently of its redox state (Das and Das, 2000), Trx exerts most of its 
antioxidant properties through its cooperation with the peroxide scavengers 
peroxiredoxins (Prx) (Powis and Montfort, 2001).  
 
Peroxiredoxins are a conserved family of proteins, which catalyse the reduction of 
H2O2 and organic peroxides, using thiol-based reducing equivalents, to water and 
alcohol respectively (Chae et al., 1994). The most predominant class of 
peroxiredoxins possesses two cysteine residues within its catalytic site, a peroxidatic 
residue and a resolving one. Upon the reduction of peroxides, the peroxidatic 
cysteine undergoes oxidation followed by the formation of disulfide bond with the 
resolving cysteine, which is then reduced by thioredoxin to restore the active 
peroxidase (Fig. I.5) (Halliwell, 2006; Bell and Hardingham, 2011). The peroxidatic 
and resolving cysteines are on different molecules and so 2-Cys peroxiredoxins exist 
as functional homodimers. However, Prxs are susceptible to inactivation by H2O2- 
induced hyperoxidation, whereby the peroxidatic cysteine is oxidized to sulfinic 
derivatives (Fig. I.5). Sulfinic derivatives are resistant to reduction by thioredoxin, 
therefore hyperoxidation of Prx catalytic cysteine residue to sulfinic acid (Prx-SO2H) 
was thought to be irreversible. Studies on the fate of the hyperoxidized Prx have 
shown that it can be reduced back to its catalytically active form by the action of two 
enzymes sulfiredoxin (Biteau et al., 2003; Chang et al., 2004) and sestrin 2 (Budanov 
et al., 2004) in an ATP-dependent manner (Fig. 1.5), however, the role of the latter is 
controversial (Essler et al., 2009; Wood et al., 2003).  
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Sulfiredoxin (Srxn1) was initially identified by its robust upregulation in response to 
H2O2 and by the reduced H2O2 tolerance when genetically ablated (Biteau et al., 
2003). The Srxn protein family is present in lower and higher eukaryotes, whose 
members sharing a conserved cysteine residue required for the reduction of Prx in 
addition to ATP-hydrolysis, Mg2+ and thiol as a reducing equivalent. Sulfiredoxin 
reduces the overoxidized Prx through catalysing the formation of a sulfinic acid 
phosphoric ester on Prx, which then can be reduced by thioredoxin (Rhee et al., 
2007). Although Srxn prevents bursts of ROS from permanently inactivating Prx, 
Srxn expression, however, is tightly regulated, suggesting that Prx inactivation is 
desired in some circumstances to accommodate for the intracellular messenger 





























Figure 1.5. The thioredoxin-peroxiredoxin system.  
Schematic illustrating the detoxification of H2O2 by the classical 2-Cys 
peroxiredoxins (Prx-SH) by the oxidation of peroxidatic Cys residue to cysteine 
sulfenic acid (Prx-SOH) and the subsequent formation of disulfide bond between the 
peroxidatic and resolving cysteine residues. This intermolecular disulfide bond is in 
turn reduced by thioredoxin resulting in the conversion of thioredoxin’s 2 cysteine 
active site into a disulfide bond. This oxidized form is then reversibly reduced to its 
active form by the action of thioredoxin reductase (TrxR) and NADPH. Under 
increased oxidative stress, Prx-SOH can sometimes undergo further oxidation by 
H2O2 resulting in the generation of the inactive cysteine sulfinic acid (Prx-SO2H) 
form, which cannot be reduced by thioredoxin. However, hyperoxidized 
peroxiredoxin can be restored back to its catalytically active form by the action of 
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1.4.3. Ascorbate 
In addition to GSH, the brain is enriched in several low molecular mass non-
enzymatic antioxidants, especially ascorbate. Ascorbate (vitamin C) is a water-
soluble vitamin, present in human CSF at levels exceeding those in the plasma 
(Spector and Eells, 1984). In the CNS, neurons and glia are able to concentrate 
ascorbate further via the sodium-vitamin C transporter 2  (SVCT2) (Tsukaguchi et 
al., 1999; Rice, 2000). Intracellular ascorbate contributes to numerous functions in 
the CNS, including antioxidant protection, collagen synthesis, formation of myelin 
sheath (Passage et al., 2004), and protection against glutamate toxicity (May, 2012). 
The primary function of the vitamin is scavenging of free radicals to prevent damage 
of macromolecules particularly lipids (Blake et al., 1987). The antioxidant function 
of ascorbate is due to its electron donor properties. Given its low redox potential, 
ascorbate acts as broad-spectrum free radical scavenger (Rice, 2000). Due to its 
antioxidant activity, ascorbate is oxidized to semi-dehydroascorbate and 
dehydroascorbate, which then can be reduced and recycled by GSH-dependent 
reactions (Rose, 1993; Meister, 1994) or NADPH-dependent enzymes including 
thioredoxin reductase (May et al., 1997). GSH can either directly reduce ascorbate or 
act as an electron donor in the enzyme-dependent reduction of ascorbate (May, 
2012). However, at low concentrations and in the presence of metal ions (an event 
which occures during brain damage), ascorbate can be a strong prooxidant, 
stimulating the hydroxyl radical generation and accelerating lipid peroxidation 
(Halliwell and Gutteridge, 1990). However, in vivo studies highlight the importance 
of ascorbate for the CNS and for perinatal survival. For instance, mice lacking 
SVCT2 die within the first day of birth with cerebral haemorrhage and respiratory 
failure (Sotiriou et al., 2002). Moreover, supplements with dehydroascorbate, the 
oxidized and blood-brain barrier transportable form of vitamin C, markedly 
decreased infarct size, mortality and neurological deficits in mouse models of stroke 
(Huang et al., 2001). 
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1.5. The Nrf2/ARE control of antioxidant defences  
Exposure of mammalian cells to elevated levels of ROS, causes damage to 
macromolecules, and consequently leads to various pathological conditions such as 
cancer and neurodegenerative diseases. Higher animals have developed adaptive, 
dynamic defence programs to protect against oxidative stress; central among them 
are the phase II detoxification proteins (involved in the detoxification of xenobiotics) 
and antioxidant enzymes (Ishii et al., 2002). Biochemical analysis of the promoter 
region of phase II genes revealed a central role for the regulatory DNA sequence 
element referred to as the antioxidant response element (ARE) (Rushmore et al., 
1991). Studies conducted in many laboratories strongly suggest the intimate 
involvement of the Nrf2 protein in ARE-driven gene expression (Zhang, 2006; 
Nguyen et al., 2000; Itoh et al., 1997).   
 
1.5.1. The antioxidant response element (ARE) 
The ARE is a cis-acting regulatory element, which was originally identified in the 
promoters of rodent genes coding for two important antioxidant enzymes. Initially it 
was identified within a 41-bp section from the 5′ upstream region of the rat 
glutathione S-transferase A2 subunit (Gsta2) (Rushmore and Pickett, 1990) and 
shortly after it was discovered in the promoter of mouse NADPH: quinone 
oxidoreductase 1 (Nqo1) (Favreau and Pickett, 1991). This enhancer sequence was 
designated the ARE, due to its response to phenolic antioxidants and metabolizable 
planar aromatic compounds such as tert-butylhydroquinone (tBHQ) and β-
naphthoflavone respectively and was later found to respond to reactive oxygen 
species including H2O2 (Rushmore et al., 1991). The ARE consensus sequence, 
determined through deletion and mutational analysis studies is defined as 5′- 
 
	   32	  
gagTcACaGTgAGtCggCAaaatt-3′ (with the essential nucleotides shown in capitals) 
(Nioi et al., 2003).   
Some AREs harbour two or more 12-O-tetradecanoylphorbol-13-acetate (TPA) -
response elements (TRE) within their core sequences that are recognized by 
members of the activator protein-1 (AP-1) family of transcription factors (Xie et al., 
1995; Prestera et al., 1995). The AP-1 transcription factor belongs to the bZip class 
of transcription factor, and is formed by a dimeric association between the Jun and 
Fos family of proteins or other proteins including activation transcription factor- 4 
(ATF4) (Hai and Curran, 1991). Because of the resemblance between the AP-1 
binding sequence and the ARE, AP-1 was initially believed to play a role in the ARE 
activation. However, despite this resemblance, studies have indicated that the 
transcription factors that activate the ARE sequences are quite distinct from those 
that activate the TRE (Nguyen et al., 1994; Lee and Johnson, 2004). More recently, 
data obtained from in vivo and in vitro studies has demonstrated a crucial role for the 
Nrf2 transcription factor in regulating ARE-dependent transcription (Itoh et al., 
1997; Chanas et al., 2002; Lee et al., 2003).  
 
1.5.2. The Nrf2 protein 
Nrf2 was initially identified during attempts to screen for factors that can interact 
with the nuclear factor erythroid-2 (NF-E2), which regulates globin gene expression 
in erythroid cells (Moi et al., 1994). Unlike NF-E2, which is solely expressed in 
developing erythroid cells (Igarashi et al., 1994), Nrf2 is present in a wide number of 
tissues, particularly those that are exposed to the external environment, including 
lung and skin and those involved in the detoxification processes such as kidney and 
liver (Motohashi et al., 2002). Nrf2 belongs to the CNC (“cap and collar”) subset of 
the basic lucine zipper (bZip) family of transcription factors (Moi et al., 1994). This 
family of transcription factors also includes Nrf1and Nrf3.  
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Nrf2, like the rest of the bZip proteins, functions as a heterodimeric transcription 
factor by pairing with other members of the family including small-Mafs (Itoh et al.,  
1997) and AP-1 (Venugopal and Jaiswal, 1998). While, Nrf2 binds the ARE with 
high affinity and specificity upon heterodimerization with small-Maf proteins (Itoh et 
al., 1997), overexpression of Maf proteins, which lack intrinsic transactivation 
activity (Motohashi et al., 2002), serves to suppress Nrf2-mediated ARE activation 
(Nguyen et al., 2000). One plausible explanation for this observation is that Maf 
proteins are capable of binding DNA as homodimers thereby restricting Nrf2 access 
to the ARE promoter (Dhakshinamoorthy and Jaiswal, 2000). 
In addition to small-Mafs, other members of the bZip family have also been reported 
to form heterodimers with Nrf2 serving to modulate its transcriptional activity. Jun 
and Fos have been shown to interact with Nrf2 and differentially regulate the 
transcriptional activity of Nrf2. Co-expression of Nrf2 and Jun was reported to 
activate ARE-mediated transcription in human hepatoma cells (Venugopal and 
Jaiswal, 1998), whereas co-expression of Nrf2 and Fos had the opposite effect on 
ARE activity (Venugopal and Jaiswal, 1996). 
A cross-species comparison of Nrf2 amino acid sequence enabled the identification 
of six well-conserved domains (Itoh et al., 1995), termed Nrf2-ECH homology (Neh) 
domains (Itoh et al., 1997) (Fig. 1.6). The Neh1 (residues 427-560) domain is located 
in the C-terminal half of the protein and contains the conserved CNC and bZip 
motifs responsible for DNA binding and dimerization with small-Maf proteins (Itoh 
et al., 1999a). The Neh2 (residues 1-96) is a redox-sensitive degron located in the 
proximal N terminus and contains the interaction points with the E3 ubiquitin ligase 
adaptor Keap1 (Itoh et al., 1999b). Adjacent to Neh2 are the main transactivation 
domains (TADs); Neh4 (residues 111-141) and Neh5 (residues172-201) (Katoh et 
al., 2001). Within the central part of Nrf2 lies the Neh6 (residues 330-380) degron, 
which is responsible for the interaction with the newly identified E3 ubiquitin ligase 
adaptor β-transducin repeat-containing protein (β-TrCP) (Rada et al., 2011). In 
contrast to the other domains, the Neh3 (residues 561-597) located at the C-terminus  
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of Nrf2, has not been well characterized. However, a study suggests that Neh3 may 





Figure 1. 6. Nrf2 functional domains.  
Schematic representation of the six conserved functional domains in the mouse Nrf2 
protein. Refer to above text for details. 
 
Although growing evidence emphasizes the central role of Nrf2 in the regulation of 
ARE-driven gene expression (Copple et al., 2010). Nrf1 also appears to have an 
overlapping function with Nrf2 in the regulation of ARE. However, Nrf1 is less 
potent than Nrf2 at transactivating ARE-dependent gene expression as demonstrated 
by reporter genes expression driven by ARE-containing sequences from the 
promoters of mouse Nqo1 and Gclm as well as the human PBGD (porphobilinogen 
deaminase), whereby Nrf1 exhibited less transactivation activity in comparison to 
Nrf2 (Zhang et al., 2006). Furthermore, Nrf1- knockout mice embryos die during 
mid gestation as a result of foetal liver abnormalities and subsequent anaemia (Chan 
et al., 1998).  
In contrast to Nrf1 KO mice, Nrf2 is dispensable for normal growth and development 
(Chan et al., 1996), however, Nrf2 KO mice have lower basal and inducible 
expression of phase II enzymes, and display enhanced susceptibility to a variety of 
diseases, including cancer (Fahey et al., 2002), neurodegeneration (Johnson et al., 
2008), and inflammation (Rangasamy et al., 2005). Moreover, aged Nrf2 KO mice 
develop lupus-like autoimmune symptoms (Yoh et al., 2001; Ma et al., 2006) and  
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vacuolar leukoencephalopathy (Hubbs et al., 2007). Contrary to the extensively 
studied homolog Nrf2, our current knowledge on the function and role of Nrf3 in the 
protection against cellular stress is less advanced. Furthermore, Nrf3 null mice 
develop normally and exhibit no obvious phenotype (Derjuga et al., 2004). 
 
1.5.3. Keap1 
 In the cytoplasm, Nrf2 associates with the kelch-like ECH-associated protein 1 
(Keap1) forming a regulatory system, which serves as a sensor of oxidative and 
electrophilic stress and controls the transcriptional activity of Nrf2 (Giudice and 
Montella, 2006) Keap1 is an actin cytoskeleton binding protein homologous to the 
Drosophila Kelch protein.  It consists of three distinctive domains; the BTB domain 
at the N-terminal region involved in the homodimerization of the protein (Zipper and 
Mulcahy, 2002), a cysteine-rich region known as the linker or intervening region 
(IVR) crucial for the activity of Keap1 (Zhang and Hannink, 2003) and a C-terminal 
double glycine (DGR or Kelch) region comprising six conserved Kelch motif repeats 
forming the Nrf2/Keap1 binding site (Fig. 1.7) (Li et al., 2004).  According to 
previous studies, the amino acid sequence of Keap1 is highly conserved among 
human, mouse and rat (Giudice and Montella, 2006). 
Keap1 was initially described as a negative regulator of Nrf2. Under normal 
physiological conditions, Keap1 sequesters Nrf2 in the cytoplasm, preventing it from 
traveling to the nucleus and activating ARE-dependent gene expression. However, 
when cells are exposed to oxidative or electrophilic stimuli Nrf2 evades Keap1-
mediated suppression, translocates to the nucleus, and activates ARE-driven phase II 
detoxifying and antioxidant genes (Zhang, 2006). Studies using functional ARE 
reporter assays, revealed that overexpression of Keap1 in quail fibroblast cells (Itoh 
et al., 1999b), rodent neuronal and glial primary cultures (Soriano et al., 2008a) and 
zebrafish (Kobayashi et al., 2002), reduces Nrf2-mediated transactivation of the 
ARE-reporter gene.   
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Furthermore Keap1 has an inhibitory effect on the Nrf2/ARE signalling pathway not 
only by anchoring Nrf2 in the cytoplasm but also by targeting Nrf2 for ubiquinitation 
and subsequent proteasomal degradation. In unstressed cells, Nrf2 exhibits a short 
half-life of 10-30 mins (Alam et al., 2003; He et al., 2006). The rapid degradation of 
Nrf2 protein under basal conditions has been attributed to constitutive ubiquitin-
proteasomal degradation (Zhang and Hannink, 2003; Cullinan et al., 2004). Keap1 
was shown to mediate Nrf2 ubiquitination and proteosomal degradation, through its 
function as a substrate adaptor for a Cullin-dependent E3 ubiquitin ligase complex 
(Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004; Furukawa and 
Xiong, 2005).  
Several models have been proposed for the Nrf2-Keap1 interaction (Fig. 1.8). The 
widely accepted model was first proposed by Dinkova-Kostova et al., in which 
modifications of specific Keap1 cysteine residues by ARE-inducers lead to the 
liberation of Nrf2 (Dinkova-Kostova et al., 2002). Other studies have proposed Nrf2 
phosphorylation as a mechanism for the release of Nrf2 from Keap1-mediated 
repression (Bloom and Jaiswal, 2003; Huang et al., 2002), however, this model is 
debatable. Accumulating evidence from various laboratories, suggests that ARE 
inducers such as tBHQ don’t evoke complete dissociation of Nrf2 from Keap1. 
Conversely, such molecules may actually increase the association of Nrf2 with 
Keap1, probably via disrupting Keap1-mediated degradation. In support of this, Nrf2 
translocation into the nucleus following the application of Nrf2 inducers such 
diethylmaleate (Itoh et al., 2003) or tBHQ, (Kobayashi et al., 2006) was inhibited by 
cycloheximide. This observation was first documented by Itoh et al. (Itoh et al., 
2003) and later by others (Eggler et al., 2005; Zhang, 2006), forming the initial basis 
for the "hinge and latch" or the two-site substrate recognition model. In this model 
Nrf2 is proposed to interact with the Keap1 homodimer via two distinct sites within 
the Neh2 domain; the low-affinity DLG and the high-affinity ETGE motifs (Tong et 
al., 2007).  Under conditions of oxidative/chemical stress, conformational changes 
occur in the Keap1 IVR domain provoking the loss of the DLG motif binding, whilst 
Nrf2 association with Keap1 is still maintained trough the high- 
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affinity ETGE binding motif. Consequently, Nrf2 is no longer positioned in the 
correct orientation to accept ubiquitin and thus Nrf2 proteasomal degradation is 
ceased. As a result, Keap1 becomes saturated with Nrf2 that cannot be degraded 
efficiently, allowing newly synthesized Nrf2 to translocate into the nucleus and 
activate ARE-dependent transcription (McMahon et al., 2006). Of note, a very recent 
study provided evidence suggesting that inhibition of Nrf2 ubiquitination by 
prototypical Nrf2 inducers (sulforaphane and 5,6-dihydrocyclopenta-1,2-dithiole-3-
thione (CPDT)) doesn’t result from Nrf2 release from Keap1, as Nrf2-Keap1 
complex were detected in both the nucleus and  cytoplasm following drug 
application (Li et al., 2012). Finally, an alternative model proposes Cul3 dissociation 
from Keap1 as a mechanism of Nrf2 activation (Rachakonda et al., 2008).  
Additionally, the Cuadrado group recently reported a Keap1- independent Nrf2 
degradation mechanism, in which phosphorylation of the Neh6 domain of Nrf2 by 
glycogen synthase kinase (GSK), leads to ubiquitination via a β-TrCP /Cul1 E3 
ligase complex (Rada et al., 2011). 
In addition to Keap1, other proteins have been implicated in the control of Nrf2 
activity. Wang and Zhang recently reported a novel Nrf2- repressor termed the 
ectodermal neural cortex-1 (ENC1), which belongs to the same family as Keap1 and 
decreases the rate of Nrf2 synthesis (Wang and Zhang, 2009).  Another group 
described the involvement of cancer and Parkinson’s disease associated protein 
DJ1/PARK7 in stabilizing Nrf2 protein thereby conveying protection against 
stressors (Clements et al., 2006). More recently Maruyama et al. has identified 
[KRAB (Krüppel-associated box)-associated protein 1] KAP1 as a novel Nrf2-NT-









Figure 1. 7. Keap1 functional domains.  
Schematic representation of the three major functional domains in the mouse Keap1 










Figure  1. 8. Proposed models of Nrf2 activation.  
Under basal homeostatic conditions, Keap1 anchors Nrf2 in the cytoplasm via two 
binding sites in the Neh2 domain, the high affinity ETGE motif and the low affinity 
DLG motif, and functions as an adaptor protein for the Cul3-based E3 ligase system, 
facilitating the rapid ubiquitination and proteasomal degradation of Nrf2. Two main 
models of Nrf2 activation (in response to oxidative stress or Nrf2 inducers) have 
been proposed; the hinge and latch and the Nrf2 liberation model. In the hinge and 
latch model, oxidative stress or Nrf2 inducers cause conformational changes within 
Keap1 resulting in the detachment of the weakly binding DLG motif (latch) from 
Keap1, whilst the high-affinity ETGE (hinge) is maintained. Consequently, Nrf2 
ubiquitination and the subsequent proteasomal degradation are abolished. Newly 
synthesized Nrf2 translocates into the nucleus, where it transactivates ARE-driven 
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phase II genes. In the liberation model, oxidative stress/Nrf2 activators induce 
chemical modifications in either Keap1 or Nrf2 or both, resulting in the release of 
Nrf2 from the Keap1/Cul3 complex.   
 
1.6. Nrf2 and neurodegeneration 
A growing body of evidence demonstrates the neuroprotective ability of Nrf2 and its 
downstream genes against a variety of insults in both cell culture and animal models 
of neurodegeneration. The presence of Nrf2 has been shown to contribute to 
neuroprotection, or conversely, to increase sensitivity when Nrf2 is lacking. The 
activation of the Nrf2 pathway has been shown to increase neuronal resistance to 
oxidative insults triggered by H2O2 (Li et al., 2002) and glutamate (Murphy et al., 
1991) in neuronal cell lines, as well as in primary cortical cultures (Kraft et al., 
2004).  
 
In recent years, a great deal of research has been focused on understanding the status 
of the Nrf2-ARE pathway in different models of neurodegenerative diseases. Nrf2 
status was mainly inferred from the subcellular distribution of Nrf2 and the 
expression level of ARE-driven genes.  
  
Studies performed on in vitro models of amyotrophic lateral sclerosis (ALS), 
revealed a reduction of Nrf2 mRNA and protein expression in the primary motor 
cortex and in the spinal cord neurons derived from ALS postmortem tissues (Sarlette 
et al., 2008). A similar decrease in mRNA encoding Nrf2 was observed in embryonic 
motor neurons isolated from rat models of ALS (Pehar et al., 2007). On the contrary, 
laser–capture microdissected motor neurons from mouse models of ALS show no 
change in Nrf2 expression or in ARE-driven genes (Ferraiuolo et al., 2007). Despite 
these apparent discrepancies, changes in the expression levels of Nrf2 and its target 
gene heme oxygenase-1 (Hmox1) (Alam et al., 2003) were reported in SOD1 G93A 
mouse model of ALS (Vargas et al., 2005). Hmox1 is an oxidative stress inducible 
cytoprotective enzyme that catalyses the conversion of haem to bilirubin, CO and 
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free iron (Ryter and Choi, 2002). Elevated Hmox1 expression has been reported in 
neurodegenerative diseases including ALS. Increased Nrf2 and Hmox1 expression 
was found in the spinal cord of early- stage symptomatic SOD1 G93A rats, which 
may represent an endogenous neuroprotective response in early stages of the disease 
that could be overwhelmed with the disease progression by other mechanism(s) 
leading to neuronal loss (Vargas et al., 2005). Moreover, pharmacological or genetic 
activation of Nrf2 rescues motor neurons from toxicity mediated by astrocytes 
expressing mutated human SOD1 in vitro and delays onset and increases life span in 
ALS mouse models when over expressed under the control of an astrocyte specific 
promoter (Nagai et al., 2007; Vargas et al., 2006; Vargas et al., 2008). This was one 
of the earliest in vivo studies to demonstrate the beneficial effect of Nrf2 activation in 
astrocytes on neighbouring neurons in chronic neurodegenerative conditions. 
 
In the case of PD, postmortem PD brain tissue analysis revealed an increase in 
HMOX-1 (Schipper, 2004) and NQO1 expression (van Muiswinkel et al., 2004) in 
glial cells and induced nuclear localization of Nrf2 in the substantia nigra, however, 
this response appears to be insufficient to confer neuroprotection against 
degeneration (Ramsey et al., 2007). In vitro Nrf2 activation has been shown to limit 
the extent of neurotoxicity resultant from the exposure to dopamine analogue 6-
hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
(Yamamoto et al., 2007; Jakel et al., 2007; Wruck et al., 2007). In addition Nrf2 KO 
mice display increased MPTP sensitivity, whereas astrocyte-specific Nrf2 
overexpression in a Nrf2-KO background completely reverses MPTP toxicity (Chen 
et al., 2009). Furthermore, activation of Nrf2 in vitro by tBHQ or in vivo via Nrf2-
overexpressing astrocyte grafts, resulted in protection against 6-hydroxydopamine 
(Jakel et al., 2007). 
 
Similar to PD, data obtained from immunohistochemistry experiments performed in 
post-mortem temporal cortex and hippocampus of AD patients showed a significant 
increase in astrocytic HMOX-1 expression compared to the non-demented group 
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(Schipper et al., 2006). In addition to HMOX-1, NQO1 expression and activity was 
reported to be elevated both in neurons and astrocytes from individuals with AD 
(Raina et al., 1999; Wang et al., 2000; Santa-Cruz et al., 2004). In contrast to the 
nuclear localization of Nrf2 in substantia nigra neurons from PD cases, Nrf2 staining 
in hippocampal neurons of AD cases was predominantly cytoplasmic. The aberrant 
distribution of Nrf2 in AD could be due to differential regulation of Nrf2 localization 
in various neuronal subpopulations (Ramsey et al., 2007). Moreover, the expression 
of Nrf2 and its target genes including Nqo1 was reduced in mouse models of AD 
(APP/PS1) upon accumulation of Aβ deposits. However, Nrf2 induction either by 
tBHQ or through adenovirus-mediated overexpression protected cultured neurons 
from Aβ toxicity (Kanninen et al., 2008). 
 
The status of the Nrf2-ARE pathway is less clear in Huntington’s disease (HD). 
However, Nrf2 activation was shown to protect neurons against mitochondrial toxins 
(e.g. 3-nitropropionic acid (3-NP) and malonate), which produce striatal 
degeneration similar to that observed in HD. Nrf2 deficiency in primary neurons 
potentiated 3-NP toxicity and rendered mice more vulnerable to striatal lesions 
caused by administration of 3-NP or malonate (Calkins et al., 2005; Calkins et al., 
2009). Dietary administration of tBHQ or adenoviral overexpression of Nrf2 
attenuated 3-NP-induced striatal lesioning (Shih et al., 2005). In addition, Nrf2-
overexpressing astrocytes grafted into the striatum provided remarkable protection to 
the surrounding neurons against malonate toxicity (Calkins et al., 2009).  
 
Besides its beneficial role in neurodegenerative diseases, Nrf2 activation was 
reported to protect in acute neurodegenerative scenarios such as ischemia and 
intracerebral haemorrhage. Work from the Murphy laboratory has demonstrated the 
neuroprotective effect of Nrf2 activation in ischemic injury, whereby intracerebral or 
intraperitoneal tBHQ administration, significantly reduced cortical damage and 
sensorimotor deficit at 24 h and up to 1 month after ischemic-reperfusion in rats. In 
contrast, loss of Nrf2 function exacerbated cortical damage after permanent ischemia 
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and abolished the protective effect of tBHQ (Shih et al., 2005). In line with this, 
systemic administration of the Nrf2 inducer sulforaphane has been shown to decrease 
cerebral infarct volume following focal ischemia (Zhao et al., 2006) and 
sulforaphane treatments significantly reduced neurologic deficit produced by 
intracerebral haemorrhage in Nrf2 WT not KO mice (Zhao et al., 2007).  
 
1.7. The locus of Nrf2 activation in the CNS 
The locus of Nrf2 activation in brain tissues is a controversial aspect of the Nrf2 
pathway. A large number of studies have shown that activation of the Nrf2 pathway 
preferentially occurs in astrocytes not neurons.  For instance, in rodent primary 
cerebellar neuronal cultures, basal transcriptional levels and enzymatic activity of the 
ARE-driven antioxidant enzymes NAD(P)H:quinone oxidoreductase (QR) and 
glutathione-S-transferases (GSTs), are remarkably greater in astrocytes than in 
neurons. Moreover, inducibility following the application of tBHQ or hydroquinone 
was only visible in astrocytes (Ahlgren-Beckendorf et al., 1999). Analysis of the 
ARE-driven gene expression in rat brain slices and primary cortical cultures, using a 
heat-stable human placental alkaline phosphatase reporter (hPAP), revealed that 
ARE-mediated gene expression was almost exclusive to the astrocyte subpopulation 
(Murphy et al., 2001). In line with this, a study using primary cortical cultures 
derived from hPAP-ARE transgenic mice reported that the increase in hPAP activity 
post-tBHQ or sulforaphane application was predominantly associated with GFAP-
positive astrocytes as seen by immunofluorescence staining using an antibody 
against hPAP in conjunction with anti-GFAP. They also combined the use of cell 
sorting and gene chip technology in an effort to determine the cell-specific 
contribution to tBHQ-mediated ARE activation and found that the majority of the 
ARE-driven genes up-regulated by tBHQ were observed in astrocyte enriched 
populations (Kraft et al., 2004). 
 
 On the contrary, some studies have documented a functional Nrf2 pathway in 
neurons. Johnson et al. reported an increased histochemical staining for hPAP and 
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NQO1 activity after tBHQ treatment in both glia and neurons in primary cortical 
neuronal cultures derived from transgenic reporter mice for ARE core sequence 
coupled to hPAP (Johnson et al., 2002). They also showed in a separate study, 
cellular staining of ARE-hPAP in motor neuron cell bodies and astrocyte processes 
of 90 day old mice expressing mutant SOD1 (Kraft et al., 2007). In line with this 
notion, a more recent study suggesting that Nrf2 plays a role in the transcriptional 
regulation of excitatory amino acid transporter 3 (EAAT3) in the context of oxidative 
stress, has shown increased EAAT3 expression and GSH levels in neurons of mice 
that have received striatal injections of either tBHQ or in neurons overexpressing 
Nrf2 under a neuron-specific promoter (Escartin et al., 2011). In addition, treatment 
with sulforaphane was shown to activate the ARE/Nrf2 pathway in hippocampal 
neurons conferring protection against oxygen glucose deprivation (OGD)-induced 
cell death via Nrf2-dependent gene expression (Soane et al., 2010). 
 
 
1.8. The role of astrocytes in neurodegenerative diseases 
Decades of neuropathological studies have been neuron-centric in addressing the 
causes of these disorders, but there is growing evidence pointing towards the 
important role of astrocytes in determining neuronal survival and demise. Until 
recently, the general thinking has been that the main function of astrocytes along 
with other cells of glial lineage is to hold neurons together. However, it is becoming 
clear that astrocytes serve many housekeeping functions, including amino acid 
metabolism, nutrient transport, ion homeostasis and modulation of excitatory 
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Studies performed on human tissue and transgenic models of ALS have provided 
evidence that astrocytic abnormalities and dysfunction precede clinical disease. For 
instance, markers of astrocytosis were detected months prior to the clinical onset in 
the spinal cord of G85R SOD1 mice (Bruijn et al., 1997). Similarly, Howland and 
co-workers reported loss of glutamate transporter EAAT2 (GLT-1) with concomitant 
astrocytosis proceeding motor neuron degeneration and the clinical onset of the 
disease (Howland et al., 2002). However, EAAT2 overexpression in astrocytes of 
mutant SOD1 mouse model increased motor neuron survival and delayed disease 
onset, which indicate that astrocytic EAAT2 influences the timing of disease onset 
and motor neuron survival (Howland et al., 2002; Guo et al., 2003). Mutant SOD1 
expression in neurons or motor neurons was insufficient to lead to neuronal death 
except when neurons were surrounded by mutant SOD1 expressing astrocytes 
(Clement et al., 2003). 
 
 
The association of reactive astrocytes with neuritic plaques was first observed by 
Alois Alzheimer and has been subsequently confirmed to be a morphological 
characteristic of plaque-infested AD (Wisniewski and Wegiel, 1991). While 
activated astrocytes may mediate the cytotoxic effects of Aβ by releasing 
interleukins, cytokines and nitric oxide among other potentially cytotoxic molecules 
(Gitter et al., 1995; Griffin et al., 1998; Hu et al., 1998; Wallace et al., 1997), 
accumulating evidence demonstrates the involvement of astrocytes in the clearance 
of Aβ (DeWitt et al., 1998; Koistinaho et al., 2004; Matsunaga et al., 2003). 
However, Aβ internalization appears to induce detrimental changes in astrocytes 
including oxidative stress, mitochondrial dysfunction, accumulation of intracellular 
calcium and depletion of glutathione (Abramov et al., 2003; Abramov et al., 2004). 
 
Astrocytes have a dual role in PD, as they can be injurious or protective depending 
on the context. They can confer neuroprotection to dopaminergic neurons either 
through the clearance of extracellular α-synuclein or through the release of 
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antioxidants and trophic factors. α-synuclein is a small protein abundantly available 
in the presynaptic terminals, which has the tendency to form insoluble neurotoxic 
aggregates under various pathological conditions (Rappold and Tieu, 2010). Under 
pathological conditions, astrocytes appear to induce neurodegeneration by releasing 
cytotoxic molecules including the active toxic cation MPP+, a product of MPTP 
metabolism by MAO-B, which is readily taken up by neighbouring dopaminergic 
neurons and terminals where it induces neurotoxicity. In addition, proinflammatory 
cytokines are also released from astrocytes as a result of α-synuclein accumulation in 
astrocytes beyond their degradation capacity (Rappold and Tieu, 2010). 
 
1.9. The NMDAR control of pro-death and pro-survival pathways 
1.9.1. NMDA receptors in the CNS 
NMDARs are cation channels gated by glutamate, the predominant excitatory 
neurotransmitter in the CNS, and  are permeable to Na+, K+ and Ca2+ ions. They play 
a key role in synaptic transmission and in mediating synaptic plasticity , learning and 
memory. Besides NMDARs, α-amino-3-hydroxy 5-methyl 4-isoxazolepropionic acid 
receptors (AMPARs) and Kainate receptors are also glutamate gated ion channels 
that act in concert with NMDARs to mediate glutamatergic neurotransmission. 
However, most of the neurochemical foundations of perception, learning and 
memory are set by synaptic activity via the NMDARs (Bliss and Collingridge, 1993; 
Aamodt and Constantine-Paton, 1999). NMDARs are also present on 
oligodendrocytes (Karadottir et al., 2005) and astrocytes (Schipke et al., 2001), as 
well as non-neural cells such as osteoclasts (Szczesniak et al., 2005) and 
lymphocytes (Tuneva et al., 2003), however,  NMDARs function in these types of 
cells is not well-defined. 
 
The majority of mammalian NMDARs in the CNS occur as hetero-tetramers and are 
typically comprised of a pair of glycine-binding GluN1 subunits and another pair of 
glutamate-binding GluN2 subunit.  Four types of GluN2 subunits (GluN2A-D) in 
	   46	  
addition to 2 types of GluN3 subunits (GluN3A and GluN3B) provide NMDARs 
variety (Kohr, 2006).  Studies of NMDAR subunit expression in the developing rat 
CNS revealed that GluN2B and GluN2D subunits occur prenatally, whereas GluN2A 
and GluN2C start to appear near birth. GluN1 however, is ubiquitously expressed 
throughout development and in the adult brain (Monyer et al., 1994).  
The NMDAR receptor display several characteristic features that distinguish it from 
other types of glutamate receptors, those include; relatively high permeability to Ca2+ 
compared to AMPAR and Kainate receptors, voltage dependent block by 
extracellular Mg2+ and modulation by glycine (Masu et al., 1993; Cull-Candy et al., 
2001). Normally, at negative resting membrane potential, the NMDAR pore is 
directly blocked by Mg2+   ions preventing other ions (Ca2+, Na+ and K+) from passing 
through freely. This block is lifted following membrane depolarization, which occurs 
when presynaptic glutamate release causes Na+  influx through AMPAR in the 
postsynaptic cell. Thus, allowing the NMDARs to function as “coincidence 
detectors”, whereby glutamate release must synchronize with membrane 
depolarization before the channel will pass current. 
Ca2+  entry through the NMDARs can lead to a range of alterations in neuronal 
function through  regulation of channel oppening, neurotransmitter release and also 
by influencing gene expression (Burgoyne, 2007). Excessive Ca2+   influx  can trigger 
cell death. The differing outcomes of NMDAR-mediated Ca2+   influx are  dependent 
on the magnitude of the stimulus, be it intensity or duration, and the location of the 
receptors (synaptic vs. extrasynaptic) (Soriano and Hardingham, 2007). 
At the synapse NMDAR are organized in multiprotein signalling complexes 
embedded within a dense protein matrix forming a distinct specialization known as 
the postsynaptic density (PSD) (Sheng, 2001). NMDARs are anchored in the PSD 
through interaction between cytoplasmic C-termini of GluN2 subunits, and the PDZ  
 
domains of PSD-95 (Collins et al., 2006). PSD-95, is a prominent organizing protein 
in the PSD and a member of the membrane-associated guanylate kinase (MAGUK) 
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superfamily of proteins, which couples NMDARs to intracellular proteins and 
signaling enzymes such as nitric oxide synthase (nNOS), protein phosphatase 2b 
(calcineurin) and calmodulin dependent protein kinase II (CamKII) (Waxman and 
Lynch, 2005). As such, PSD facilitates NMDAR activation and the subsequent signal 
transduction. 
 
1.9.2. Death and survival signalling from the NMDAR 
Excessive NMDAR activity can contribute to neuronal loss in acute events such as 
traumatic brain injury and seizure, as well as certain chronic neurodegenerative 
diseases such as AD. However, physiological levels of synaptic NMDAR activation 
can promote neuroprotection (Papadia and Hardingham, 2007).  Thus, responses to 
NMDAR activity follow a bell shaped curve: both excessive and poor activity can be 
harmful (Lipton and Nakanishi, 1999). Moreover, the nature of response to an 
episode of NMDAR activity is influenced by the stimulus intensity, NMDAR 
location and subunit composition (Martel et al., 2012). Recent studies show that 
stimulation of synaptic NMDAR can promote neuroprotection, whereas activation of 
extrasynaptic NMDAR promotes cell death (Hardingham and Bading, 2010). 
 
1.9.2.1. Pro-survival signalling from the NMDAR 
Neuronal health is more complex than that offered by the dichotomous description of 
neurons as either dead or alive. According to the dynamic equilibrium theory for 
neuronal health, neurons exist in a spectrum of states ranging between protected and 
fully functional to vulnerable and dysfunctional. A neuron’s status within this 
spectrum is constantly influenced by internal and external stimuli (Isacson, 1993),  
 
 
but is known to be shifted towards health and robustness by NMDAR-mediated 
synaptic activity (Papadia and Hardingham, 2007).  
	   48	  
 
The notion that activity can be survival promoting stemmed from previous studies in 
which activity blockade caused death in the disconnected neurons (Mennerick and 
Zorumski, 2000). Analysis of brain sections from rat pups treated with NMDAR 
antagonist (MK-801) during the first postnatal week, displayed increased 
morphological changes associated with cell death within the dentate gyrus (Gould et 
al., 1994). In the developing brain, elimination of NMDAR activity triggers 
widespread apoptotic neurodegeneration in the rat forebrain (Ikonomidou et al., 
1999), increases the rate of apoptotic elimination of granule neurons (Monti and 
Contestabile, 2000), causes a large increase in cell death in the somatosensory 
thalamus (Adams et al., 2004) and also enhances trauma-induced injury (Pohl et al., 
1999). In addition, NMDAR blockade exacerbates neuronal loss in mature brain 
already undergoing neurodegeneration or subjected to traumatic injury (Ikonomidou 
et al., 2000), and prevents the survival of newly generated neurons in the adult 
dentate gyrus (Tashiro et al., 2006). 
 
The activity-dependent neuroprotection has been recapitulated in vitro in neuronal 
cultures where enhanced synaptic NMDAR activity has been shown to render 
neurons more resistant to various death-inducing stimulus including trophic 
deprivation, retinoic acid (Papadia et al., 2005) and H2O2 (Papadia et al., 2008). Also, 
in mouse cortical cultures, the protective effect of oxygen glucose deprivation 
(OGD) preconditioning, in which transient exposure to non-lethal episode of OGD 
increases tolerance to a subsequent more lethal episode of OGD, was shown to be 
sensitive to NMDAR antagonists (Grabb and Choi, 1999). The protective role of 
endogenous NMDAR activity in injured brain is one of the contributing factors to the 
failure of clinical trials for stroke utilizing NMDAR antagonists (Ikonomidou and 
Turski, 2002). 
	   49	  
 
1.9.2.1.1. Anti-apoptotic effect of synaptic NMDAR signalling 
Physiological levels of synaptic NMDAR activation maintain neuronal health, 
longevity and boosts endogenous antioxidant defences (Papadia et al., 2008). 
Synaptic NMDAR activity confers neuroprotection via triggering posttranslational 
modification of existing proteins or changes in gene expression. The PI3K/Akt 
pathway is a key signalling pathway through which synaptic NMDAR activity exerts 
a neuroprotective effect. PI3K/Akt activity causes inhibitory phosphorylation of the 
pro-apoptotic Bcl-2 family member BAD (Brunet et al., 2001), as well as glycogen 
synthase kinase-3 beta (GSK3β); a kinase closely involved in neuronal apoptosis 
(Hetman et al., 2000) and implicated in various neurodegenerative diseases (Kaytor 
and Orr, 2002). In addition, Akt controls the activity of two pro-death transcription 
factors; p53 and FOXO.  P53 has the ability to induce the transcription of various 
pro-death genes, including those encoding Bax, Noxa and Puma (Amaral et al., 
2010). Activated Akt was shown to promote survival in hippocampal neurons by 
inhibiting the activity of p53 (Yamaguchi et al., 2001).  The underlying mechanism, 
however, doesn’t appear to involve direct phosphorylation of p53 by Akt, but rather 
the phosphorylation /activation of the p53 negative regulator Mdm2 (murine double 
minute-2) by Akt (Ogawara et al., 2002). On the other hand, Akt directly 
phosphorylates Foxos, triggering their nuclear export and inhibiting their ability to 
induce the expression of pro-death genes (Leveille et al., 2010). Finally, stimulation 
of synaptic NMDAR activity promotes the nuclear exclusion of both Foxo and 
GSK3β in a PI3K-dependent fashion (Soriano et al., 2006).  
 
Besides pro-death gene suppression, synaptic activity also promotes neuroprotection 
by inducing the expression of survival genes. One important mediator of activity-
dependent gene expression is the transcription factor cyclic-AMP response element 
binding protein (CREB), which binds to the cAMP response element and 
transactivates a number of pro-survival genes. CREB has a well-documented role in 
neurosurvival. For instance, CREB-dependent gene expression was found to be 
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required for the long-lasting activity-dependent neuroprotection against apoptotic 
(Papadia et al., 2005) and excitotoxic insults (Lee et al., 2005). More recently, 
studies by Zhang et al. identified a nuclear calcium-regulated genomic program that 
contribute to synaptic NMDAR-mediated acquired neuroprotection. This program 
consists of about dozen genes, termed activity-regulated inhibitors of death (AID), 
which have been shown to confer neuroprotection both in cell culture and in animal 
models of neurodegeneration (Zhang et al., 2009). Some of these genes, which 
include B-cell translocation gene 2 (Btg2) and B-cell lymphoma 6 (Bcl6), appear to 
be CREB targets and may provide neuroprotection through enhancing mitochondrial 
resistance to cellular stress or toxic insults. Brain derived neurotrophic factor 
(BDNF), which has a well-characterized neuroprotective effect, is another target for 
























Figure 1.9. Anti-apoptotic effect of synaptic NMDAR activity.  
Synaptic NMDAR signalling supresses the intrinsic apoptosis cascade at multiple 
levels. PI3K/Akt pathway is a key signalling pathway through which synaptic 
NMDAR activity inactivates pro-death transcription factors such as Foxos and p53 
and results in the subsequent suppression of their target genes expression. Activation 
of PI3K/Akt also leads to the inhibitory phosphorylation of Bad and GSK3β. 
Synaptic activity also supresses the extrinsic pathway via the downregulation of 
Foxo-mediated FasL expression. In addition, synaptic activity induces the expression 
of pro-survival genes (as shown) via a number of transcription factors including 
CREB (for review see (Hardingham and Bading, 2010).  
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1.9.2.1.2. Antioxidant effect of synaptic NMDAR signalling 
 In addition to their well-established anti-apoptotic effects, physiological patterns of 
synaptic NMDAR activity can also confer protection against oxidative insults by 
enhancing neuronal intrinsic antioxidant defences. In an early study conducted in our 
laboratory, we showed that complete NMDAR blockade increases neuronal 
sensitivity to H2O2-indcued cell death, while enhancing synaptic activity protects 
against it (Papadia et al., 2008). Moreover, suppression of physiological NMDAR 
activity promotes neuronal apoptosis associated with oxidative damage in P6 mice 
cortex (Papadia et al., 2008). Investigation into the molecular basis for this protection 
revealed a mechanism that at least in part, involves changes within the thioredoxin-
peroxiredoxin antioxidant system. Synaptic activity prevented the oxidative insult-
induced overoxidation of Prx (an antioxidant enzyme described earlier in section 
1.4.2) by enhancing the expression of the two genes, Srxn1 and Sesn2, who’s 
products are involved in resorting the hyperoxidized Prx to its active form (Papadia 
et al., 2008). The activity-dependent up-regulation of Srxn1 was mediated mainly by 
two AP-1 sites (Papadia et al., 2008; Soriano et al., 2008). Interestingly, synaptic 
activity not only boosts the expression of these genes but also suppresses the 
expression of the thioredoxin inhibitor Txnip, a Foxo target gene, through promoting 
the nuclear export of Foxo1 in a PI3K-dependent manner (Soriano et al., 2006; 
Papadia et al., 2008). However, whether synaptic activity induces long-term changes 
to Foxo1 activity beyond its acute nuclear exclusion is unknown and is investigated 
in this thesis.  
 
As well as boosting the antioxidant defences centred on the thioredoxin-
peroxiredoxin system, synaptic activity also enhances the activity of the 
transcriptional co-activator peroxisome proliferator-activated receptor-γ coactivator 
1α (PGC-1 α), which has been implicated in many cellular processes including 
energy homeostasis, β-oxidation of fatty acids, as well as glucose and ROS 
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metabolism (St-Pierre et al., 2006). PGC-1α supresses ROS via mediating the 
induction of ROS-detoxifying enzymes such as SOD1, SOD2, catalase and GPx1 in 
response to oxidative stress (St.-Pierre et al., 2006). PGC-1α overexpression protects 
neurons from excitotoxic and oxidative stress in a cell autonomous manner, while 
knockdown rendered the neurons more vulnerable to insults. The mechanism by 
which synaptic activity enhances PGC-1α activity, involves triggering the nuclear 
export of the transcriptional co-repressor silencing mediator of retinoic acid and 
thyroid hormone receptors (SMRT), which specifically antagonizes PGC-1 α-
mediated antioxidant responses. Furthermore, synaptic activity boosts PGC-1 α 
transcription in vitro and in vivo and enhances its transcriptional activity in vitro 
(Soriano et al., 2010). Interestingly, PGC-1 α under expression has been associated 
with disease progression in models of HD (Cui et al., 2006; Weydt et al., 2006; 
Soriano et al., 2011), PD (Shin et al., 2011) and AD (Qin et al., 2009), however, 


















Figure 1.10. Antioxidant effect of synaptic NMDAR activity.  
Schematic representation showing the antioxidant effect of synaptic NMDAR 
activity.  Synaptic activity enhances the thioredoxin-peroxiredoxin pathway via 
Txnip suppression and the upregulation of Srxn1 and Sesn2. Synaptic activity also 
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1.9.2.2. NMDAR-mediated cell death 
Excitotoxicity is a pathological process in which excessive activation of glutamate 
receptors (particularly NMDARs) results in neuronal death. Excitotoxicity is a major 
cause of neuronal death following acute insults such as hypoxia, ischemia and 
trauma. It is also implicated in the etiology of a number of chronic neurodegenerative 
diseases including AD, PD and ALS (Papadia and Hardingham, 2007). The build up 
of extracellular glutamate during pathological scenarios such as ischemia (Rossi et 
al., 2000; Camacho and Massieu, 2006) induces excessive activation of NMDAR, 
which results in Ca+2-dependent cell death (Arundine and Tymianski, 2004). Strong 
Ca+2 influx through the NMDAR triggers cell death via diverse mechanisms. In 
severe excitotoxicity, simple overload of Ca+2  may mediate fast necrotic cell death. 
However, in many cases, active mechanisms could be involved such as 
mitochondrial dysfunction.  
Excessive uptake of Ca+2  by the mitochondria through the potential-driven uniporter 
causes membrane depolarization and the subsequent reversal of mitochondrial 
ATPase. The reversal of mitochondrial ATPase inhibits ATP production and can 
even cause depletion of cytosolic ATP. This loss of ATP further limits the neuron’s 
ability to maintain ion homeostasis and eventually leads to cell’s demise (Papadia 
and Hardingham, 2007). Furthermore, Ca+2 uptake can trigger apoptosis through the 
release of cytochrome c.  
While it had been generally accepted that Ca+2 influx promotes the generation of 
ROS (Nicholls, 2004), recent studies have made the case that ROS production 
following severe excitotoxic episodes is non-mitochondrial in origin (Nicholls, 
2008). However, this does not rule out a role for oxidative stress in mediating 
NMDAR-dependent cell death, as a recent  study demonstrated that activation of 
NADPH oxidase is the primary source of ROS generation by excessive NMDAR 
activation and therefore blocking this event was neuroprotective (Brennan et al., 
2009). 
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In addition to impairing the mitochondrial function, NMDAR over-activation 
perturbs Ca+2  efflux. In neurons, the plasma membrane Ca+2  ATPase pump (PMCA) 
and the plasma membrane Na+/ Ca+2  exchangers (NCXs) are the two routes through 
which Ca+2 can exit the cell. Excessive NMDAR-mediated Ca+2 influx activates 
calpains, Ca+2-dependent proteases, which cleave a major isoform of the plasma 
membrane Na+/ Ca+2  exchanger (NCX3), impairing its function in cerebellar granule 
neurons (Bano et al., 2005). Moreover, excitotoxic insults suppress PMCA activity 
via mechanisms attributed to both calpains (Pottorf et al., 2006) and caspases 
(Schwab et al., 2002). Striatal enriched tyrosine phosphatase (STEP), is another 
important substrate for NMDAR-mediated calpain cleavage. STEP cleaved from is 
unable to interact with its normal substrates such as p38 mitogen-activated protein 
(MAP). MAP kinase, which is known to contribute to neuronal death in response to 
chronic NMDA or glutamate exposure, is negatively regulated by STEP and 
therefore inhibition of calpain-mediated STEP cleavage is neuroprotective 
(Hardingham and Bading, 2010). 
 
Furthermore, NMDAR-dependent Ca+2   influx stimulates neuronal nitric oxide 
synthase (nNOS) activity, which triggers toxic down stream responses, including 
mitochondrial dysfunction, p38 mitogen activated protein-kinase signalling, and 
activation of the transient receptor potential melastatin (TRPM) channel (Papadia 
and Hardingham, 2007). nNOS is coupled to NMDAR receptors via the post-
synaptic density protein PSD95 and in an excitotoxic context produces nitric oxide 
(NO), which in excess can be toxic both on its own or when it interacts with other 
ROSs such as superoxide resulting in the formation of peroxynitrite (ONOO —) 
(Hardingham, 2009). NO/ONOO— has been shown to cause damage to cellular 
components, inhibit mitochondrial respiratory chain enzymes and promote 
depolarization. In addition, both NO and ONOO— can damage DNA, leading to 
overactivation of  the DNA repair enzyme, poly (ADP ribose) polymerase 1 (PARP-
1). In the CNS, PARP-1 overactivation can promote neuronal death through 
mechanisms involving the depletion of cellular NAD(+) levels and the mitochondrial 
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release of the apoptosis activating factor (AIF) (Kauppinen and Swanson, 2007; 
Andrabi et al., 2008). Moreover, ONOO — activates the cation channel TRPM7, 
which itself passes Ca2+, resulting in a positive feedback loop on nitric oxide activity 
(Aarts et al., 2003).  
 
Activation of the stress-activated protein kinases (SAPKs) such as p38 and c-Jun N-
terminal kinases (JNKs) represents another mechanism for NMDAR-dependent cell 
death. For instance, the activation of p38 leads to caspase-independent cell death in 
both cerebellar granule and cortical neurons (Kawasaki et al., 1997; Cao et al., 2004; 
Soriano et al., 2008b).  JNK activation has been shown to contribute to NMDAR-
dependent cell death in cortical neurons, both in vivo and in vitro (Borsello et al., 
2003). In addition to its role in excitotoxicity, p38 was reported to promote 
neuroprotection through the activation of myocyte enhancer factor 2 (MEF2) 
(Okamoto et al., 2000) and to be activated by neuroprotective synaptic NMDAR 
activity (Soriano et al., 2008b; Soriano et al., 2010) Further studies have revealed 
new components of the excitotoxic cell-death pathway such as Rho, a member of the 
Rho-family of GTPases, which was associated with glutamate-induced p38α- 
dependent excitotoxic neuronal death (Semenova et al., 2007).  
 
Besides the stimulation of SAPKs, Foxo activation has been implicated in NMDAR-
dependent cell death. Unlike synaptic NMDAR activity, which inactivates pro-
apoptotic Foxo, extrasynaptic NMDAR-evoked signals fail to trigger Foxo nuclear 
export and instead increase Foxo nuclear localization, which subsequently 























Figure 1.11. Pro-death signalling from NMDARs.  
Excessive activation of NMDAR results in Ca+2-dependent cell death via various 
mechanisms including the activation of Foxos, calpains, nNOS, JNK, as well as 
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1.10. Aims  
In previous studies, Nrf2 activation was achieved artificially either by astrocyte-
specific over expression of Nrf2 (Shih et.al., 2003; Shih et al., 2005; Nagai et al. 
2007; Vargas et al. 2008; Kanninen et al., 2008), or by treatment with well-
characterized small molecule activators of the pathway such as tBHQ and 
sulforaphane (Shih et al., 2005; Zhao et al., 2006; Zhao et al., 2007; Jakel et al., 
2007; Kanninen et al., 2008), or by transplantation of Nrf2-overexpressing astrocytes 
(Jakel et al., 2007; Calkins et al., 2009). However, the extent to which endogenous 
Nrf2 could respond to intrinsic signals such as mild oxidative stress and subsequently 
mediate a physiologically relevant endogenous neuroprotective response is less clear.  
 
Another issue is the locus of Nrf2 activation in brain tissues, which represent a 
controversial aspect of the Nrf2 pathway. While a large number of studies have 
shown that activation of the Nrf2 pathway preferentially occurs in astrocytes not 
neurons (Ahlgren-Beckendorf et al., 1999; Murphy et al., 2001; Kraft et al., 2004), 
this is controversial (Johnson et al., 2002; Kraft et al., 2007; Escartin et al., 2011). 
These studies whether supporting the astrocyte specific or non-specific activation of 
the ARE-Nrf2 pathway don't, however, establish the locus of endogenous Nrf2 
activity in response to endogenous signals such as oxidative stress. Thus in this thesis 
I wish to investigate (1) the extent to which the endogenous Nrf2 pathway can 
respond to intrinsic signals such as mild oxidative stress by triggering antioxidant 
genes up-regulation, and (2) the locus of endogenous Nrf2 activation in vitro. 
 
In line with the previously reported activity-dependent suppression of Foxo1 
(Papadia et al., 2008; Leveille et al., 2010) I wished to investigate whether synaptic 
NMDAR activity: (1) promotes the nuclear exclusion of the other major neuronal 
Foxo, Foxo3, and (2) influences the expression of Foxo1. 
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The aims of the research presented here are summarized in the points below: 
• To determine whether synaptic activity induces changes to Foxo1 activity 
beyond its acute export from the nucleus. 
• To determine the extent to which the endogenous Nrf2/ARE pathway can 
respond to intrinsic signals such as mild oxidative stress and the locus of its 
activation in our in vitro system of astrocyte containing primary cortical 
cultures. 
• To investigate the mechanism(s) by which mild oxidative stress activates the 
endogenous Nrf2/ARE pathway. 
As will be discussed in the concluding remarks of this thesis, our data provide a 
better insight into the regulation of intrinsic neuroprotective pathways, and therefore 
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2.1. Neuronal cultures  
Cortical neurons were cultured from embryonic day 17.5 (E17.5) CD1 mice or from 
E21 Sprague Dawley (SD) rat pups. The pregnant mothers and their pups were culled 
in accordance with schedule 1 of the home office guidelines on human killing of 
animals. Mouse pups were decapitated and rat pups were anaesthetized with an 
intraperitoneal injection of pentobarbital (Ceva Sante Animale, La Ballastiere, 
France) before decapitation. To dissect the cortices, the brains were removed and 
placed in plastic dishes containing dissociation medium (81.8 mM Na2SO4, 30mM 
K2SO4, 5.84mM MgCl2, 0.252 mM CaCl2, 1mM HEPES, 0.001% Phenol Red, 20 
mM D-glucose,) (Sigma-Aldrich, Dorset, UK) supplemented with 1mM kyurenic 
acid and 10 mM MgCl2 to prevent excitotoxic neuronal damage via NMDAR during 
the dissection and the enzymatic digestion stage. Micro-dissections were performed 
under a light microscope to isolate the cortices, which then were transferred to 15 ml 
round bottom plastic tubes and incubated with 1-2ml of dissociation media 
containing papain enzyme (10 enzymatic units/ml; Worthington Biochemical 
Corporation, Lakewood, NJ, USA) for 20 minutes at 37°C (waterbath), stirring every 
10 minutes. After that, the papain solution is removed and replaced with a fresh one 
for a second round of 20 minutes incubation. Next the cortices were washed twice 
with pre-warmed dissociation medium after removing the papain solution to wash off 
any membranous or blood-containing tissues. Similarly, the cortices were washed 
twice but this time with pre-warmed growth medium consisting of Neurobasal-A 
medium (Invitrogen, Paisley, UK) supplemented with 1% rat serum (Harlan 
Laboratories), B-27 Supplement (1:50 of 50X stock, Invitrogen), 1mM glutamine, 
and 1:100 antibiotic/antimycotic (Gibco®, Life technologies, Paisley, UK). After the 
repeated washing steps, the cortices were homogenized by rapid trituration in 10 ml 
of pre-warmed growth medium using a 2 ml pipette, whereby repeated rounds of 
filling and emptying the barrel of the pipette facilitate the dissociation into single 
cells. The homogenized cells were then diluted with a Opti-MEM (Invitrogen) 
plating media supplemented with 20 mM D-glucose (Invitrogen) and 1:100 
antibiotic/antimycotic. The cell suspension is then plated out at 0.5ml/well in 24-
wells cell culture plates (Grenier Bio-One, Stonehouse, UK). These plates were pre-
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coated with poly-D-lysine (1.33% w/v in H2O; from BD Biosciences, Oxford, UK) 
and laminin (0.5% w/v) at 37°C for 2 h prior to the cells plating step. The cultures 
were then placed in a humidified 5% CO2 atmosphere at 37°C for 2 h, after which the 
medium was replaced with 1ml growth medium. To obtain astrocytes containing 
cultures (AC), 1 ml of growth medium containing 9.6 µM cytosine β-D-
arabinofuranoside hydrochloride (AraC) (Sigma-Aldrich, Dorset, UK) was added on 
(DIV04 Days in vitro) to prevent glial proliferation. 
 
2.2. Nrf2 and Keap1 KO cultures  
Nrf2 and Keap1 KO mice, originally developed by Prof. M. Yamamoto laboratory 
(University of Tohoku) (Itoh et al., 1997; Wakabayashi et al., 2003), were obtained 
from Prof. John. D. Hayes (University of Dundee). However, Nrf2 KO mice have 
been backcrossed over six generations onto C57BL/6 genetic background (Higgins et 
al., 2009b). An offspring of Nrf2 KO mice was generated through breeding of Nrf2 
KO females and males. Matching C57BL/6 WT animals were used to generate 
parallel WT cultures. Keap1 heterozygote males and females were mated to produce 
WT and KO littermates. The offspring genotypes were verified through multiplex 
PCR analysis of cerebellum genomic DNA using DNA easy blood and tissue kit 
(Qiagen UK, Crawley, UK). The primers used are listed in table M1 and the PCR 
conditions were as follows: 5 minutes at 95°C followed by 34 cycles of 94°C for 30 
seconds, 55°C for 1 minute and 72°C for 1 minute, followed by an extension step at 
72°C for 10 minutes.  
The size of the bands produced by this reaction are distinctive based on the genotype 
of the sample DNA whereby Keap1 WT and KO samples generate bands of 235 and 
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Table 2.1. Keap1 genotyping PCR primers sequences. 
PCR Primer Sequence  
D123 5’-CGGGATCCCCATGGAAAGGCTTATTGAGTTC-3’ 
2nd Ex 3’ 5’-GAAGTGCATGTAGATATACTCCC-3’ 









Figure 2.1. Keap1 genotyping PCR 
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2.3. Stimulations and reagents 
 Prior to performing the experiments, cells were placed into trophically deprived 
medium (TMo) containing 10% MEM (Invitrogen, Paisley, UK) and 90% salt-
glucose-glycine (SGG) medium (114 mM NaCl, 0.219% NaHCO3, 5.292 mM KCl, 
1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM Glycine, 30 mM Glucose, 
0.5 mM sodium pyruvate, 0.1% Phenol Red; osmolarity 325 mosm/l) (Bading et al., 
1993) and allowed to equilibrate for (2-16h) before stimulation. Treatments of 
cultured cells were performed after 8-10 DIV. Reagents were either dissolved in H2O 
or in dimethyl-sulfoxide (DMSO). 
 
2.3.1. Induction of synaptic NMDAR activity in neurons 
Stimulations of cultured neurons were done in most cases after a culturing period of 
8–10 days, during which neurons develop a network of processes, express functional 
NMDA-type and AMPA/kainate-type glutamate receptors, and form synaptic 
contacts. Bursts of action potential firing were induced by treatment of neurons with 
50 µM bicuculline (Tocris bioscience, Bristol, UK), a GABAA receptor inhibitor, and 
250 µM 4-amino pyridine, a K+ channel antagonist, to enhance burst frequency 
(Calbiochem, Merk Millipore, Germany) (Hardingham et al., 2001). 
 
2.3.2. Other stimulations  
Sub-toxic doses of H2O2 (Sigma-Aldrich) were utilized to model oxidative stress in 
vitro. tBHQ (Acros Organics, Fisher’s scientific, Belgium) treatments were used to 
model pharmacological activation of the Nrf2 pathway. 50 µM LY 294002 
(Calbiochem, Merk Millipore, Germany) was used to inhibit the PI3K pathway. 
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2.4. Assessment of neuronal cell death 
For cell death quantification, neurons were fixed with 4% paraformaldehyde (PFA) 
and subjected to 4’,6’ diamidino-2-phenylindole (DAPI) (Vector Laboratories, 
California, USA) nuclear staining and cell death was quantified by counting the 
number of pyknotic nuclei as a percentage of the total. Approximately 1500 cells 
were scored across several random fields within 3-4 independent experiments. 
 
2.5. Transfections 
Neurons (on DIV08) or HEK-293 cells were transfected using Lipofectamine 2000 
(Invitrogen). In a 24-wells culture plate, each well is transfected with a total up to 
0.65µg of plasmid DNA (pDNA). The pDNA is then diluted in 33µl of TMo medium 
from the wells and in another tube 2.33µl of Lipofectamine was diluted in the same 
manner. The diluted preparations were then combined and incubated at room 
temperature for 20 minutes. Following the incubation period, 285µl of medium from 
the wells was added to the tube containing the pDNA and Lipofectamine mixture and 
mixed gently. Finally, the medium was removed from each well and replaced with 
333µl transfection mixture, after which the cells were maintained at 37°C in a CO2 
for 2-4 h. Of note, transfections were scaled up as needed, in which reagents, DNA, 
cells and medium were used in proportion to the relative growth surface area. At the 
end of the transfection period, the medium on the cells was replaced with either fresh 
growth medium or TMo to prevent cytotoxicity. Transfection efficiency using this 
protocol is approximately 2-5%, of which >99% of the eGFP-expressing cells are 
NeuN-positive neurons and less than 1% GFAP positive astrocytes.  
 
For astrocyte transfection, the same protocol was employed except that transfections 
are carried out on DIV02 instead of DIV08. The rationale behind the early 
transfection is the fact that quiescent (AraC-treated) glial cells are not amenable to 
transfection, whereas (non-AraC-treated) non-quiescent glial cells appear to be more 
amenable to transfection (Soriano et al., 2008). This observation was based on 
quantifying the eGFP-expressing astrocytes in AC cultures transfected with eGFP 
either on DIV02 or DIV8 and subjected to GFAP and GFP immnunofluorescnce. 
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The percentage of transfected astrocytes was calculated as the number of 
GFP+/GFAP+ cells over the total number of GFAP+ cells, and it was 6.7% and 1.6% 
for transfections carried out on DIV02 and DIV08 respectively. 
 
2.6. Plasmids and reporter assays 
2.6.1. Preparation and digestion of plasmids  
Gift plasmids received on filter paper were soaked in 40 µl nuclease free water and 
placed at 4°C overnight. The following day, transformation was preformed by 
mixing 10-15ng of pDNA with 50 µl of ice-cold JM109 competent cells (Promega, 
Southampton, UK) and incubated on ice for 30 minutes, then the mixture was subject 
to 45 seconds heat shock in 42°C water bath. After brief cooling of the mixture for 
few seconds on ice 1ml of Luria-Bertani (LB) broth media (Sigma-Aldrich) was 
added to each mixture tube and placed in a 37°C shaker for 45 minutes, following 
that the mixture was spread on LB agar plates containing 50 ng/ml of ampicillin and 
incubated overnight at 37°C. The following day, colonies were picked and seeded 
into 50ml of LB supplemented with ampicillin and were incubated at 37 °C for 12-16 
hrs with aggressive shaking. The bacterial cells were then harvested by 
centrifugation at 6000Xg for 15 minutes at 4°C and plasmids were purified using the 
Qiagen Plasmid Midi kit (Qiagen). 
Digestion procedure was carried out on ice by mixing 10-30 ng of pDNA with 5 
units of the desired restriction enzyme and the appropriate buffer supplied with the 
enzyme, then the reaction volume was made up to 25 µl with PCR grade water. The 
mixture then was incubated at 37 °C for 2 hr or overnight. When the digestion was 
complete, few microliters of the resulting product was subjected to electrophoresis 
analysis on 0.8% agaros gel containing Syber Safe DNA gel stain (Invitrogen) and 
then visualized with a U:Genius UV illuminator (Syngene, Cambridge, UK). If the 
DNA fragments were required for subsequent procedures, the DNA bands were 
excised from the gel and DNA was extracted using QIAquick Gel Extraction kit 
(Qiagen). 
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2.6.2. Constructs generation 
Foxo1-Luc construct was created by amplifying 1100bp segment of the rat Foxo1 
upstream promoter region from genomic DNA using Picomaxx DNA Polymerase 
(Agilent Technologies, Cheshire, UK) with the following primes: forward, 5'- atc tcg 
agt ctc taa aca ctc tcc tct gac c -3'; reverse, 5'- atg ata tca act taa ctt cgc tgg gtc ac -3'. 
The resulting PCR product was digested with XhoI and EcoRV (sites within primers 
italicized) and cloned into the corresponding sites upstream of the firefly luciferase 
construct in PGL4.10.  
 
For the construction of Keap1-Luc approximately 890bp of the rat Keap1 upstream 
region was amplified from genomic DNA using PicoMaxx high fidelity PCR system 
(Agilent Technologies) with the following primers: forward 5'- caa ctc gag gcg tga 
cag tcg ctc act ta-3'; revrese, 5'- cgt aga tct tcc acc act agc gat tag gg-3'. The resulting 
PCR product was digested with XhoI and BglII (sites within primers italicized) and 




2.6.3. Luciferase reporter assay 
For Foxo1-reporter assay, neurons were transfected on DIV08 with Foxo1-firefly 
luciferase (Foxo1-Luc) or the mutant variants, plus a pTK-renilla (Promega) 
normalization vector at a DNA ratio of 4:1 respectively. Whereas, in the experiments 
aiming to evaluate the responsiveness of Foxo1 promoter to Foxo transcription 
factors, the cells were transfected with either Foxo1-Luc or the mutant variants and 
pTK-renilla along with a vector encoding either Foxo1, Foxo3, or beta-globin 
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In the experiments aimed at evaluating the effect of synaptic activity on Nrf2-driven 
ARE-Luc activity, neurons were transfected on DIV08 with ARE-Luc along with 
pTK-renilla, and also pcDNA3.1/ V5HisBim Nrf2 or beta-globin (control), plus 
pcDNA3.1/V5HisCmKeap1 or beta-globin (control).  
 
For the Gal4-based reporter assay, astrocytes containing neuronal cultures (AC-
neurons) were transfected using an astrocyte specific transfection protocol 
(previously described in the Transfections section) where the astrocytes are 
transfected with the reporter plasmid Gal4-Luc and pTK-renilla and either of the 
effector plasmids; GBD-Nrf2, GBD-Neh(2-4), GBD-Neh5 or GBD only.  
 
As for the Neh2-Luc reporter system, AC-neuron were transfected using the  
astrocyte transfection protocol, in which astrocytes were transfected with Neh2-Luc 
along with pTK-renilla normalization vector; or transfected with a plasmid encoding 
for the luciferase reporter gene not fused to Neh2  (for this purpose we utilized SV40 
driven luciferase reporter) along with pTK-renilla. The DNA ratio of the plasmids 
transfected into the cells is 4:1 for Neh2-Luc or Luc only: renilla respectively. 
 
Prior to performing the Foxo1-Luc, or ARE-Luc, or Keap1-Luc assays, neurons were 
stimulated with 50µM bicuculline and 250 µM 4-aminopyridine for 24 h after 24 h of 
recovery from transfection. As for the Gal4 and Neh2 luciferases reporter systems, 
stimulations were performed 6 days post transfection whereby the cells were treated 
with either 10 µM tBHQ or (25-75 µM) H2O2 for 8 h prior to carrying out the 
luciferase assay. 
 
Luciferase assays were performed using the Dual-Glo luciferase system kit  
(Promega) and relative light units were measured in a FLuostar OPTIMA 
luminometer (BMG Labtech, Aylesbury, UK). Firefly luciferase activity was 
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routinely normalized to Renilla luciferase activity and the results were obtained from 
at least 4 independent experiments, each carried out in duplicates.  
Table 2.2. List of plasmids used. 
Plasmid name Description Reference 
Foxo1-Luc 1100bp segment of the rat Foxo1 upstream 
promoter region fused to luciferase reporter 
gene (refer to construct generation) 
This study (generated by 
Prof. Giles Hardingham) 
PGL4.10 Luciferase reporter vector Promega 
pFoxo1myc Myc epitope tagged mouse Foxo1   A gift from Dr. Domenico 
Accili (Nakae et al., 2000) 
pGFP-Foxo3a GFP epitope tagged mouse Foxo3 A gift from Dr. Domenico 
Accili     
pTK-RL Thymidine kinase promoter deriven Renilla 
luciferase reporter 
Promega 
Keap1-Luc 890bp of the rat Keap1 upstream region fused 
to luciferase reporter gene (refer to construct 
generation) 
This study (generated by 
myself) 
ARE-Luc Human Hmox1 ARE fused to luciferase 
reporter 
A gift from Dr. Satoshi 




Murine Nrf2 coding sequence A gift from Dr. Michael 
McMahon  
 
(McMahon et al., 2003) 
pcDNA3.1/V5HisC 
mKeap1 
Murine Keap1 coding sequence 
Gal4-Luc Luciferase reporter bearing 4 copies of Gal4-
binding site  
Promega 
GBD-Nrf2 Gal4 DNA binding domain fused to the full 
length Nrf2 
A gift from Prof. Masayuki 
Yamamoto (Katoh et al., 
2001) 
GBD-Neh5 Gal4 DNA binding domain fused to Neh5 
domain (153-227 amino acids) 
GBD-Neh(2-4) Gal4 DNA binding domain fused to both 
Neh2 and Neh4 domains (1-156 amino acids) 
GBD Gal4 DNA binding domain only 
Neh2-Luc Neh2 domain fused to luciferase gene (Neh2-
Luc)  
a gift from Dr. Irina  
Gazaryan (Smirnova et al., 
2011) 
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2.6.4. Site directed mutagenesis 
Foxo1 promoter mutants were generated by Prof. Giles Hardingham using the 
QuikChange II XL site-directed mutagenesis kit (Stratagene), following the 
manufacturer’s instructions. The proximal Foxo site on Foxo1 was mutated to 
GTCGACAA (bold indicates nucleotides changed, underlined sequence indicates 
creation of SalI diagnostic site). The distal IRS-like site on Foxo1 was mutated to 
TCTAGACAAA (bold indicates nucleotides changed, underlined sequence indicates 
creation of XbaI diagnostic site).  
 
For the GBD-Neh5 mutation studies, the reactive cysteine residue 191 (Cys-191) was 
substituted with alanine. To obtain this, QuikChange II XL site-directed mutagenesis 
kit (Stratagene) was used along with the mutagenic primer and its reverse 
complementary sequence containing the mismatches 5′CATTCCCGAATTA 
CAGGCCCT TAATACCGAAAACAAG-3′ (bold indicates nucleotides changed, 
underlined sequence indicates creation of Eco01091 diagnostic site). All mutants 
were verified by performing diagnostic cuts with the indicated restriction enzymes 
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2.7. Immunocytochemistry 
Cells grown in 24-well plates were fixed with PFA for 20 minutes at room 
temperature, washed once with 1X phosphate buffer saline (PBS) (Invitrogen) and 
permeabilized with NP40 (Invitrogen) for 5 minutes, and then rinsed twice with 1X 
PBS. Fixed cells were incubated with 0.5 ml of the primary antibody diluted in PBS 
overnight at 4°C with gentle rocking. The next day, the primary antibody is retained 
and the cells were incubated with either fluorophore-conjugated or bioten-conjugated 
secondary antibody/antibodies, away from light for 1 h at room temperature after 
rinsing the cells twice with 1X PBS. Following secondary antibody incubation, cells 
were washed rinsed twice with 1X PBS. In the case of bioten-conjugated secondary 
antibody, an additional incubation with Cy3-stripdavidin-conjugated antibody 
(Jackson immunoResearch Laboratories, Inc., Pennsylvania, USA) diluted at 1:500 
in PBS was carried out for 1 h in the same conditions.  Finally, the cells were rinsed 
twice with 1X PBS and then one drop of DAPI was added after aspirating off the 
PBS and each well was covered with a glass cover slip. Primary antibodies used in 
immunocytochemistry were as follows: rabbit anti- HO1 used at (1:1000) (Stressgen 
Biotechnologies Corporation, British Columbia, Canada), mouse anti-GFAP used at 
(1:400) (Sigma-Aldrich), rabbit anti-GFP used at (1:750) (Invitrogen). Secondary 
antibodies were all used at (1:200) dilution in 1X PBS and were as follows; biotin-SP 
conjugated anti-mouse and Dylight 488-conjugated anti-rabbit (Jackson 
ImmunoResearch Laboratories). Images were obtained using Leica AF6000 LX 
imaging system, with a DFC350 FX monochrome digital camera. Using the 
appropriate filter set, images were initially taken in black and white, and colour was 
applied after image acquisition.  
 
For measuring Hmox1 immunostaining intensity, non-saturating pictures were taken 
on a Leica AF6000 LX imaging system, with a DFC350 FX digital camera at a 
magnification of 20X and fluorescence intensity quantified on Image J. Gray scale 
images were obtained at the following settings; exposure time (751-935ms), gain (5) 
and intensity (4). To ensure consistency, all settings were kept the same for pictures 
taken of other conditions within each experiment. Fluorescence intensity was 
quantified for each cell across 4-5 fields, each field containing 10-18 cells. 
Background intensity was subtracted from each cell’s intensity and then the mean of 
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cells intensities was calculated for each condition and normalized to the control 
condition.  
    
 
2.8. Western blotting and antibodies  
Cells were cultured in 35 mm dishes, and lysed in 110 µl of 1.5 X sample buffer 
consisting of (1.5 MTris pH 6.8; Glycerol 15%; SDS 3%;β-mercaptoethanol 7.5%; 
bromophenol blue 0.0375%). Total cell lysate was then boiled at 100°C for 5 
minutes and the samples were resolved in precast gradient (4–12%) NuPAGE-
Novex- Bis-Tris gels (Invitrogen). Electrophoresis was performed using Xcell 
Surelock system (Invitrogen). 20 µl of each protein sample was loaded per well and 
electrophoresis was carried out using 1 X NuPAGE® MOPS SDS running buffer 
(Invitrogen) at 160V for ~ 1.5 h. When the protein migration was satisfactory, the 
protein samples were then electrophoretically transferred from the gel onto a 
ployvinylidene difluoride (PVDF) membrane (Merck Millipore, Germany) in a 
buffer consisting of (96mM glycine, 12mM Tris and 20% Methanol) at 45 V for ~ 2 
h. Once the transfer is complete, the membrane was then blocked for 1 h at room 
temperature in TBS solution (20mM Tris, 137 mM NaCl and 0.1% Tween 20%) 
supplemented with 5% skimmed dried milk. The membrane was then incubated over 
night at 4°C in TBS+5% milk solution containing the appropriate dilution of the 
primary antibody. The next day, the membrane was rinsed three times for 5 minutes 
in TBS, and placed in a solution consisting of the appropriate horseradish 
peroxidase-conjugated antibody prepared at the desired dilution in TBS+5% milk. 
The membrane was left to incubate in this solution at room temperature for 1 h, after 
which the secondary antibody was removed by rinsing the membrane three times for 
5 minutes in TBS. Proteins were detected by enhanced chemiluminescence, whereby 
the membrane is incubated for 1 minute in LumiGlo reagent and peroxide (Cell 
signaling technology, Massachusetts, USA) and then a Kodak X-Omat film was 
exposed to the membrane. Western blots were analysed by digitally scanning the 
blots, followed by densitometric analysis using (imageJ) software. The densities of 
the bands were normalized to an appropriate loading control, which was obtained by 
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stripping the membrane of the antibodies using Reblot Plus Strong Stripping 
Solution (Merck Millipore, Germany). The procedure involves incubating the 
membrane for 15 minutes in the stripping solution, followed by three washes with 
TBS, and then re-probing with the desired anti-body following the primary anti-body 
incubation protocol described earlier.  
 
The primary antibodies used were: rabbit anti-FOXO1 (1:1000, Cell signaling 
technology),  mouse anti-Akt (1:500, Cell signaling technology), goat anti- Keap1 
(1:500, Santa Cruz Biotechnology, California, USA ), mouse anti-β-tubulin isotype 
III (1 : 125 000, Sigma-Aldrich), mouse anti-GAL4 (DBD) (1:500, Santa Cruz 
Biotechnology), and rabbit anti-beta actin (1:2000, abcam, Cambridge, UK). FOXO1 
bands were normalized to Akt, Keap1 bands were normalized to β-tubulin and GAL4 
bands were normalized to beta-actin. Horse-radish peroxidase-conjugated secondary 
antibodies used in this analysis are anti-mouse, anti-goat (1:1000, Dako, 
Cambridgeshire, UK), and anti-rabbit (1:2000, Santa Cruz Biotechnology). 
 
2.9. RNA isolation, RT-PCR and Quantitative-PCR 
Total RNA was isolated using High Pure RNA Isolation Kit (Roche, Welwyn 
Garden City,UK) including a DNase-treatment step to degrade genomic DNA and 
samples were eluted in 35-45µl of  the elution buffer provided with the kit. cDNA 
was synthesized from 1-5µg RNA using Transcriptor First Strand cDNA Synthesis 
Kit (Roche). Briefly, the reverse transcription reaction was carried out on ice by 
mixing 7 µl of RNA with 13 µl RT mix containing Anchored-oligo(dT) primer: 
random hexamer primer 1:2 (total 3 µl), 4 µl  Transcriptor Reverse Transcriptase 
Reaction Buffer (5X), 0.5 µl Protector RNase Inhibitor (40 U/ µl), 2 µl 
Deoxynucleotide Mix (1mM each:dATP,dGTP,dTTP, and dCTP), 0.5 µl 
Transcriptor Reverse Transcriptase (20 U/ µl) and 3 µl nuclease free water. In 
parallel, at least one NoRT control was generated per isolation and all samples were 
vortexed and spun down before placing them in a thermal block cycler with a heated 
lid. cDNA synthesis reactions were all carried out at 25°C for 10 minutes for primer 
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annealing, 30 minutes at 55°C for RT reaction, 5 minutes at 85°C for enzyme 
inactivation and then cooled down to 4°C. The resulting cDNA was then diluted to 6 
ng and was used to perform real-time quantitative PCR using FS Universal SYBR 
Green MasterRox (Roche) and the reaction was carried out in an Mx3000P qPCR 
system (Agilent Technologies, Cheshire, UK). In short, 15 µl of the qPCR reaction 
mix was pipetted into each well, containing 1 µl template cDNA, 7.5 µl SYBR Green 
master mix (containing optimized amount of DNA polymerase, dNTP, reaction 
buffer and Rox dye), 0.6 µl forward and reverse primers at a final concentration of 
200 nM and 5.3 µl nuclease free water. In each experiment, technical duplicates were 
used for every sample including NoRT and No-template controls. The cycling 
parameters were as follows: 10 minutes of initial denaturation at 95°C; 40 cycles of 
30 seconds at 95°C, 40 seconds of annealing at 60°C with detection of fluorescence 
and 30 seconds of extension at 72°C; followed by one cycle of 1 minute at 95°C, the 
temperature was ramped from 55°C to 95°C over 30 seconds at 1°C per step with 
continuous fluorescence detection (for dissociation curve analysis to confirm the 
amplification of a single product). The mRNA level of the gene of interest was 
normalized to Gapdh levels and expressed compared to levels in control samples 
using the 2(-ΔΔCt) efficiency corrected method (Livak and Schmittgen, 2001). For 
each set of primers, the amplification efficiencies were measured using a 5-fold 
dilution standard curve and were limited between 1.74 and 2.112. Primers sequences, 
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Table 2.3. List of qPCR primers used. 
Gene Efficiency 
(%) 
Forward primer (5′-3′) Reverse primer (5′-3′) 
Gapdh 
(Mouse) 










74 ATACTCCAGAACACGGGCAG AGTTCCACCCAGACTCGAAC 
Srxn1 
(Mouse) 
102 GACGTCCTCTGGATCAAAG GCAGGAATGGTCTCTCTCTG 
Hmox1 
(Mouse) 
112 AGCACAGGGTGACAGAAGAG GGAGCGGTGTCTGGGATG 
Foxo1 
(Rat) 









2.10. Statistical analysis 
All results are presented as mean ± standard error of the mean. Statistical testing 
involved a 2-tailed paired student t test (Excel Microsoft). For studies using multiple 













                                      
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Chapter 3 
 Synaptic NMDAR activity control of Foxo1 and Nrf2            

















The thioredoxin-peroxiredoxin system provides protection against oxidants by 
neutralizing ROS and maintaining normal redox homeostasis. (Chae et al., 
1994; Schulze et al., 2004). Thioredoxin anti-oxidative function is suppressed 
by an endogenous inhibitor known as thioredoxin interacting protein (Txnip). 
(Schulze et al., 2004; Yoshida et al., 2005). Our group has previously shown 
that synaptic activity enhances thioredoxin activity by causing Txnip down 
regulation, whereby synaptic activity promotes PI3K-directed nuclear exclusion 
of Foxo (Papadia et al., 2008). However, the Foxo-inhibiting capacity of 
PI3K/Akt pathway is thought to be short- lived. This is attributed to a key 
aspect of Foxo regulation, which is once PI3K/Akt activity has returned to 




In this study, I demonstrate that synaptic NMDAR activity not only triggers Foxo 
export, but also suppresses the expression of Foxo1. I also found that blockade of 
PI3K activity prevented both Foxo3 nuclear export and suppression of Foxo1 
expression, raising the possibility that Foxo1 is itself a Foxo target gene. 
Moreover, the data presented here revealed that Foxo3, and to a lesser extent 
Foxo1 transactivates the Foxo1 promoter via a consensus Foxo binding site (GTA 
AAC AA), and also an upstream sequence resembling a classical Foxo-binding 
insulin response sequence (CAA AAC AA). The proximal (GTA AAC AA) 
sequence mediated both the activity-dependent and the IGF-1-dependent 
suppression of Foxo1 promoter. Thus, through a feed-forward inhibition 
mechanism, synaptic activity triggers Foxo export resulting in suppression of 
Foxo1 expression. These published results suggest that Foxo-inactivating signals 
are likely to result in longer-term inhibition of Foxo target gene expression than 
previously thought (Al-Mubarak et al., 2009). 
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In addition to its suppressing effect on Foxo, I found that synaptic activity 
downregulates the Nrf2/ARE antioxidant pathway inhibitor, Keap1. I have shown  
that synaptic activity enhances Nrf2 capacity to drive ARE-reporter and reduces 
Keap1 expression at both mRNA and protein levels in an NMDAR-dependent 
fashion. I also demonstrated that the activity-dependent regulation of Keap1 occurs, 
at least in part, at a transcriptional level. 
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3.2. Results 
 
3.2.1. Foxo1 expression is suppressed by synaptic activity 
Synaptic activity had been observed to rapidly inhibit Foxo pro-oxidative target 
gene Txnip, through promoting Foxo1 cytoplasmic retention and its dissociation 
from the Txnip promoter (Papadia et al., 2008). In line with this reported 
finding, I sought to determine whether synaptic activity induced longer-lasting 
changes to Foxo1 activity other than its acute export from the nucleus. Rat cortical 
neurons were placed in trophically deprived medium and synaptic activity was 
stimulated using the established method of network disinhibition, in which the 
GABAA receptor antagonist bicucullin (BiC) was co-applied with the K+ channel 
antagonist 4-aminopyridine (4-AP) (which enhances burst frequency, referred to 
hereafter as BiC) (Hardingham et al., 2001; Papadia et al., 2005). In time course 
experiments, the expression of Foxo1 was strongly suppressed 4h after 
enhancing synaptic activity with BiC and this was maintained at 24 h post-
stimulation (Fig.3.1A). However, MK-801 (an established  NMDAR   antagonist) 
co-treatments   attenuated   Foxo1 transcriptional suppression indicating that the 
inhibitory effect of synaptic activity is NMDAR-dependent. Next, the level of 
Foxo1 protein was assayed by western blot 24 h post-stimulation. The results 




























Figure 3.1. Synaptic NMDAR activity suppresses expression of Foxo1.  
A) QRT-PCR analysis of Foxo1 mRNA levels in neurons placed in trophically 
deprived medium and stimulated as indicated. Levels of Foxo1 mRNA are 
normalized to those of GAPDH. n=3, *p<0.05. B) Example western blot 
demonstrating that activity-dependent suppression of Foxo1 mRNA levels results 
in lower protein expression. Example western of total protein lysates are shown  
t o  illustrate the effect of  BiC stimulation on Foxo1 protein levels after 24 h. For 
comparison, Akt levels are shown to be unaltered. The experiment was repeated 
three times across three independent cultures
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3.2.2. Synaptic activity regulation of Foxo1 is PI3K-dependent 
 
Having shown that synaptic activity down regulates Foxo1 expression, we sought 
to decipher the mechanism by which Foxo1 expression is suppressed by synaptic 
activity. Since Foxo itself, is subject to activity dependent nuclear export via the 
PI3K-Akt pathway (Papadia et al., 2008; Martel et al., 2009), we first sought to 
analyse the Foxo1 promoter. Interestingly, two potential Foxo binding sites were 
detected. A proximal site at –306 nt. near the transcription start site (GTA AAC 
AA) matching the exact Foxo-binding consensus (Furuyama et al., 2000) and a 
consensus insulin-response sequence (IRS, CAA AAC AA) at -483 nt (Guo et al., 
1999). The sequence of these elements is evolutionarily conserved in rodents and 
humans genomes, indicative of functional importance (Fig. 3.2A). Of note, the in 
silico studies as well as the promoter constructs generation was all performed by 
Prof. Giles Hardingham. Before evaluating the significance of these consensus 
sites directly, we sought to identify which signal transduction pathway was 
required in the activity dependent down regulation. Given the observed blockade 
of the activity-dependent nuclear export of the Foxo1 (Papadia et al., 2008; Martel 
et al., 2009), I sought to determine whether synaptic activity promotes the nuclear 
exclusion of Foxo3 in the same manner. To that end, neurons were transfected 
with GFP-tagged Foxo3 and 24 h post transfection the cells were stimulated with 
BiC for 1 h in the presence or absence of LY294002 and GFP-Foxo3 subcellular 
localization was assessed by immunofluorescence using anti-GFP antibody. 
Subcellular distribution of GFP-Foxo3 was scored as either nuclear (higher levels 
of GFP immunostaining in nucleus than cytoplasm or when a defined nuclear 
border is visible), nuclear + cytoplasmic (even distribution in nucleus and 
cytoplasm), or cytoplasmic (higher levels of GFP immunostaining in cytoplasm 
than nucleus) and the percentage of each category was calculated for each 
condition. The analysis revealed that synaptic activity triggers Foxo3 export in a 
PI3K-sensitive manner as pre-treatments with LY294002 attenuated the activity-
dependent nuclear export (Fig. 3.2 C and D) Next, I wanted to test if synaptic 
activity exploits the same signalling transduction pathway to elicit Foxo1 
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suppression. To that end, neurons were pre-incubated with LY294002 then treated 
with BiC for 24 h. The BiC derived suppression of Foxo1 expression was 
completely reversed by LY294002 confirming that synaptic activity suppresses 
Foxo1 in a PI3K-dependent manner (Fig. 3.2B). Similarly, LY294002 was shown 
to block the activity-dependent down regulation of Txnip, which was found to be a 










































































Figure 3.2. Synaptic activity suppresses Foxo1 and promotes Foxo3 nuclear 
export in a PI3K-dependent manner.  
A) Schematic illustrating the position and conservation of the putative FOXO-
response elements within the Foxo1 promoter. Nucleotide positions refer to the rat 
gene. B) QRT-PCR analysis of Foxo1 mRNA levels in neurons placed in trophically 
deprived medium and stimulated with BiC in the presence or absence of LY294002 
(50 µM), n=3, *p< 0.05. C, D) Neuronal activity promotes the nuclear export of 
Foxo3 via PI3K. Neurons were transfected with GFP-tagged Foxo3 and 24 h later 
were stimulated with BiC for 1 h in the presence or absence of PI3K inhibitor 
LY294002 (50 µM). The cells were then fixed and processed for 
immunofluorescence with an anti-GFP antibody as described in section 2.7. C) 
Example pictures are shown from the experiments performed. D) Quantification of 
the subcellular distribution of GFP-Foxo3 using the scoring system described earlier 
in section 3.2.2. 15-35 cells were analysed for each condition, n=4,  *p< 0.05 
assessment of the effect of the indicated treatment on GFP-Foxo3 localization 
compared to control, #p< 0.05 assessment of the effect of blocking the PI3K pathway 
on the activity-derived Foxo3 nuclear exclusion.
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3.2.3. Foxo1 is a Foxo target gene 
 
To test the hypothesis that Foxo1 is a Foxo target gene, we isolated a 1 kb 
fragment of the Foxo1 promoter and cloned it in front of a luciferase reporter 
gene. We next created a mutant version of it with the proximal putative Foxo 
consensus site mutated to GTCGACAA (Foxo1(mut1)- Luc,  bold  underlined  
indicates  the  altered  nucleotides).  Of note, the  Foxo1-Luc construct  and  the  
mutant  versions  were generated  by  Prof.  Giles Hardingham, while Foxo1-
Luc reporter activity experiments were carried out by myself and Prof. Giles 
Hardingham. Transfections were performed on neurons with Foxo1- Luc and 24 
h later cells were stimulated for 24 h with BiC or left untreated. We observed 
that Foxo1-Luc activity was strongly repressed by BiC-induced neuronal activity.  
(Fig.3.3A).  Mutation of the proximal Foxo  consensus  site  produced  a 
significant reduction in the basal Foxo1 promoter activity. Altogether, our results 
suggest that the proximal (GTA AAC AA) Foxo consensus site is involved in 
the activity-dependent Foxo1 promoter activity suppression. 
 
In accordance to published work on the trophic factors-triggered Foxo1 nuclear 
export (Soriano et al., 2006), we preformed the same assay placing the neurons 
in trophic rich medium containing insulin, which activates neuronal IGF-1 
receptors and obtained a similar effect as inducing synaptic activity-strong 
suppression of Foxo1 promoter activity that is blocked by mutation of the Foxo 
consensus site (Fig. 3.3A).  
 
In order to investigate whether the identified proximal site is a Foxo- responsive 
element, neurons were co-transfected with either Foxo1-Luc or (Foxo1(mut1)-Luc, 
along with vectors driving the constitutive expression of either the major neuronal 
Foxos, Foxo1 and Foxo3, or a control (β-globin). Our data shows that expression 
of Foxo3 and, to a lesser extent Foxo1 both strongly enhanced the wild type  
Foxo1  promoter  activity.  In contrast, expression of Foxo3 and Foxo1 produced a  
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modest increase in Foxo1(mut1)-Luc activity  (Fig. 3.3B). These results indicate 
that the proximal Foxo consensus site on the Foxo1 promoter is indeed Foxo- 
responsive.  However, the small increase in  Foxo1(mut1)-Luc  activity  observed 
following Foxo expression, is suggestive of  the presence of an additional Foxo-
responsive  element  within  the  Foxo1  promoter  (Fig. 3.3B). One obvious 
candidate was the upstream IRS consensus sequence (CAA AAC AA). We 
therefore tested the effect of mutating this site on the responsiveness of the Foxo1 
promoter to Foxo3  (since Foxo3 has the  largest  transactivating  effect  on  Foxo1  
promoter). Mutation of the IRS-like element to CTAGACAA also reduced Foxo-
responsiveness of the Foxo1 promoter both when introduced independently 
Foxo1(mut2)-Luc and also when combined with the first mutation  
Foxo1(mut1+2)-Luc (Fig. 3.3C). Thus our data   underscore   the   need   for   both   
elements   for   achieving   full   Foxo responsiveness. To our surprise, the 
doubly mutated Foxo1(mut1+2)-Luc  reporter displayed a higher basal activity 
compared with the Foxo1(mut1)-Luc (Fig. 3.3 C).  The reason behind this is not 
clear, since mutation of the IRS site alone does not raise basal promoter activity 
(compare WT Foxo1-Luc with Foxo1(mut2)-Luc, Fig. 3.3C). While these data 
indicate that both sites are required for full activation of the Foxo1 promoter by 
Foxos, they don’t however, assess whether Foxo1 or Foxo3 bind directly to Foxo1 
promoter. On the same note, Essaghir et al. reported a direct association of FOXO1 
and FOXO3 with FOXO1 promoter in HEK293T cells as seen by chromatin 
immunoprecipitation (CHIP) assay (Essaghir et al., 2009). However, whether this 
direct interaction exists in neurons could be addressed in future studies by 
























Figure 3.3. Foxo consensus site mediates the activity-dependent suppression and    
Foxo-mediated transactivation of Foxo1 promoter.  
A) Neurons were transfected with either Foxo1-Luc or Foxo1(mut1)-Luc, plus a 
pTK-renilla normalization vector. Neurons were stimulated where indicated with 
BiC or placed in trophically deprived medium containing insulin for 24 h after which 
reporter activity levels were measured (normalized to renilla levels). n=6, B) 
Neurons were transfected with either Foxo1-Luc or Foxo1(mut1)-Luc, plus a pTK-
renilla normalization vector. In addition, they were co-transfected with a vector 
encoding Foxo1, Foxo3, or beta-globin (control). Reporter activity levels were 
measured (normalized to renilla levels) at 48h post-transfection. *p < 0.05 
assessment of the effect of Foxo expression relative to appropriate control, #p < 0.05 
assessment of the effect of the mutation on basal, and Foxo-induced activity of the 
Foxo1 promoter (n =7). C) Neurons were transfected with either Foxo1-Luc, or 
mutated variants, plus a pTK-renilla normalization vector. In addition, they were 
cotransfected with a vector encoding either Foxo3, or beta-globin (control). Reporter 
activity levels were measured (normalized to renilla levels) at 48 h post-transfection. 
*p < 0.05 (n = 5). 




3.2.4. Synaptic activity induces Nrf2-driven ARE reporter activity 
Having established that synaptic activity may promote neuronal-survival signalling 
through inhibiting Foxo1, I wanted to determine whether synaptic activity could boost 
antioxidant defences particularly those regulated by the ARE/ Nrf2/ Keap1 pathway. Our 
group has previously reported that Keap1 forced expression reduces the activity-
dependent induction of Srxn1 reporter (Soriano et al., 2008). Based on this observation, I 
wanted to investigate whether if synaptic activity can elicit a similar effect on the Nrf2-
driven ARE activity and whether it was Keap1 sensitive. Therefore, I studied the effect 
of Keap1 overexpression on the Nrf2-driven ARE-Luc activity in control and BiC-
stimulated rat cortical neurons. The analysis revealed that synaptic activity dramatically 
increases Nrf2 capacity to induce ARE-Luc activity (Fig. 3.4), however this induction 
was blocked upon Keap1 co-expression suggesting that the activity dependent induction 
of Nrf2 driven ARE-Luc activity is exerted via Keap1 suppression.









































Figure 3.4. Synaptic NMDAR activity induces Nrf2-driven-ARE-promoter activity 
in a Keap1 sensitive manner.  
Neurons were transfected with ARE-Luc plus pcDNA3.1-Nrf2 (or pGlobin), plus 
pcDNA3.1-Keap1 (or pGlobin). 24h post- transfection, neurons were stimulated where 
indicated with BiC for 24 h, after which reporter activity levels were measured 
(normalized to renilla levels). *p <0.05, (n = 6). 
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3.2.5. Characterization of Keap1 suppression by synaptic activity 
 
A previous mouse microarray expression data showed marked down regulation of 
mouse Keap1 (Nrf2 negative regulator) mRNA by BiC treatment (in MK-801 
sensitive manner) at 4 h time point. To confirm this finding, mouse and rat cortical 
cultures were treated with BiC for 4h, before harvesting RNA and the subsequent 
evaluation of Keap1 and Srxn1 (as a an example of an activity-regulated gene) mRNA 
expression by qRT-PCR (Fig. 3.5 A and B). The results revealed a large reduction in 
Keap1 mRNA levels following BiC treatment in both mouse and rat primary neuronal 
cultures (Fig. 3.5 A and B) supporting the initial microarray results. In contrast, 
synaptic activity strongly induced Srxn1 mRNA expression consistent with previous 
studies (Papadia et al., 2008). The suppressing effect of synaptic activity on Keap1 
mRNA was reduced by co-application of MK-801, which restored Keap1 mRNA 
expression to a level slightly lower than that of the control but not significantly 
different, indicating that synaptic NMDAR activity is important for the suppressing 
function of synaptic activity (Fig. 3.5 C). The repression of Keap1 expression by 
synaptic activity was also reflected at the protein level as evaluated by western blot, 
whereby 4 h of BiC treatment resulted in a significant down-regulation of Keap1 






































Figure 3.5. Synaptic NMDAR activity suppresses Keap1 expression. 
QRT-PCR analysis of rat Keap1 mRNA levels in neurons placed in trophically 
deprived medium and stimulated with BiC. Levels of Keap1 mRNA are normalized to 
GAPDH. A, B) Synaptic activity down regulates Keap1 mRNA expression and up-
regulates Srxn1 mRNA expression in A) mouse and B) rat neurons at 4 h time point. 
*p<0.05, (n=3-4). C) Neurons were treated with BiC in the presence or absence of the 
NMDAR antagonist MK-801 (10µM). *p<0.05, not significant (n.s.), (n=6-7). D) 
Quantification of Keap1 protein expression in response to 4h treatment with BiC 
normalized to β-tubulin. *p<0.05compared with control (n=5). E) Example western 
blot picture of Keap1 expression and β-tubulin loading control. 
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 3.2.6. Synaptic activity regulates Keap1 at a transcriptional level 
 
I next wanted to investigate the mechanism by which synaptic activity down- 
regulates Keap1. The most likely mechanism of activity-dependent suppression 
of Keap1 expression is transcriptional, although other potential mechanisms may 
exist, such as regulation of mRNA stability. To address this, I created a Keap1-
luciferase reporter construct by cloning approximately 890 bp of the rat Keap1 
promoter and 5´ UTR upstream of a luciferase reporter gene. Neurons were 
transfected with Keap1- Luc and 24 h later were treated for another 24 h with BiC 
or left untreated before carrying out the luciferase assay. I found that BiC 
stimulations reduce Keap1-Luc activity by around 40% compared to the un-
stimulated neurons and this suppressive effect was reversed by co-application of  
MK-801 (Fig. 3.6A). These results suggest that synaptic activity elicits its 
suppressing effect on Keap1 by directly downregulating the transcriptional 
activity of Keap1 promoter. Given this, I wondered if Keap1 could be a down 
stream target of Foxo, since Foxos are subject to synaptic activity regulation. To 
test this, I looked at the effect of LY294002 treatment on synaptic activity-
induced downregulation of Keap1 mRNA levels. The rationale behind this, is if 
Keap1 is a Foxo target gene and given the pre-established involvement of PI3K 
pathway in the activity-dependent regulation of Foxo, then LY294002 pre- 
treatments shall attenuate the suppressive effect of BiC on Keap1 mRNA 
expression. However, data obtained from qPCR analysis showed no change either 
in Keap1 basal expression or in the activity-induced repression of Keap1 mRNA, 





























Figure 3.6. Synaptic NMDAR activity downregulates the transcriptional                                                              
activity of Keap1 promoter.  
A) Neurons were transfected with Keap1-luciferase reporter, plus a TK-Renilla 
control vector. At 24 h after transfection, neurons were stimulated with the indicated 
drugs for 24 h, and firefly luciferase reporter activity was measured, normalized to 
the Renilla control. *p<0.05, (n=4). B) QRT-PCR analysis of Keap1 mRNA levels in 
neurons placed in trophically deprived medium and stimulated as indicated in the 
presence or absence of the PI3K inhibitor 50µM LY294002, (n=2).




3.3.1. Synaptic NMDAR activity suppresses Foxo1 expression via a cis-acting 
FOXO binding site 
In this study we have demonstrated that Foxo1 is a Foxo target gene and as a 
result, its expression is subject to feed-forward inhibition by synaptic NMDAR 
activity, which promotes Foxo nuclear exclusion. Thus, the suppressive effects 
of Foxo export on the expression of Foxo target genes may last considerably 




Synaptic activity exerts its inhibitory effect on Foxo1 activity not only through 
inducing post-translational changes (Foxo1 nuclear export, Papadia et al., 2008; 
Martel et al., 2009) but also through altering Foxo1 expression. I found that 
Foxo1 expression was strongly suppressed following synaptic activity stimulation 
(Fig. 3.1). The activity-induced suppression of Foxo1 and export of Foxo3 was 
PI3K- dependent, as treatments with LY294002 completely blocked the effect of 
synaptic activity (Fig. 3.2B and C). This observation led us to analyse the 
promoter region of Foxo1, which revealed two potential Foxo binding sites (Fig. 
3.2A). Mutating the proximal Foxo consensus site reduced Foxo1 promoter 
activity and abolished both the effect of synaptic activity and the effect of IGF-I 
on Foxo1 promoter, emphasizing the importance of this consensus site in 
mediating Foxo-inactivating signals (Fig.3.3A). We also found this consensus site 
to be strongly activated by Foxo3 and, to a lesser extent Foxo1 (Fig 3.3B). 
Moreover, the proximal consensus site was not the only Foxo-responsive element 
within the Foxo1 promoter, as a small but significant increase was observed in the 
activity of Foxo1(mut1)-Luc following the expression of Foxo3. This observation 
led us to identify the upstream IRS consensus sequence as a Foxo responsive 
element (Fig. 3.3C). 
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In neurons, Foxos are mostly involved in promoting cell death in response to 
various stress stimuli such as oxidative stress (Lehtinen et al., 2006), loss of 
trophic factor (Gilley et al., 2003) and ischemic injury (Fukunaga and Shioda, 
2009). However, activation of synaptic NMDAR has been shown to render 
cultured neurons more resistant to oxidative stress, this effect was in part attributed 
to the suppression of Foxo1 target gene Txnip through promoting the PI3K-
dependent Foxo1 nuclear exclusion. In contrast, elimination of NMDAR activity 
upregulates Txnip both in vivo and in vitro and promotes vulnerability to oxidative 
stress (Papadia et al., 2008). On the other hand, activation of extrasynaptic 
NMDAR promotes Foxo3 nuclear accumulation, which subsequently contributes 
to NMDAR-mediated neuronal death in hippocampal neurons. However, neurons 
depleted of endogenous Foxo3 or undergoing prolonged periods of synaptic 
activity are more resistant to excitotoxic insults (Dick and Bading, 2010).  
Furthermore, exposure of neurons to the phenolic antioxidant tBHQ protects 
against NMDA-evoked excitotoxicity, at least in part, by promoting Foxo3 
cytoplasmic retention (Bahia et al., 2012). Neurotrophic factors are thought to 
promote neuronal survival at least in part through triggering the nuclear export of 
Foxo and the subsequent suppression of Foxo-directed gene expression, and the 




Although a large body of evidence shows that cell death is the most likely outcome 
of Foxos activation in neurons, work from the Kalb group has shown that genetic or 
pharmacological manoeuvres that promote nuclear accumulation of Foxo3 confers 
protection against known causes of motor neuron diseases in mouse spinal cord 
cultures (Mojsilovic-Petrovic et al., 2009). Their findings are in direct contrast to 
previous studies where overexpression of Foxo3 led to the death of motor neurons 
and cerebellar granule neurons (Brunet et al., 1999; Barthelemy et al., 2004). The 
disparities between these two observations may relate to the levels of transgene 
expression, the nature of stimulus used or differences in the neuronal cell types used  
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(Nemoto and Finkel, 2002). However, it is plausible that Foxo may need to be 
activated in the proper ‘window’ of time/magnitude in order to confer 




The regulation of Foxo1 promoter by Foxos may serve as an important feed-forward 
mechanism aimed to reinforce the effect of Foxo-inactivating or -activating signals 
such as synaptic activity or oxidative stress respectively, on FOXO1-target genes 
expression. This aspect of Foxo1 regulation could be unfavourable particularly in 
tumours, where abnormal activation of the PI3K-Akt pathway is an important step in 
their initiation and maintenance, Akt-mediated Foxo export may then lead to 
suppression of Foxo1 expression, exacerbating the situation further. 
 
 
Shortly before the publication of this study, the Demoulin group performed a study 
on FOXO regulation in human fibroblast and arrived at the same conclusion that 
FOXO1 is a FOXO target gene (Essaghir et al., 2009). In agreement with our 
observations, they reported that FOXO3 displayed a stronger transactivating effect 
on FOXO1 promoter in comparison to FOXO1 (Fig 3.3B). They also identified the 
same proximal Foxo consensus site (GTA AAC AA) as mediating a large portion 
of the observed Foxo responsiveness, which was responsible for growth factor-
induced transcriptional suppression. Interestingly, they found that mutation of this 
proximal site reduced the activation of the promoter by FOXO3 overexpression, 
but did not abolish it completely. This raises the possibility that the IRS-like 
sequence identified in our study may be mediating the remaining induction. It is 
therefore likely that Foxo-inactivating signals are capable of suppressing Foxo1 
expression in a variety, if not all, cell types. 
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3.3.2. Synaptic NMDAR activity suppresses Keap1 expression 
 
Keap1 was initially described as a cytoplasmic inhibitor of Nrf2 that binds to 
actin cytoskeleton and Nrf2 to retain Nrf2 in the cytoplasm and target it for 
subsequent ubiquitination and degradation. In this study, the results suggest that 
synaptic NMDAR activity could induce the Nrf2/ARE signalling pathway by 
suppressing Keap1. Synaptic activity enhanced exogenous Nrf2 capacity to 
induce ARE-Luc activity in a Keap1 sensitive manner (Fig. 3.4) In addition, I 
showed that induction of synaptic activity results in the downregulation of Keap1 
mRNA and protein expression in an NMDAR-dependent manner (Fig 3.5).  The 
activity-dependent regulation of Keap1 appears to occur, at least in part, at a 
transcriptional level as BiC stimulations results in a significant suppression of 
Keap1 promoter activity (Fig. 3.6A). Although Keap1 suppression could be a 
plausible mechanism by which synaptic activity could boost the Nrf2-controled 
antioxidant defences, I didn’t pursue this study further, as I find later in section 
4.2.3 that the endogenous Nrf2 pathway is inactive in neurons and that it is 
predominantly astrocytic. Nevertheless, it is conceivable that synaptic activity 




Besides binding to its well-characterized substrate, Nrf2, Keap1 has been 
reported to bind other proteins directly or indirectly through its DGR domain. 
Recent studies have suggested a role for Keap1 in regulating cellular apoptosis 
through altering the activity of pro-apoptotic and anti-apoptotic proteins such as 
ASK1 and Bcl-2/Bcl-xL respectively (Stepkowski and Kruszewski, 2011). 
Phosphoglycerate mutase 5 (PGAM5), a recently characterized atypical member 
of the phosphoglycerate mutase family and a direct binding partner of the Bcl-xL 
anti-apoptotic protein, have been reported to interact with the DGR domain of 
Keap1 (Niture and Jaiswal, 2011a). PGAM5 acts as a bridge mediating Keap1 
interaction with Bcl-xL and controlling Keap1-mediated degradation of Bcl-xL. 
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Further studies revealed that overexpression of Keap1 leads to increased 
degradation of both PGAM5 and Bcl-xL, which increases/activates pro-apoptotic 
factors and eventually resulting in increased cell apoptosis and decreased cell 
survival. On the other hand, siRNA inhibition of Keap1 or treatments with 
antioxidants such as tBHQ leads to the stabilization of Bcl-xL and increases cell 
survival (Niture and Jaiswal, 2011a). 
 
 
Bcl-2 is another recently reported substrate for Keap1. Unlike Bcl-xL, Keap1 DGR 
domain directly interacts with the BH2 domain of Bcl-2 and facilitates the Keap1- 
Cul3 mediated ubiquitination of Bcl-2 lysine17 residue and degradation of Bcl-2 
(Niture and Jaiswal, 2011b). Overexpression of Keap1 can promote apoptosis by 
degrading Bcl-2 and decreasing Bcl-2: Bax heterodimers. For instance, Keap1 
overexpression enhanced etoposide- mediated apoptosis in cancer cell. However, 
antioxidants antagonize Keap1: Bcl-2 interaction, leading to the release and 
stabilization of Bcl-2, increased Bax:Bcl-2 heterodimer and cell survival. The 
stabilization of the anti-apoptotic proteins Bcl-2 and Bcl-xL and prevention of 
apoptosis are presumably important mechanisms by which the cells protect 
themselves from dying in acute stress (Niture and Jaiswal, 2011b). 
 
 
ASK-1 was identified as the main MAPK kinase kinase and a pivotal component 
in the mechanism of cytokine- and stress-induced apoptosis (Saitoh et al., 1998). 
Dephosphorylation of ASK-1 by PGAM5 leads to its activation, which 
contributes to apoptosis in various stress conditions such toxification, 
neurodegenerative diseases, immune responses (Stepkowski and Kruszewski, 
2011) and oxidative stress (Niso-Santano et al., 2010). Whereas thioredoxin, an 
Nrf2-traget gene, binds and inhibits ASK-1.The link between ASK-1 and 
Nrf2/Keap1 pathway was demonstrated in the study of paraquat-induced cell 
death, in which Keap1-deficient mouse embryonic fibroblasts (MEFs) were 
insensitive to paraquat-mediated cell death and this effect was attributed to the 
inability to activate ASK-1, whilst ASK-1 was constitutively activated in Nrf2-
deficient MEFs displaying hypersensitivity to the same insult (Niso-Santano et 
al., 2010). However, whether Keap1/PGAM5 binding affects ASK-1 
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dephosphoryaltion is unclear. 
 
 
The activation of NF-κB family of transcription factors has been associated with 
the development and/or progression of cancer by regulating the expression of 
genes involved in cell growth and proliferation. Recently, IkB kinase (IKKβ), a 
positive regulator of NF-κB, was found to be destabilized by Keap1, which 
resulted in the inhibition of NF-κB-induced tumourgenesis (Lee et al., 2009; Kim 
et al., 2010). Moreover, genomic alterations of Keap1 fail to facilitate IKKβ 
degradation, which then leads to the activation of NF-κB pathway in human 
cancers (Lee et al., 2009). Thus, Keap1 acts as a tumour suppressor through 
negative regulation of three substrates Nrf2, IKKβ and Bcl-2/Bcl-xL. 
 
 
The notion that the activity-dependent inhibition of Keap1 may promote cell 
survival requires further investigation. Future studies will be needed to address 
the effect of synaptic activity on the stability of the anti-apoptotic proteins Bcl-2 
and Bcl-xL and/or the activity of ASK-1 and NF-κB, and to determine whether 
this effect is conferred through Keap1 suppression. However, this is beyond the 
scope of this thesis as we are primarily interested in the regulation of the 
endogenous Nrf2/ARE pathway in response to intrinsic stimuli rather than the 
regulation of Keap1- mediated pro-death signalling. 











              Mild oxidative stress activates the Nrf2 pathway in    
  astrocytes but not neurons 
 




4.1. Summary  
Since Nrf2 plays an important role in sensing and combating oxidative stress        
(Kensler et al., 2007; Cullinan et al., 2004), I postulated that sub-toxic levels of 
oxidative stress might be sufficient to turn on the Nrf2-dependent cytoprotective  
genes expression. To recreate oxidative stress in vitro, I utilized sub-toxic doses of 
H2O2. I chose three previously established markers of Nrf2 activation to evaluate: 
Srxn1 (Soriano et al., 2008) Hmox1 and xCT (Alam et al., 2000; Ishi et al., 2000; 
Shih et al., 2003). I found that all three markers were transcriptionally induced in 
astrocytes containing neuronal cultures (AC-neurons) following sub-toxic H2O2 
application. However, the inductive effect of H2O2 was abolished in cultures 
prepared from Nrf2-/- mice, confirming Nrf2-dependent mechanism of action. I also 
found that application of H2O2 or tBHQ to AC-neurons induces Hmox1 
immunostaining in astrocytes but not neurons. Moreover, neither mild oxidative 
stress, tBHQ nor Keap1 genetic ablation could induce Nrf2 target gene expression in 
neuronal cultures devoid of astrocytes. However, Nrf2 forced expression in neurons 
was capable of inducing endogenous Hmox1 expression. These results therefore, 
demonstrate that the endogenous Nrf2 pathway is responsive to mild oxidative stress 
and that astrocytes are the sole locus of Nrf2 activation in our model. Of note part of 
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4.2. Results 
4.2.1. Establishment of culture systems and H2O2 stimulations 
Cortical mouse neurons from E17.5 CD1 mice were cultured as described in section 
2.1. In this study I utilized three types of cortical cultures: astrocytes containing 
neuronal cultures, astrocyte-free neuronal cultures designated as (AC-neurons) and 
(AF-neurons) respectively and astrocytes enriched cultures (astrocytes). To control 
for non-neuronal cell proliferation, cultures were grown in the presence or absence of 
the anti-mitotic AraC. To obtain (AC-neurons) comprising (more than 90% NeuN+ 
and and less than 10% GFAP+  cells), cultures were treated  with AraC on DIV04 
(Fig. 4.1 A). For (AF) cell population, comprising more than 98%  Neu N+ and less 
than 0.2% GFAP+  cells, AraC was added to cultures on DIV0 (Fig. 4.1 B). Astrocyte 
cultures were prepared as described in section 2.1 and grown in the absence of AraC 
, which results in a cell population comprising of more than 96%  GFAP+  and less 
than 4%  Neu N+ cells (Fig. 4.1 C) (Bell et al., 2011a). 
  
Various experimental approaches have been developed to model oxidative stress in 
primary neural cell cultures, which include exposure to pro-oxidative conditions such 
OGD (Furuichi et al., 2005), GSH-deprivation (Ratan et al., 1994) and addition of 
external chemical compounds with the capacity to undergo redox cycling such as 
Paraquat (PQT) (Comporti, 1989; Escartin et al., 2011) or addition of H2O2 (Rojo et 
al., 2008) Papdia et al., 2008; Soriano et al., 2008). In addition, some studies utilize 
tBHQ to induce oxidative stress-mediated Nrf2 activation, however, reports differ on 
the involvement of oxidative stress in the tBHQ-mediated Nrf2 activation. While 
tBHQ was shown to lead to OH•  radical formation, which was inhibited upon the 
addition of catalase in human hepatoma cells (Pinkus et al., 1996), activation of the 
ARE by tBHQ in human neuroblastoma cells (Lee et al., 2001) or in primary cortical 
cultures derived from ARE-hPAP reporter mice (Johnson et al., 2002) was 
independent of oxidative stress as pre-treatment with antioxidants or antioxidant 
enzymes didn’t inhibit tBHQ-induced ARE activation. 
 In the present study, I have utilized H2O2 to model oxidative stress in vitro because 
it’s endogenously produced and can easily diffuse through cell membranes (Halliwell 
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and Gutteridge, 1989; Hogg et al., 1992). Cells were pre-incubated in TMo for ~ 16 





















Figure 4.1. Establishment of cell culture systems and oxidative stress model.  
Example pictures showing GFAP immunostaining (red) with nuclear DAPI stain (blue). 
A) AC-neurons. B) AF-neurons C) Astrocytes. D) To induce oxidative stress a range of 
H2O2 doses (25µM-100µM) was utilized and cell viability was evaluated in AC- neurons 
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 4.2.2. Mild oxidative stress upregulates Nrf2-dependent gene expression 
In an effort to determine whether mild oxidative insult could activate the Nrf2 pathway, 
AC-neurons were exposed to either 10 µM tBHQ, as a positive control for Nrf2-dependent 
gene expression induction (Lee et al., 2003), or to a range of H2O2 doses  (25-100µM) for 
6 h after which RNA was harvested and converted to cDNA for subsequent qPCR 
analysis. Treatments with H2O2 showed marked upregulation of Srxn1 and Hmox1 gene 
expression (Fig. 4.2A, B). As for xCT mRNA levels, a modest yet significant induction 
was observed (Fig. 4.2 C). To look at dependence on Nrf2, cultures derived from Nrf2-/- 
mice were subjected to the same protocol. In these cultures, H2O2 was unable to induce 
Nrf2-target genes expression, highlighting the central role of Nrf2 in mediating the H2O2-
induced gene upregulation (Fig. 4.2). Loss of Nrf2 not only abolished the inductive effect 
of H2O2, but also dramatically reduced Hmox1 basal expression. Similar observation was 
reported in human endothelial cells, whereby transfection with Nrf2 siRNA produced a 
significant reduction in HMOX-1 mRNA expression (Jyrkkanen et al., 2008). Moreover, 
xCT basal expression was reduced but to a lesser extent in Nrf2 -/- cultures, while Srxn1 
basal levels remained unchanged. 
 
   
 
 















Figure 4.2. Mild oxidative stress-mediated upregulation of phase II genes 
expression is Nrf2 dependent.  
AC-neurons were treated for 6 h in trophically deprived medium with H2O2 or tBHQ 
at the indicated doses, followed by RNA isolation and qPCR analysis of gene 
expression (normalized to Gapdh) and compared to WT-control. (n=5-6) #p<0.05 
significantly different from WT-control ; *p<0.05 significantly different from 
corresponding treatment in Nrf2-/-, not done (N.D). A) Srxn1 mRNA levels. B) 
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4.2.3. Mild oxidative stress-mediated Nrf2 activation is restricted to astrocytes  
The site of Nrf2 activation has been a matter of controversy. While most reports 
suggest that Nrf2 activation is predominantly astrocytic (Shih et al., 2003; Kraft et 
al., 2004; Vargas and Johnson, 2009), several lines of evidence show that Nrf2 could 
be induced in neurons in vitro (Johnson et al., 2002) and in vivo (Kraft et al., 2007).  
I therefore resolved to determine the locus of Nrf2 activation, in our in vitro model of 
oxidative stress by measuring the mRNA levels of Nrf2 downstream genes in AC-
neurons following 6 h exposure to H2O2 or tBHQ. The same experiment was 
performed with AF-neurons and astrocytes. QPCR analysis revealed a large 
induction of Srxn1, Hmox1, and xCT gene expression in both AC-neurons and 
astrocyte post H2O2 application (Fig. 4.3). By contrast, the absence of astrocytes in 
AF-neurons completely abolishes the H2O2-mediated gene induction (Fig. 4.3).   
However, in astrocytes, H2O2 triggers a stronger Nrf2-dependent gene expression 
(Fig 4.4) compared to the other culture types. These results strongly indicate that 
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Figure 4.3. Nrf2 activation by mild oxidative stress is astrocytes dependent.  
AC and AF-neurons were treated in parallel with H2O2 or tBHQ at the indicated 
doses for 6 h, before harvesting RNA for qPCR analysis of gene expression 
(normalized to Gapdh). (n=5-9),  *p<0.05 significantly different from AC-neurons 
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Figure 4.4. H2O2 treatments trigger robust Nrf2-dependent induction in 
astrocytes.  
Astrocytes were treated with the indicated doses of H2O2 for 6 h, before harvesting 
RNA for qPCR analysis of gene expression (normalized to Gapdh). (n=5-9), #p<0.05 
significantly different from control ; *p<0.05 significantly different from 
corresponding treatment in Nrf2-/-. A) Srxn1 mRNA levels. B) Hmox1 mRNA levels. 
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4.2.4. The Nrf2 pathway can't be activated in neurons even when surrounded by 
astrocytes  
The induction of Nrf2-dependent gene expression observed in AC-neurons is most 
likely attributable to Nrf2 activation in astrocytes, since AF-neurons devoid of 
astrocytes fail to respond to Nrf2 inducers (Fig. 4.3). However, I sought to rule out 
the possibility that Nrf2 could be activated in neurons when surrounded by 
astrocytes. One way to examine this notion is by performing immunofluorescence in 
AC-neurons using antibody to Hmox1 protein in conjunction with an antibody to the 
astrocytic marker GFAP. The analysis demonstrated an increase in Hmox1 
expression co-localized to GFAP positive cells following treatment with either tBHQ 
or H2O2 (Fig. 4.5A), whereas cells displaying neuronal morphology not only failed to 
respond to the treatments but also exhibited significantly lower basal expression 
compared to astrocytes (Fig. 4.5B). These results suggest that the Nrf2 pathway is 
inactive in neurons even when in contact with astrocytes and further confirms that 





























Figure 4.5.  Activation of the Nrf2 pathway is confined to astrocytes.  
AC-neurons were treated with either H2O2 or tBHQ at the indicated doses for 24 h 
and then were stained with anti-Hmox1 (green) and anti-GFAP (red) and with DAPI 
(blue). A) Representative images of Hmox1 immunofluorescence staining showing 
that Hmox1 induction in response to either H2O2 or  tBHQ is specific to GFAP- 
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4.2.5. Alleviating the Keap1-mediated Nrf2 suppression fails to activate the 
endogenous Nrf2 pathway, while forced Nrf2 expression rescues the pathway in 
neurons   
The failure to activate the Nrf2 pathway following the application of H2O2 or tBHQ 
in AF-neurons (Fig. 4.3) or even in neurons when surrounded by astrocytes in the 
AC-neurons (Fig. 4.5) led me to hypothesize that this was due to increased Keap1 
inhibition of Nrf2 in neurons. To test this, I evaluated the mRNA expression of Nrf2-
downstream genes in cultures derived from Keap1-/- mice.  Constitutively active Nrf2 
has been reported in Keap1 null MEF (Wakabayashi et al., 2003) and in Keap1 
knockdown cortical astrocytes (Gan et al., 2010) leading to the induction of Nqo1.  
Similarly, cortical mixed neuron/astrocyte cultures derived from Keap1-/- mice 
displayed an upregulation in phase II enzymes resulting in increased resistance of 
neurons against oxidative stress (Satoh et al., 2009).  In agreement with the previous 
reports, I have observed an elevation in the basal expression of Nrf2-target genes in 
AC-neurons and astrocytes prepared from Keap1-/- mice, whereas Keap1 deletion 
had no effect in AF-neurons (Fig. 4.6). The possibility that the lack of Nrf2 activity 
in neurons is due to low Nrf2 (Nfe2l2) gene expression was tested in our laboratory. 
A qPCR analysis of Nfe2l2 and Keap1 basal mRNA levels in the three culture types 
performed by Dr.Bell showed no significant difference in Keap1 expression between 
neurons and astrocytes, while interestingly Nfe2l2 mRNA levels were substantially 
lower in neurons (0.079 ± 0.027 and 4.9 ± 1.53 in AF- and astrocyte respectively, 
compared to AC-neurons). The diminished Nrf2 expression could account in part for 
the lack of Nrf2 activity in neurons. However, limited Nrf2 access to its target genes 
promoters is another plausible explanation for the lack of Nrf2 activity in neurons. 
To this end, I resolved to test if ectopic expression of Nrf2 in neurons could revive 
the pathway. Using a neuron-specific transfection protocol, neurons were co-
transfected with Nrf2 driven by the elongation factor-1α promoter (EF-Nrf2) and a 
CMV promoter driven eGFP (used as marker for transfected cells). GFP-positive 
neurons overexpressing Nrf2 displayed an increased Hmox1 staining as seen by 
immunofluorescence analysis (Fig. 4.7). This preliminary result suggests that ectopic 
Nrf2 is capable of transactivating its target genes and could be activated in neurons 
when available at sufficient levels, however, the same experiment should be repeated 
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to include appropriate controls in which neurons are transfected with a control 
plasmid such as Globin along with the eGFP and the intensity of Hmox1 expression 
should be evaluated in Nrf2 and Globin overexpressing neurons. All together these 
results suggest that the inactivity of endogenous Nrf2 in neurons and the failure to 
boost it through lifting the Keap1-mediated suppression is a result of Nrf2 low 












Figure 4.6. Keap1 genetic ablation is not sufficient to activate Nrf2 
transcriptional pathway in neurons.  
AC-neurons, AF-neurons and astrocytes were prepared from WT or Keap1-/- mice 
littermates. Cells were lysed and RNA was harvested for qPCR analysis of Srxn1, 
xCT and Hmox1 constitutive mRNA levels (normalized to Gapdh). (n=6-15),*p 























Figure 4.7. Nrf2 ectopic expression induces endogenous Hmox1 expression in 
neurons.  
Example pictures from preliminary immunocytochemistry experiments showing that 
Nrf2 forced expression could induce endogenous Hmox1 expression, however, 
inclusion of appropriate controls is required for more conclusive results. AC-neurons 
were co-transfected with pEF-Nrf2 and eGFP as a transfection marker (green) and 
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4.3. Discussion  
  Data presented herein are the first demonstrating that intrinsic cellular signals such 
as mild oxidative stress are capable of activating the endogenous Nrf2 pathway and 
mediating Nrf2-dependent phase II gene induction in an astrocyte specific manner. I 
also report the lack of neuronal response to Nrf2 activation by H2O2, Nrf2 specific 
inducer tBHQ or Keap1 genetic ablation. In addition, restricted induction of Hmox1 
to astrocytes in AC-neurons, excludes the possibility of neuronal contribution to the 
Nrf2-dependent gene upregulation observed post H2O2 or tBHQ treatments as a 
results of a specific neuron-astrocyte signalling. 
 
4.3.1. Nrf2-dependent gene expression is strongly induced in response to mild 
oxidative stress  
In this current study I have shown that endogenous Nrf2-dependent antioxidant 
response could be strongly triggered by mild oxidative stress (Fig. 4.2).  Robust 
induction was observed in Hmox1 gene expression levels following treatment with 
H2O2 (Fig. 4.2B), this elevation was also reflected at the protein level as seen by 
increased Hmox1 immunofluorescence staining (Fig. 4.5A).  Similarly, sub-toxic 
H2O2 doses increased Srxn1 and xCT mRNA levels (Fig. 4.2 A, C). I confirmed the 
Nrf2 specific requirement in the H2O2-mediated upregulation of phase II genes 
expression, as loss of Nrf2 completely ablated the inductive effect of H2O2. The 
impact of Nrf2 loss was not limited to the inducible levels of these genes, it also, as 
anticipated altered the basal mRNA expression of Hmox1 and xCT. Hmox1 basal 
levels dropped markedly in Nrf2-/- AC-neurons to about one tenth of that in WT, 
whereas xCT constitutive expression was reduced by around 30% in Nrf2-/- cells (Fig. 
4.2B, C). Moreover, Keap1 deficient cultures displayed constitutive upregulation of 
Hmox1 and xCT gene expression, further confirming the role of Nrf2 in controlling 
the basal expression (Fig. 4.6). This is in agreement with previous reports, 
documenting a significant upregulation of phase II enzymes gene expression or 
protein expression in the absence of Keap1 (Wakabayashi et al., 2003; Satoh et al.,  
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2009; Gan et al., 2010). Interestingly, while loss of Keap1 induced Srxn1 basal 
mRNA levels, no change was observed in Nrf2-/- cultures. Given that Srxn1 harbours 
composite ARE/AP-1 sites within its promoter (Soriano et al., 2008), its plausible 
that compensatory genetic mechanism controlled through the AP-1 site accounts for 
the lack of change in Srxn1 basal mRNA levels in Nrf2 deficient cells. 
H2O2 has been implicated in the pathway leading to the Ischemic-preconditioning 
phenomenon (IPC), in which sub-lethal ischemic episode renders the cells more 
resistant to a subsequent and normally lethal ischemic insult (Furuichi et al., 2005).  
In regard to this, our group has recently shown that Nrf2 activation contributes to the 
neuroprotective effect of IPC in both in vitro and in vivo models of ischemia. 
Exposure to oxygen glucose depravation  (OGD) preconditioning stimulus resulted 
in a significant induction of Srxn1 and Hmox1 gene expression. This effect was also 
extended to include upregulation of the glutathione pathway genes expression in 
vitro (Bell et al., 2011b). Similar results were obtained when adult mice were 
subjected to transient occlusion of the middle cerebral artery (MCAO). Moreover, 
mild oxidative stress-induced Srxn1 and Hmox1 gene up-regulation in human 
embryonic stem cell (HESC)-derived astrocytes (Bell et al., 2011a). 
A recent study identified an Nrf2-independent mechanism for H2O2-induced 
astrocyte-dependent neuroprotection (Haskew-Layton et al., 2010). A unique 
enzymatic system was employed in this study to allow for the control of duration and 
level of intracellular H2O2 production in astrocytes. To that end, H2O2-producing 
enzyme (D-amino acid oxidase) was heterologously expressed in astrocytes that 
metabolizes an exogenous substrate (D-alanine) enabling regulated generation of 
H2O2. The controlled continuous sub-toxic H2O2 production in astrocytes rendered 
adjacent neurons resistant to an oxidative insult. However, they reported that the sub-
toxic doses of H2O2 fail to activate the Nrf2 pathway in astrocytes and trigger 
neuroprotection via a mechanism independent of Nrf2 and possibly involving the 
inhibition of protein tyrosine phosphatase (Haskew-Layton et al., 2010).  One 
potential explanation for the discrepant findings between the two studies is that H2O2 
doses greater than 30 µM were not explored in their study, because 100 µM H2O2 
was reported to be toxic to astrocytes as determined by 3-(4,5-Dimethylthiazol-2-yl)-
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2,5-diphenyltetrazolium (MTT) assay or by ethidium homodimer-1, a chemical 
which only stains the nuclei of dead cells (Haskew-Layton et al., 2011). However, 
the MTT assay measures cellular NADPH-reducing activity, which could drop in 
response to sub-toxic oxidative stress (due to the NADPH-dependent enzymatic 
H2O2 detoxification) resulting in overstated toxicity. In contrast, we observe no 
evidence of H2O2-induced toxicity at 100 µM H2O2 neither in astrocytes (Bell et al., 
2011a) nor in AC-neurons (Fig. 4.1D), as assessed by ATP assay and/or nuclear 
integrity. The discrepancies in the H2O2-induced toxicity results may be due to 
differences in the seeding density of the astrocyte cultures used. This observation 
was previously reported in rat neuronal and astrocytic primary cultures, whereby the 
degree of H2O2 toxicity/detoxification, at the same dose of H2O2, varied with cells 
seeding density (Dringen et al., 1999a; Song et al., 2004). 
 
Another possible reason for the disparities between the two studies lies in the Nrf2 
activity assay utilized by Haskew-Layton and co-workers, in which a luciferase 
reporter incorporating the ARE from the NQO1 promoter was employed. However, 
different AREs can have different Nrf2 dependencies for basal and/or inducible 
activity and unpublished data from our laboratory revealed a weak induction of Nqo1 
by 100 µM H2O2. Therefore the ARE promoter from NQO1 is not as sensitive as 
other ARE promoters and may not be a good indicator of Nrf2 response to H2O2. 
Regardless of the contradicting results, both studies confirm the importance of 
astrocytes in mediating neuroprotection. While our results emphasize the importance 
of astrocytic Nrf2-dependent pathway as a mediator of neuroprotective responses to 
oxidative stress, it is feasible that astrocyte-dependent neuroprotection against 
oxidative stress involves both Nrf2-dependent and Nrf2-indepedent signalling 
pathways. However, the contribution of one pathway or the other could depend on 
the developmental stage or the magnitude or nature of the oxidative insult (Bell et al., 
2011a; Bell et al., 2011b). 
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4.3.2. Mild oxidative stress activation of Nrf2 is astrocyte specific  
Previous studies aimed to determine the site of Nrf2 activation, in which genetic or 
pharmacological approaches were utilized to activate Nrf2, have generated 
contrasting results. While some studies are in support of the astrocyte-specific 
activation of the Nrf2/ARE pathway (Ahlgren-Beckendorf et al., 1999; Murphy et 
al., 2001; Kraft et al., 2004), other studies documented functional Nrf2 pathway in 
neurons (Johnson et al., 2002; Kraft et al., 2007; Escartin et al., 2011). Discrepancies 
in this regard, could be due to many factors such as the differences in the detection 
methods for markers of Nrf2 activation, the developmental stage, the brain region 
under investigation and the nature and intensity of the stimuli. Despite the disparities 
in the results from these studies, they collectively don't establish the locus of 
endogenous Nrf2 activity in response to endogenous signals such as oxidative stress. 
This study provides, for the first time, in vitro evidence of the locus of endogenous 
Nrf2 activation by intrinsic stimulus such as mild oxidative stress. I have observed 
no induction in Nrf2-dependent gene expression in cultures devoid from astrocytes 
neither with H2O2 nor with tBHQ treatments (Fig. 4.3). On the other hand, astrocytes 
displayed a very robust gene expression induction in response to either treatments 
(Fig. 4.4). Although astrocytes are represented by a small population (~10%) in our 
AC-neurons, they account for the strong Nrf2 response to H2O2 or tBHQ. This 
observation was further confirmed through immunfluorescent analysis revealing an 
increased Hmox1 expression by H2O2 or tBHQ co-localized with GFAP-positive 
astrocytes but not with cells displaying neuronal morphology (Fig. 4.5).  
Previous studies have been focused on the role of astrocytes in rodent systems in 
mediating a neuroprotective response to Nrf2-activating stimuli, however, this 
response was recently shown to be relevant to human systems. A study by Gupta et 
al. demonstrated that HESC-derived astrocytes are capable of promoting the 
protection of HESC-derived neurons against oxidative insults and that their 
neuroprotective capacity can be greatly enhanced by treatment with the Nrf2 inducer 
1[2-Cyano-3,12-dioxool-eana-1,9(11)-dien-28-oyl] trifluoroethylamide (CDDOTFEA) 
(Gupta et al., 2012). Moreover, treatment of HESC-derived neurons with CDDOTFEA 
failed to induce Nrf2 target genes and more importantly elicited no significant 
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protective effect against oxidative insults. This study supports the notion that 
astrocytes are the locus of endogenous Nrf2 activation in rodent (Fig 4.3-4.6) as well 
as in human systems  (Gupta et al., 2012). 
 
4.3.3. Nrf2 pathway is inactive in neurons 
Activation of ARE/Nrf2 pathway by tBHQ has been observed in neurons of mixed 
culture systems when in close proximity to astroytes  (Johnson et al., 2002). I 
therefore wanted to determine if neurons within AC-neuronal culture system could 
contribute to the strong Nrf2-dependent gene upregulation observed  following H2O2 
or tBHQ treatments, as a result of obligatory factors release from neighbouring 
astrocytes. Treatments with either H2O2 or tBHQ led to Hmox1 induction that was 
specific to GFAP-positive astrocytes, while it had no effect on Hmox1 expression 
pattern in the neuronal population in our cultures of AC-neurons (Fig. 4.5) and (Bell 
et al., 2011a). Moreover, AF-neurons failed to display an upregulation of Nrf2 target 
genes when treated with H2O2 or tBHQ (Fig. 4.3).  
Primary cultures derived from Keap1-/- mice or treated with (siRNA) directed against 
Keap1 display an increase in phase II mRNA levels as a result of constitutively 
active Nrf2 pathway (Satoh et al., 2009; Williamson et al., 2012). Consistent with the 
previous studies, Keap1 genetic ablation led to a significant induction of Nrf2-
dependet gene expression in both astrocytes and AC-neurons (Fig. 4.6). In contrast, 
knocking out Keap1 bore no effect on Nrf2 target genes expression in AF-neurons 
(Fig. 4.6). However, overexpression of Nrf2 in conjunction with eGFP revealed a co-
localization of Hmox1 staining to the GFP-positive neurons as seen by 
immunofluorence staining (Fig. 4.7). Similarly, Nrf2 overexpression in neurons 
induced endogenous Srxn1 staining (Soriano et al., 2008). This implies that 
ARE/Nrf2 pathway is functional in neurons and capable of driving ARE-gene 
transcription in the presence of adequate levels of Nrf2. Taken these data together, it  
 
is likely that lack of ARE/Nrf2 pathway activity is due to diminished Nrf2 
expression levels in neurons. In support of this notion, enriched glial cultures were 
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reported to express ~12 folds more of Nrf2 protein comparing to enriched neuronal 
cultures (Shih et al., 2003). In addition, unpublished data from our laboratory show 
significantly lower Nrf2 (Nfe2l2) mRNA expression in AF-neurons compared to AC-
neurons and astrocytes, while no difference was detected in the mRNA levels of 
Keap1. The loss of Nrf2 signalling in neurons could be a result of epigenetic 
regulation of Nrf2 expression. The basis for this are under investigation in our 
laboratory and not the focus of this thesis, however, I was interested in investigating 
the molecular events underlying the H2O2-mediated Nrf2 activation in astrocytes 
which I will address in the next chapter. 
 






                                              
                                            
 
                                          Chapter 5 
 Mild oxidative stress activates the astrocytic Nrf2 pathway  
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5.1. Summary 
 In non-neural cells, the prevailing view has been that activation of Nrf2 by oxidative 
stress is achieved through allowing Nrf2 to evade Keap1-mediated suppression. This 
effect is attributed at least in part to chemical or oxidative modification of specific 
reactive cysteine residues of Keap1, which may result in conformational changes in 
the Keap1/Nrf2 complex and ultimately stabilization of Nrf2 (Dinkova-Kostova et 
al., 2005; Fourque et al., 2010). 
 Having established that mild oxidative stress induced by the application of sub-toxic 
doses of H2O2   stimulates the astrocytic Nrf2 pathway (Fig 4.2-4.5), I attempted in 
this study to investigate the molecular mechanism(s) underlying the H2O2-mediated 
activation of the astrocytic Nrf2. Given the well-defined role of Keap1 in regulating 
Nrf2 activity in response to oxidative or chemical stress, I sought to test the 
involvement of Keap1 in the activation of astrocytic Nrf2 following exposure to mild 
oxidative stress. Contrary to the established dogma, I found that mild oxidative stress 
induces the astrocytic Nrf2 pathway in a manner distinct from the classical Keap1 
antagonism employed by prototypical Nrf2 inducers. The mechanism was found to 
involve direct regulation of Nrf2's transactivation properties and can act additively to 
and independently of the classical Keap1-antagonism pathway. Furthermore, I show 
here that mild oxidative stress enhances Nrf2 transactivation activity specifically 
through its Neh5 transactivation domain and that this effect is mediated by a specific 
previously identified redox-sensitive cysteine residue within the Neh5 domain. These 
findings suggest that therapeutic manipulation of Nrf2 activity may be achievable 
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5.2. Results  
Although I have shown in section 4.2.3-4.2.5 that Nrf2 is active only in astrocytes, 
all our experiments were performed in AC-neurons rather than astrocytes. The reason 
for this is that astrocytes when grown in isolation from neurons have been reported to 
display altered morphology and changes in specific genes expression. Previous 
studies revealed that astrocytes in vitro undergo morphological alteration from an 
epithelial cell-like (or polygonal) shape to a process-bearing shape, that is more 
characteristic of astrocytes in situ, when co-cultured with neurons (Matsutani and 
Yamamoto, 1997; Swanson et al., 1997). These morphological changes were also 
associated with changes in gene expression pattern of the astrocytic glutamate 
transporters such as the excitatory amino acid transporters (EAAT) (Matsutani and 
Yamamoto, 1997). 
 
5.2.1. Mild oxidative stress upregulates Nrf2-dependent gene expression even in 
the absence of Keap1  
Previously, I have shown that sub-toxic does of H2O2 upregulate Srxn1, Hmox1 and 
xCT expression specifically in astrocytes in an Nrf2-dependent manner (Fig. 4.2-4.5), 
however, the mechanism behind the upregulation is not clear. Studies of Nrf2 
regulation in non-neural cells suggest that oxidative stress induces Nrf2 activity 
through antagonizing Keap1-dependent suppression (Dinkova-Kostova et al., 2005; 
Fourque et al., 2010). I therefore sought to determine whether H2O2-mediated Nrf2 
activation occurs through the antagonism of Keap1. To test this, WT and Keap1-/- 
AC-neurons were treated with either a range of sub-toxic doses of H2O2 or tBHQ, 
which exemplifies a Keap1-dependent mechanism of Nrf2 activation (Zhang and 
Hannink, 2003), for 6 h after which RNA was harvested and Nrf2 target gene 
expression was evaluated. Real-time qPCR analysis revealed a significant induction 
of Nrf2 target genes expression following H2O2 regardless of Keap1 status (Fig. 
5.1A, C, E). Consistent with previous studies (Wakabayashi et al., 2003; Satoh et al., 
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2009; Gan et al., 2010), the absence of Keap1 elevated the basal expression of Nrf2 
target genes. Approximately  
 
three-fold increase in Srxn1 and xCT  basal expression was observed in Keap1-/- 
cultures (Fig 5.1 A, E). Given the important role of Nrf2 in controlling the basal 
expression of Hmox1, reflected by the dramatic decrease of Hmox1 basal expression 
in Nrf2-/- cultures (Fig 4.2 B), I predicted a large induction in Hmox1 basal levels in 
Keap1-/- cultures. To my surprise, the absence of Keap1 resulted in a modest yet 
significant increase in Hmox1 basal expression. The reason for this is not clear, 
however, one possible explanation is the contribution of other Nrf2-related factors in 
addition to Keap1 in the regulation of Hmox1 basal levels.  
Intriguingly, application of H2O2 produced further induction in Srxn1, xCT and 
Hmox1 genes expression in the absence of Keap1 (Fig. 5.1A, C, E), while the 
absence of Keap1 as predicted, abolished the tBHQ-mediated induction of Srxn1 and 
xCT expression (Fig 5.2 B, F). On the other hand, the absence of Keap1 didn't 
completely occlude the tBHQ-mediated induction of Hmox1 expression as a small 
yet significant increase was observed in Keap1-/- cultures (Fig. 5.2D). Although a 
number of studies have shown that tBHQ-mediated Nrf2 activation occurs through 
post-translational modification of Keap1 Cys 151 residue (Zhang and Hannink, 
2003; Zhang, 2006; Abiko et al., 2011), a recent study has demonstrated the 
contribution of calcium in the tBHQ-induced expression of HMOX1 in human 
hepatoma and colon carcinoma cell lines (Cheung et al., 2011). The reported 
involvement of calcium in the tBHQ-induced expression of HMOX1 could provide a 
possible explanation for the induction of Hmox1 expression observed in Keap1-/- 
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Figure 5.1. Mild oxidative stress induces Nrf2-regulated gene expression in 
Keap1 deficient cultures. 
Gene expression was assessed using qPCR in AC-neurons derived from WT or 
Keap1-/- mice and stimulated as indicated for 6 h. Srxn1 mRNA levels in response to 
A) H2O2 or B) to tBHQ. Hmox1 mRNA levels in response to C) H2O2 or D) to 
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5.2.2. H2O2 and tBHQ induce Nrf2-dependent gene expression via separate 
mechanisms 
As another approach to confirm the existence of a Keap1-indepedent mechanism of 
H2O2-mediated Nrf2 activation, I explored the effect of combined treatment with 
tBHQ and H2O2 on Nrf2-dependent gene expression. Since tBHQ acts through 
antagonizing Keap1 (Fig. 5.1B, F) and (Zhang and Hannink, 2003; Zhang, 2006; 
Abiko et al., 2011), I hypothesized that H2O2 and tBHQ co-treatment would 
additively induce Nrf2 activity. To examine this, I co-applied 10 µM tBHQ and 100 
µM H2O2 to AC- neurons, then harvested RNA for qPCR analysis 6 h later. As 
revealed by the qPCR analysis of Srxn1 and Hmox1 mRNA levels, tBHQ and H2O2 
combined treatment produced a significant upregulation of Nrf2 target genes 
expression greater than that achieved by the either treatment alone (Fig 5.2).  
As a further test of the Keap1-independent mechanism of H2O2-mediated Nrf2 
activation, I utilized a firefly luciferase reporter fused to the human Neh2 domain of 
Nrf2, responsible for Keap1-dependent Nrf2 degradation, referred to here and after 
as (Neh2-luc). This Neh2-luc reporter system is a recently developed tool that allows 
for real-time monitoring of the direct effect of a particular compound on Nrf2 
stability (Smirnova et al., 2011). The principle behind it is that under control 
conditions, Neh2-luc should undergo Keap1-mediated proteasomal degradation, 
which would result in a low luciferase activity. However, treatments with Nrf2 
activators such as tBHQ, which disrupt the Keap1-mediated Nrf2 degradation 
(Zhang and Hannink, 2003), would stabilize the Neh2-luc leading to a measurable 
increase in luciferase activity as illustrated in (Fig. 5.3A) (Smirnova et al., 2011). 
One advantage of this system, is that it would allow discrimination between Keap1-
dependent and -independent mechanism of action of Nrf2 inducers. I hypothesized 
that if H2O2 activates Nrf2 via a mechanism distinct from tBHQ, I then should 
observe no induction in Neh2-luc activity. To examine this, AC-neurons were 
transiently transfected on DIV02, using the astrocyte transfection protocol, with 
Neh2-luc reporter plasmid along with pTK-renilla normalization vector. Then on 
DIV08 the transfected cells were exposed to either tBHQ or H2O2 for 8 h prior to 
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measurements of luciferase activity. Parallel experiments were performed with cells 
transfected with a luciferase reporter (not fused to Neh2) along with pTK-renilla 
normalization vector, where they serve as a negative control. Consistent with the 
previous report (Smirnova et al., 2011), tBHQ stimulated Neh2-luc activity (Fig. 
5.3B), while, as predicted no change was observed in Neh2-luc activity following 
H2O2 treatments (Fig. 5.3B). Taken together, these findings suggest that mild 
oxidative stress activates the Nrf2 pathway via mechanism(s) separate from the 














Figure 5.2. H2O2 acts additively to the classical Keap1-dependent mechanism 
employed by tBHQ.  
Concomitant treatment of AC-neurons with 10µM tBHQ and 100 µM H2O2 for the 
indicated time followed by RNA isolation and qPCR analysis. A) Srxn1 gene 
expression. B) Hmox1 gene expression. (n=6), *p<0.05.  
 

























Figure 5.3. Neh2-luc responds to tBHQ-mediated activation but not H2O2. 
Transient transfection experiments were carried out on AC-neurons employing 
astrocyte transfection protocol. On DIV02, cells were transfected with Neh2-luc or 
luciferase only reporter plasmid along with pTK renilla transfection control. 6 days 
post transfection (DIV08) cells were treated with tBHQ or H2O2 at the indicated 
doses for 8 h before assessing luciferase reporter activity. Luciferase expression was 
normalized to Renilla control. (n=3),*p<0.05. 
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5.2.3. Inhibition of GSK-3β  potentiates the inductive effect of H2O2 on Hmox1 
gene expression but not Srxn1  
Apart from Keap1, GSK-3β was described as a negative regulator of Nrf2 promoting 
its nuclear exclusion and inactivation (Salazar et al., 2006; Rojo et al., 2008; Rada et 
al., 2011). However, under strong oxidative stress conditions, GSK-3β and Nrf2 are 
subject to biphasic regulation. Short-term exposure to oxidative stress activates Akt, 
which in turn leads to inhibitory phosphorylation of GSK-3β and eventually Nrf2 
nuclear translocation. On the other hand, long-term exposure results in GSK-3β 
activation and limits Nrf2 activity by expelling it from the nucleus (Salazar et al., 
2006; Rojo et al., 2008). I therefore hypothesized that if GSK-3β inhibition is the 
mechanism by which mild oxidative stress activates the Nrf2 pathway, then I should 
observe: 1) an increase in the basal expression of Nrf2 target genes, following 
treatment with GSK-3β inhibitor CT-99021, similar to that achieved following H2O2 
2) pre-treatment with CT-99021 would occlude H2O2 effect on Nrf2 target gene 
expression. To test this hypothesis, AC-neurons were treated for 6 h with H2O2 in the 
presence or absence of CT-99021. Then RNA was isolated and converted to cDNA 
for subsequent qPCR analysis. The data obtained from qPCR analysis revealed no 
significant change in Srxn1 or Hmox1 basal expression following the application of 
CT-99021 (Fig. 5.4). In addition, GSK-3β inhibition didn’t occlude the inductive 
effect of H2O2, as demonstrated by the significant upregulation of Srxn1 and Hmox1 
gene expression by H2O2 in the presence or absence of CT-99021. Co-treatment of 
H2O2 and CT-99021 results in a modest insignificant increase in Srxn1 mRNA 
expression (Fig. 5.4A). However, GSK-3β inhibition appears to potentiate the 
inductive effect of H2O2 on Hmox1 gene expression (Fig. 5.4B).The mechanism 
involved requires further studies, in which the effect of H2O2 on GSK-3β activity 











Figure 5.4. Inhibition of GSK-3β  potentiates the inductive effect of H2O2 on 
Hmox1 gene expression but not Srxn1  
AC-neurons were pre-treated with 2 µM CT-99021 for 1 h prior to treatment with 
100 µM H2O2 and then 6 h later RNA was isolated for subsequent qPCR analysis. A) 
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5.2.4. Mild oxidative stress enhances Nrf2 transactivation activity via the Neh5 
domain 
I next sought to explore if H2O2 elicits its activating effect through direct regulation 
of Nrf2 transactivation potential. To address this, a firefly luciferase reporter gene, 
linked to four Gal4 sites (Gal4-luc), was used to evaluate transcriptional activation 
by Nrf2 or by either of its two transactivation domains Neh4 and Neh5 following 
H2O2 application (Fig. 5.5A). For this purpose, I utilized constructs of Gal4-DNA 
binding domain (GBD) -Nrf2 functional domain fusion proteins previously generated 
by Katoh and co-workers (Katoh et al., 2001), in which GBD-Nrf2 contains the full 
length protein, GBD-Neh (2-4) contains both Neh2 and Neh4 domains (1-156 amino 
acids) and GBD-Neh5 contains the Neh5 domain  (153-227 amino acids) of Nrf2  
(Fig. 5.5A) (Katoh et al., 2001). GBD-Nrf2 fusion proteins mediate a strong 
activation of the reporter gene, compared to the GBD alone (Fig. 5.5B). Remarkably, 
H2O2 stimulation generated a significant induction in GBD-Nrf2 full length and 
GBD-Neh5 mediated luciferase reporter activity (Fig. 5.5B).  Moreover, the H2O2-
induced transactivation activity seems to be attributable to the Neh5 transactivation 
domain, as demonstrated by the lack of reporter activity response to H2O2 
stimulation when using GBD-Neh (2-4).  These results demonstrate that mild 
oxidative stress-mediated Nrf2 activation involves a direct regulation of Nrf2 
transactivation property.  
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Figure 5.5. Mild oxidative stress directly regulates Nrf2 transcriptional activity 
through the Neh5 domain.  
A) Schematic representation of the GBD-Nrf2 fusion effector constructs and Gal4-
luc reporter construct. B) On DIV02 AC-neurons were co-transfected with Gal4-luc 
plasmid and either of the Nrf2-GBD fusion plasmids indicated above. PTK-renilla 
was included in all transfections to normalize for transfection efficiency. On DIV08, 
cells were exposed to H2O2 for 8 h prior to analysis of firefly and renilla luciferase 
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5.2.5. Neh5 sensitivity to H2O2 is mediated by the Cys-191 residue  
I have previously demonstrated the redox reactivity of GBD-Neh5 to H2O2 (Fig. 5.5 
B), however, the molecular mechanism responsible for this response is not clear. 
Cysteine residues have a well-defined role in sensing and transducing cellular redox 
status (Barford, 2004) and have been found to be the primary targets for H2O2 
oxidizing action (Reth, 2002). In addition, Neh5 harbours a reactive cysteine residue 
that has been reported to mediate the increased nuclear translocation and 
transactivation of Nrf2 in response to H2O2 treatment observed in HeLa cells (Li et 
al., 2006). I therefore introduced a Cys to Ala mutation at postion-191 (C191A) of 
Neh5 domain to examine whether this cysteine residue is required for the H2O2- 
induced Neh5 transactivation activity. While H2O2 significantly induced Gal4-luc 
activity mediated by wild type GBD-Neh5, the C191A mutation completely 
abolished the inductive effect of H2O2. Furthermore, mutant GBD-Neh5 (GBD-Neh5 
(C191A)) displayed a reduced basal transactivation activity compared to WT (GBD-
Neh5) emphasizing the key role of this cysteine residue in mediating basal and 
inducible Neh5 transactivational activity (Fig. 5.6A). To ensure that the effect of the 
mutation on Neh5 transactivity is not due to differential expression levels between 
the WT and the mutant plasmids, I transfected HEK-293 cells with either the GBD-
Neh5 or GBD-Neh5 (C191A) and harvested the protein 24 h post-transfection for 
subsequent western blot analysis. The GBD expression level was comparable 
between the WT and mutant constructs as revealed by densitometric analysis of the 
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Figure 5.6. C191A mutation attenuates the redox reactivity of GBD-Neh5 
domain.   
A) AC-neurons were transfected on DIV02 with GBD-Neh5 or its mutant version 
GBD-Neh5 (C191A) along with Gal4-luc reporter and pTK-renilla plasmid. 6 days 
later (DIV08), cells were treated with H2O2 for 8 h before performing the luciferase 
reporter gene assay. Luciferase reporter activity was normalized to Renilla control. 
B, C) GBD-Neh5 and GBD-Neh5(C191A) expression levels B) GBD-Neh5 or its 
C191A mutant was transfected into HEK-293 cells. At 24 h post transfection, protein 
was harvested and analysed for GBD expression and β-actin loading control, (n=3). 
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5.3. Discussion 
 Contrary to the established dogma, I report here a mechanism by which mild 
oxidative stress triggers the astrocytic Nrf2, distinct from the classical Keap1 
antagonism pathway affected by small molecule Nrf2 inducers such as tBHQ. The 
mechanism involves direct regulation of Nrf2's transactivation properties, and can act 
additively to the classical tBHQ-induced pathway, suggesting that therapeutic 
manipulation of Nrf2 activity may be achievable even in astrocytes suffering 
oxidative stress. 
  
5.3.1. Mild oxidative stress activates the astrocytic Nrf2 in a Keap1-independent 
manner  
Prototypical activators of the Nrf2 pathway such as tBHQ and sulforaphane, induce 
the pathway via blocking Keap1-mediated Nrf2 ubiquitination and subsequent 
proteasomal degradation leading eventually to enhanced Nrf2 stability and activation 
of ARE-dependent gene transcription (Zhang, 2006). Herein I have presented a 
previously unrecognized mechanism for astrocytic Nrf2 activation by mild oxidative 
stress that is independent of the classical Keap1 antagonism pathway.  
In this study I found that mild oxidative stress activates the astrocytic Nrf2 
independently of Keap1. AC-neurons prepared from Keap1-/- displayed a significant 
induction in Nrf2-dependent gene expression when treated with H2O2 (Fig. 5.1). On 
the other hand, parallel experiments, in which cells were exposed to tBHQ, were 
used as a model for Keap1-dependent mechanism. Although previous studies have 
not explored the effect of knocking out Keap1 on tBHQ-mediated Nrf2 activation, 
they have identified a particular cysteine residue (C151) located in the BTB domain 
of Keap1, required for the activation of Nrf2-regulated transcription by tBHQ (Zhang 
and Hannink, 2003). In addition, a more recent report showed that C151 mutations 
could promote and accelerate Keap1 degradation upon tBHQ treatment (Kobayashi 
et al., 2006). As predicted Keap1 deletion substantially abrogated the ability of tBHQ 
to elevate Nrf2-dependent Srxn1 and xCT gene expression (Fig. 5.1B and F). While a 
modest yet significant tBHQ-mediated induction was observed in Hmox1 gene  
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expression even in the absence of Keap1 (Fig. 5.1D). This induction could be 
attributable to the calcium-regulated tBHQ activation of Nrf2. A recent study 
described the role of calcium in mediating tBHQ-induced HMOX1 expression, 
whereby chelation of calcium attenuated the enhanced binding of Nrf2 to its co-
activator CREB and to the ARE in the enhancer region of HMOX1 induced by tBHQ 
in human hepatoma and colon carcinoma cell lines (Cheung et al., 2011). 
  
In light of the qPCR data obtained from WT and Keap1-/- cultures exposed to either 
tBHQ or H2O2  revealing a Keap1-dependent and -independent mechanisms of action 
respectively (Fig. 5.1), I speculated that concomitant treatment with H2O2 and tBHQ 
would additively induce Nrf2 target genes expression. Indeed, the combined 
treatment resulted in an upregulation of Srxn1 and Hmox1 gene expression greater 
than that elicited by each treatment individually (Fig. 5.2) confirming the Keap1- 
independent mechanism of Nrf2 activation by mild oxidative stress. 
  
Further evidence for the Keap1-independent mechanism was obtained using the 
Neh2-luc reporter system. Treatment with tBHQ led to a measurable increase in 
Neh2-luc activity (Fig. 5.3B). This observation is consistent with the data generated 
by Smirnova and co-workers showing an induction in Neh2-luc activity in human 
neuroblastoma cells exposed to tBHQ (Smirnova et al., 2011) and in line with the 
widely accepted model of Nrf2 activation by tBHQ (Zhang, 2006). On the other 
hand, no induction in Neh2-luc activity was observed with H2O2 (Fig. 5.3B). These 
data correlate well with the results presented in (Fig. 5.1 and 5.2) and together 
strongly suggest that mild oxidative stress activates Nrf2 in astrocytes via a Keap1-
independent mechanism, however, it doesn’t rule out some dependence on Keap1 as 
suggested by the drop in H2O2-mediated induction of Nrf2 target genes in Keap1-/- 
cultures compared to WT (Fig. 5.1). 
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It is noteworthy, that in zebrafish embryos H2O2 induced Nrf2-dependent glutathione 
S-transferase gene (gstp1) expression but failed to cancel Keap1-mediated 
suppression of Nrf2. Unlike other species, zebrafish have two types of Keap1, 
Keap1a and Keap1b with the latter sharing higher identities (73-81%) to the 
functional domains of the mouse Keap1 protein (Li et al., 2008). H2O2 failed to 
cancel Nrf2 suppression mediated by either Keap1 proteins. This was thought to be 
due to the lack of factors additional to Nrf2 and Keap1 necessary for sensing H2O2, 
which are down regulated or non-functional at the embryonic stage (Kobayashi et al., 
2009). However, it’s plausible that the failure to alleviate Keap1 suppression by 
H2O2 is not due to Keap1 impaired sensing for H2O2 but rather due to H2O2 Keap1-
independent mechanism of action.  
 
Keap1 function as a redox sensor is mainly attributed to its possession of reactive 
cysteine, which could be subject to oxidation by H2O2 residues (Zhang and Hannink, 
2003; Holland et al., 2008; Fourquet et al., 2010). H2O2 has been shown to induce 
chemical modification to specific cysteine residues in Keap1. Two types of disulfide 
bonds could be formed upon Keap1 oxidation by various oxidants including H2O2; 1) 
an intermolecular, bridging two Keap1 monomers at Cys151, 2) an intramolecular 
disulfide bond, linking Cys 226 and Cys 613. Fourquet and co-workers reported a 
parallel between Keap1 oxidation and Nrf2 stabilization in HeLa cells exposed to 
H2O2 and suggested a cause-and-effect relationship between the two phenomena. In 
their study, H2O2 induced a transient stabilization of Nrf2 coinciding with Keap1 
oxidation. However, this effect was very short lived lasting for not more than 20 
mins and the role of Keap1 in H2O2-induced Nrf2 stability was not confirmed 
through Keap1 knock out or knock down approaches (Fourquet et al., 2010). 
Nevertheless, its is conceivable that the initial response to H2O2 could be through 
Keap1 requiring pathway which then switches to an alternative Keap1-independent 
pathway.   
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Aside from Keap1, Nrf2 is subject to dual regulation by GSK-3β, whereby the kinase 
controls its subcellular distribution (Rojo et al., 2008) and degradation in a Keap1-
independent manner (Rada et al., 2011). The data presented here (Fig. 5.4A and B) 
shows that GSK-3β pharmacological inhibition doesn’t attenuate the inductive effect 
of H2O2 on Srxn1 or Hmox1 gene expression. However, it suggests that GSK-3β 
inhibition could potentiate the inductive effect of H2O2 on Hmox1 expression as 
demonstrated by the further induction in gene expression levels beyond that achieved 
with H2O2 alone (Fig 5.4B). This potentiating effect was observed in Hmox1 gene 
expression but not Srxn1 (Fig 5.4A) and further investigation is required to decipher 
the underlying mechanism and whether H2O2 influences the activity of GSK-3β.  
 
5.3.2. Mild oxidative stress enhances Nrf2 transactivation activity  
 In the present study I have demonstrated that mild oxidative stress activates the Nrf2 
pathway in astrocytes via a mechanism independent of the classical Keap1 
antagonism pathway employed by Nrf2 small molecule inducers such as tBHQ. The 
mechanism involves a direct regulation of Nrf2 transactivation activity. H2O2-
induced activation of the ARE promoter has been previously reported in non-neural 
cells. For instance in cardiomyocytes, exposure to mild doses of H2O2 resulted in an 
increase of ARE-luc reporter activity in an Nrf2-dependent manner (Purdom-
Dickinson et al., 2007). Moreover, treatment with H2O2 induced Nrf2-mediated 
ARE-luc activity in HeLa cells (Li et al., 2006).  
    
In the present study, I utilized the GBD-Nrf2 chimera constructs and Gal4-luc 
reporter co-transfection system (Fig. 5.5A) (Katoh et al., 2001) to analyse 
transactivation activity of Nrf2 and both its transactivation domains Neh4 and Neh5 
individually in response to H2O2 stimulation. Interestingly, H2O2 triggered a strong 
GBD-Nrf2 mediated Gal4-dependent luciferase activity (Fig. 5.5B). The data also 
indicated that the H2O2-mediated increase of GBD-Nrf2 transactivation activity is 
attributed to Neh5 domain but not Neh4, since GBD-Neh5 had displayed similar 
levels of H2O2-induced activity compared to GBD-Nrf2 whereas GBD-Neh (2-4) 
showed no response to H2O2 stimulations (Fig. 5.5B).  




Many proteins including transcription factors such as p53, Jun and Fos are subject to 
redox regulation occurring through particular highly conserved cysteine residues 
(Barford, 2004; Sun and Oberley, 1996).  However the H2O2-induced oxidation of 
these transcription factors can either up- or down regulate their transcriptional 
activity (Reth, 2002). In HeLa cells, Li et al. has identified a reactive cysteine 
residue at position 183 of the human Neh5 transactivation domain that is when 
mutated results in the attenuation of the H2O2-mediated Nrf2 translocation and 
transactivation   (Li et al., 2006). Consistent with the previous study, I have found 
that the substitution of Cys 191 for Ala in the mouse Neh5 domain not only ablates 
the induction of GBD-Neh5-mediated Gal4-luc activity following exposure to H2O2, 
but also significantly reduces Neh5 basal transactivation activity (Fig. 5.6A). The 
same mutation was shown to decrease the half life of Nrf2 when overexpressed in 
Nrf2 null mouse fibroblasts and was correlated with increased Keap1 binding (He 
and Ma, 2009). However, in my hands expression levels of Neh5 and its mutant 
version were comparable (Fig. 5.6B and C). The disparities between the two results 
could be due to differences in the cell types used. Finally, oxidative stress is a 
complex event and its control of the Nrf2 pathway is expected to be intricate 
involving regulation at different levels.  
 
 











                                    Chapter 6 
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The research reported herein has shed light on some of the molecular mechanisms 
involved in the control of intrinsic antioxidant and neuroprotective pathways by 
synaptic NMDAR signalling and mild oxidative stress. I have presented here three 
key findings: 
	  
• Foxo1 is a Foxo target gene and as a result, its expression is subject to a feed-
forward inhibition by synaptic NMDAR activity, which promotes Foxo3 
export from the nucleus. 
• Mild oxidative stress activates the Nrf2 antioxidant pathway in astrocytes but 
not neurons. 
• Mild oxidative stress activates the Nrf2 antioxidant pathway in a mechanism 
independent of Keap1, which involves the induction of Nrf2 transactivation 
activity via Cys 191 residue within the Neh5 domain. 
 
The finding that Foxo1 is a Foxo target gene, as demonstrated in sections (3.2.1-
3.2.3), indicates a feed-forward regulation mechanism that may serve to reinforce the 
effect of Foxo-inactivating or -activating signals such as synaptic activity or 
oxidative stress respectively, on Foxo1-target gene expression. This suggests that the 
protective effects of synaptic activity or neurotrophic factors may last longer than 
previously thought. In agreement with this finding, a study on FOXO regulation in  
human fibroblasts also demonstrated that FOXO1 is a FOXO target gene and that 
FOXO3 was a stronger activator of the FOXO1 promoter than FOXO1 itself 
(Essaghir et al, 2009), similar to our results in section 3.2.3. Moreover, Essaghir et 
al. identified the same proximal FOXO binding site (GTA AAC AA), which was 
required for the regulation by growth factors such as IGF-I and platelet-derived 
growth factors, and mediated a large portion of the observed FOXO responsiveness 
(Essaghir et al, 2009). They also found that FOXO1 and FOXO3 were associated to 
the FOXO1 gene promoter in HEK293T cells as well as fibroblasts, which raises the 
possibility that such an association may as well exist in neurons. Although I have  
	   142	  
shown that Foxo1 is a Foxo target gene based on the results obtained from luciferase 
reporter assay experiments (see section 3.2.3), further studies should be carried out 
to: 1) confirm the luciferase assay results by looking into the effect of overexpressing 
Foxos on the mRNA and protein expression of endogenous Foxo1 2) determine 
whether the enhanced Foxo1 promoter activity is a result of direct or indirect 
regulatory effect of Foxos, which could be assessed by performing chromatin 
immunoprecipitation experiments 3) determine whether Foxo3 itself is a Foxo target 
gene.  
 
A large body of evidence shows that cell death is the most likely outcome of Foxos 
activation in neurons in response to various stresses including oxidative stress and 
trophic factor withdrawal (for review see sections 1.2.4 and 1.2.5). Moreover, 
increased Foxo1 activity was implicated in the pahtogenesis of two forms of familial 
PD; the autosomal dominant late onset leucine-rich repeat kinase 2 (LRRK2)-linked 
PD, in which LRRK2 has been reported to phosphorylate FOXO1 and enhance its 
transcriptoinal activity both in Drosophila and mammalian cells (Kanao et al., 2010), 
and in the autosomal recessive early onset PTEN-induced kinase 1 (PINK1)-linked 
PD, in which lack of Pink1 was shown to increase Foxo1 activity in MEF cells via 
inhibiting IGF-I-induced Foxo1 nuclear exclusion (Akundi et al., 2012). In addtion, a 
very recent microarray  study in the prefrontal cortex of PD and control brain 
samples revealed a significant increase in FOXO1 gene expression in PD samples 
compared to controls and identified a set of differentially expressed genes, which 
was enriched for genes regulated by FOXO1(Dumitriu et al., 2012). Therefore, the 
protective effects of Foxo inactivating signals such as neurotrophic factors and 
synaptic NMDAR activity are thought to be mediated at least in part through 
promoting Foxos export and the subsequent suppression of Foxo-mediated gene 
expression (Gan et al., 2005; Maiese et al., 2007; Soriano et al., 2006; Papadia et al., 





	   143	  
Finally, in light of the data presented here and in previous studies by our group 
(Soriano et al., 2006; Papadia et al., 2008; Martel et al., 2009), it is conceivable that 
the activity-dependent suppression of Foxos could confer neuroprotection by fighting 
oxidative stress on two fronts: 1) boosting antioxidant defenses through the 
inhibition of Foxo-target gene, Txnip (Papadia et al., 2008) and 2) blocking the Foxo-











Figure 6.1. Mechanisms by which activity-dependent suppression of Foxos could 
combat oxidative stress. 
This simplified diagram, adapted from (Hardingham and Bading, 2010), illustrates 
how synaptic activity-dependent suppression of Foxos could promote 
neuroprotection thorough turning off Foxo pro-apoptotic target genes including 
Foxo1 itself and the thioredoxin antioxidant system inhibitor, Txnip. For further 
review on the mechanism of Foxo3 activation by oxidative stress see David-Dávila 
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Despite the well-established role of oxidative stress in the etiology of neurological 
disorders, antioxidant intervention based on the administration of free radical 
scavengers and spin-traps have met with limited success in clinical trials (Kamat et 
al., 2008). This could be due to various factors including failure to maintain the drug 
in the brain at levels sufficient to neutralize ROS as and when they appear. However, 
enhancing the activity of intrinsic antioxidant pathways such as the Nrf2 is an 
alternative antioxidant approach. Emerging evidence has shown that genetic or 
pharmacological activation of Nrf2 in astrocytes confers neuroprotection against 
oxidative stress in cell and animal models of neurodegeneration (for review see 
section 1.6). In line with this, I have demonstrated in sections 4.2.2-4.2.5, that the 
endogenous Nrf2 is activated by physiologically relevant stimulus such as mild 
oxidative stress in an astrocyte-specific manner. The responsiveness of endogenous 
Nrf2 to mild oxidative stress was recently shown by our group to contribute to the 
neuroprotective effect of ischemic preconditioning in vitro and in vivo (Bell et al., 
2011a; Bell et al., 2011b). However, whether human astrocytes are capable of 
mediating a neuroprotective response to Nrf2 activating-stimuli, was addressed in a 
recent study by Gupta et al., in which HESC-derived astrocytes were shown to 
promote survival of HESC-derived neurons following oxidative injury and that their 
neuroprotective capacity can be greatly enhanced by treatment with the Nrf2 inducer 
CDDOTFEA. This neuroprotective effect was restricted to astrocytes as HESC-derived 
neurons fail to respond to CDDOTFEA either in terms of Nrf2 activation or by 
conferring neuroprotection (Gupta et al., 2012). This study is consistent with the 
results from rodent cultures (refer to section 4.2.3) and (Bell et al, 2011a) showing 
that astrocytes represent the major locus of Nrf2 activation, triggered by small 
molecules and mild oxidative stress. Moreover, the loss of Nrf2 signalling in neurons 
could be a result of epigenetic regulation of Nrf2 expression, which is currently 
under investigation in our laboratory 
 
Nrf2 activation by oxidative stress/Nrf2 inducers in non-neural cells such as HeLa 
and NIH3T3 is believed to occur through Keap1 antagonism (Itoh et al., 1999: Zhang 
and Hannink, 2003; Fourquet et al., 2010). In the study on Nrf2 stabilization in  
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NIH3T3 cells, Keap1 C151 residue was found to be uniquely required for inhibition 
of Keap1-dependent degradation of Nrf2 by sulforaphane and tBHQ-induced 
oxidative stress (Zhang and Hannink, 2003). However, the involvement of oxidative 
stress in the tBHQ-induced Nrf2 activation is controversial. While tBHQ was shown 
to lead to ROS formation, in human hepatoma cells (Pinkus et al., 1996), activation 
of the ARE by tBHQ in human neuroblastoma cells (Lee et al., 2001) or in primary 
cortical cultures derived from ARE-hPAP reporter mice (Johnson et al., 2002) was 
independent of oxidative stress (for review see section 4.2.1). Therefore, it is 
important to utilize an accurate model of oxidative stress when investigating the 
mechanism of Nrf2 regulation in response to oxidative stress. In another study, 
where H2O2 was utilized to model oxidative stress in HeLa cells, a transient 
stabilization of Nrf2 protein coinciding with the oxidation of multiple cysteine 
residues on Keap1 was observed suggesting a cause-and-effect relationship between 
the two phenomena (Fourquet et al., 2010). However, this effect was very short lived 
lasting for not more than 20 mins and the role of Keap1 in H2O2-induced Nrf2 
stability was not confirmed through either Keap1 knock out or knock down 
approaches or through immunoprecipitation experiments. 
 
Contrary to the established dogma, this study provided evidence, presented in section 
5.2, suggesting that oxidative stress activates astrocytic Nrf2 via a mechanism 
independent of the classical Keap1 disinhibition pathway. The mechanism involves 
direct induction of Nrf2 transactivation activity via Cys191 within the Neh5 domain. 
This is in agreement with a previous study in HeLa cells, in which a reactive cysteine 
residue located in the human Neh5 domain was shown to attenuate the H2O2-
mediated Nrf2 translocation and transactivation (Li et al., 2006). However, some 
aspects of the Keap1-indepedenet mechanism reported in this thesis require further 
investigation these include: 1) assessing the influence of C191A on the oxidative 
stress-induced transactivational activity of the full length Nrf2 2) determining the 
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Two important points could be inferred from identifying the existence of a Keap1-
independent mechanism of H2O2-mediated Nrf2 activation: 1) The fact that oxidative 
stress and Nrf2 inducers such as tBHQ activate Nrf2 via two independent 
mechanisms, suggests that Keap1 antagonism alone doesn’t saturate the Nrf2-driven 
antioxidant defences and that there is potential for further enhancement of Nrf2 
activity in astrocytes suffering oxidative stress (Fig 6.2). 2) Although oxidative stress 
activates Nrf2 independent of cell type, the underlying mechanism could be cell 
type-specific. The concept of cell type-specific regulation of Nrf2 was also observed 
in the context of kinase dependence of Nrf2 activation, whereby PI3K inhibition was 
shown to attenuate tBHQ-mediated ARE activation in IMR-32 (Lee et al., 2001) 
cells but not in HepG2 cells (Zipp and Aktas, 2006). Understanding the cell type-
specific mechanisms of Nrf2 activation may be valuable in designing therapies 











Figure 6.2. Nrf2 inducers could further enhance Nrf2 activity in astrocytes 
suffering oxidative stress. 
This diagram illustrates that oxidative stress activates the Nrf2 pathway in astrocytes 
independently of the classical Keap1 antagonism previously reported in non-neural 
cells. The two independent mechanism of Nrf2 activation by oxidative stress and 
Nrf2 small molecule inducers such as tBHQ, suggest that Nrf2 small molecule 
inducers could further enhance Nrf2 activity even when astrocytes are suffering 
oxidative stress.    
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In summary, these results advance our knowledge of the mechanism(s) underlying 
the control of endogenous antioxidant and anti-apoptotic pathways by mild oxidative 
stress or synaptic activity. Such knowledge could be of value for designing therapies 
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